<!DOCTYPE html>
<html lang="en" dir="ltr" class="client-nojs">
<head>
<meta charset="UTF-8" />
<title>Thalidomide - Wikipedia, the free encyclopedia</title>
<meta name="generator" content="MediaWiki 1.26wmf13" />
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Thalidomide" />
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Thalidomide&amp;action=edit" />
<link rel="edit" title="Edit this page" href="/w/index.php?title=Thalidomide&amp;action=edit" />
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png" />
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico" />
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd" />
<link rel="alternate" hreflang="x-default" href="/wiki/Thalidomide" />
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/" />
<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
<link rel="canonical" href="https://en.wikipedia.org/wiki/Thalidomide" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.uls.nojs%7Cext.visualEditor.viewPageTarget.noscript%7Cext.wikihiero%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.sectionAnchor%7Cmediawiki.skinning.interface%7Cmediawiki.ui.button%7Cskins.vector.styles%7Cwikibase.client.init&amp;only=styles&amp;skin=vector&amp;*" />
<meta name="ResourceLoaderDynamicStyles" content="" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=styles&amp;skin=vector&amp;*" />
<style>a:lang(ar),a:lang(kk-arab),a:lang(mzn),a:lang(ps),a:lang(ur){text-decoration:none}
/* cache key: global:resourceloader:filter:minify-css:7:de1ab5287c9076b96eedd3f97a84a7b6 */</style>
<script src="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector&amp;*"></script>
<script>if(window.mw){
mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Thalidomide","wgTitle":"Thalidomide","wgCurRevisionId":670707794,"wgRevisionId":670707794,"wgArticleId":51078,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["All articles with dead external links","Articles with dead external links from June 2014","CS1 errors: dates","Pages with DOIs inactive since 2015","Articles with dead external links from June 2013","All pages needing factual verification","Wikipedia articles needing factual verification from June 2013","Articles with dead external links from September 2012","CS1 German-language sources (de)","Articles with changed EBI identifier","Chemical articles having calculated molecular weight overwritten","Drugboxes which contain changes to verified fields","Drugboxes which contain changes to watched fields","Articles needing additional references from March 2014","All articles needing additional references","All articles with unsourced statements","Articles with unsourced statements from June 2015","Articles that use a Medicine navs subtemplate","Wikipedia articles with GND identifiers","Congenital amputations","German inventions","Glutarimides","Health disasters","Immunosuppressants","Leprosy","Phthalimides","Teratogens","Withdrawn drugs","Chirality","Medical controversies","Health disasters in the United Kingdom"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Thalidomide","wgRelevantArticleId":51078,"wgIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgRedirectedFrom":"Fetal_thalidomide_syndrome","wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wikilove-recipient":"","wikilove-anon":0,"wgPoweredByHHVM":true,"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"hidesig":true,"preview":false,"publish":false},"wgBetaFeaturesFeatures":[],"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","usePageImages":true,"usePageDescriptions":true},"wgGatherShouldShowTutorial":true,"wgGatherPageImageThumbnail":"//upload.wikimedia.org/wikipedia/commons/thumb/6/6e/R-thalidomide-xtal-3D-balls.png/100px-R-thalidomide-xtal-3D-balls.png","wgULSAcceptLanguageList":[],"wgULSCurrentAutonym":"English","wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgNoticeProject":"wikipedia","wgInternalRedirectTargetUrl":"/wiki/Thalidomide","wgWikibaseItemId":"Q203174"});
}</script><script>if(window.mw){
mw.loader.implement("user.options",function($,jQuery){mw.user.options.set({"variant":"en"});});
/* cache key: global:resourceloader:filter:minify-js:7:b2706269305541eba923c165462b22c4 */
}</script>
<script>if(window.mw){
mw.loader.implement("user.tokens",function($,jQuery){mw.user.tokens.set({"editToken":"+\\","patrolToken":"+\\","watchToken":"+\\"});});
}</script>
<script>if(window.mw){
mw.loader.load(["mediawiki.action.view.redirect","mediawiki.page.startup","mediawiki.legacy.wikibits","mediawiki.legacy.ajax","ext.centralauth.centralautologin","mmv.head","ext.imageMetrics.head","ext.visualEditor.viewPageTarget.init","ext.uls.init","ext.uls.interface","ext.centralNotice.bannerController","skins.vector.js"]);
}</script>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 7]><style type="text/css">body{behavior:url("/w/static/1.26wmf13/skins/Vector/csshover.min.htc")}</style><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Thalidomide skin-vector action-view">
		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>

							<div id="siteNotice"><!-- CentralNotice --></div>
						<div class="mw-indicators">
</div>
			<h1 id="firstHeading" class="firstHeading" lang="en">Thalidomide</h1>
									<div id="bodyContent" class="mw-body-content">
									<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"><span class="mw-redirectedfrom">  (Redirected from <a href="/w/index.php?title=Fetal_thalidomide_syndrome&amp;redirect=no" title="Fetal thalidomide syndrome">Fetal thalidomide syndrome</a>)</span></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-head">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><table class="infobox" style="width:22em;border-spacing:2px;">
<caption>Thalidomide</caption>
<tr>
<td colspan="2" style="text-align:center"><a href="/wiki/File:Thalidomide-racemate2DCSD.svg" class="image"><img alt="Thalidomide-racemate2DCSD.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/8/86/Thalidomide-racemate2DCSD.svg/380px-Thalidomide-racemate2DCSD.svg.png" width="380" height="116" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/8/86/Thalidomide-racemate2DCSD.svg/570px-Thalidomide-racemate2DCSD.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/8/86/Thalidomide-racemate2DCSD.svg/760px-Thalidomide-racemate2DCSD.svg.png 2x" data-file-width="2275" data-file-height="694" /></a></td>
</tr>
<tr>
<td colspan="2" style="text-align:center">
<table style="width:100%; margin:0;">
<tr>
<td style="vertical-align:top; text-align:center; width:50%;"><a href="/wiki/File:R-thalidomide-xtal-3D-balls.png" class="image"><img alt="R-thalidomide-xtal-3D-balls.png" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/6e/R-thalidomide-xtal-3D-balls.png/190px-R-thalidomide-xtal-3D-balls.png" width="190" height="98" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/6e/R-thalidomide-xtal-3D-balls.png/285px-R-thalidomide-xtal-3D-balls.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/6e/R-thalidomide-xtal-3D-balls.png/380px-R-thalidomide-xtal-3D-balls.png 2x" data-file-width="1100" data-file-height="567" /></a></td>
<td style="vertical-align:top; text-align:center; width:50%;"><a href="/wiki/File:S-Thalidomide-3D-balls.png" class="image"><img alt="S-Thalidomide-3D-balls.png" src="//upload.wikimedia.org/wikipedia/commons/thumb/0/08/S-Thalidomide-3D-balls.png/190px-S-Thalidomide-3D-balls.png" width="190" height="90" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/0/08/S-Thalidomide-3D-balls.png/285px-S-Thalidomide-3D-balls.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/0/08/S-Thalidomide-3D-balls.png/380px-S-Thalidomide-3D-balls.png 2x" data-file-width="2119" data-file-height="1000" /></a></td>
</tr>
</table>
</td>
</tr>
<tr>
<th colspan="2" style="text-align:center;background:#ddd">Systematic (<a href="/wiki/International_Union_of_Pure_and_Applied_Chemistry_nomenclature" title="International Union of Pure and Applied Chemistry nomenclature" class="mw-redirect">IUPAC</a>) name</th>
</tr>
<tr>
<td colspan="2" style="text-align:center">
<div style="word-wrap:break-word; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size:11px">(<i>RS</i>)-2-(2,6-dioxopiperidin-3-yl)-1<i>H</i>-isoindole-1,3(2<i>H</i>)-dione</div>
</td>
</tr>
<tr>
<th colspan="2" style="text-align:center;background:#ddd">Clinical data</th>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Trade_name" title="Trade name">Trade names</a></th>
<td>Thalomid</td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/American_Society_of_Health-System_Pharmacists" title="American Society of Health-System Pharmacists">AHFS</a>/<a href="/wiki/Drugs.com" title="Drugs.com">Drugs.com</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.drugs.com/monograph/thalidomide.html">monograph</a></span></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/medlineplus/druginfo/meds/a699032.html">a699032</a></span></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Licence data</a></th>
<td><a href="/wiki/European_Medicines_Agency" title="European Medicines Agency">EMA</a>:<span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&amp;mid=&amp;searchTab=searchByKey&amp;alreadyLoaded=true&amp;isNewQuery=true&amp;status=Authorised&amp;status=Withdrawn&amp;status=Suspended&amp;status=Refused&amp;keywordSearch=Submit&amp;searchType=name&amp;taxonomyPath=&amp;treeNumber=&amp;searchGenericType=generics&amp;keyword=Thalidomide_Celgene">Link</a></span>, <a href="/wiki/U.S._Food_and_Drug_Administration" title="U.S. Food and Drug Administration" class="mw-redirect">US&#160;FDA</a>:<span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&amp;SearchTerm=Thalidomide&amp;SearchType=BasicSearch">link</a></span></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Pregnancy_category" title="Pregnancy category">Pregnancy<br />
category</a></th>
<td>
<div class="plainlist">
<ul>
<li><small><abbr title="Australia">AU</abbr>:</small> <a href="/wiki/Pregnancy_category#Australia" title="Pregnancy category">X</a> (High risk)</li>
<li><small><abbr title="United States">US</abbr>:</small> <a href="/wiki/Pregnancy_category#United_States" title="Pregnancy category">X</a> (Contraindicated)</li>
</ul>
</div>
</td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Legal status</a></th>
<td>
<div class="plainlist">
<ul>
<li><small><abbr title="Australia">AU</abbr>:</small> <a href="/wiki/Standard_for_the_Uniform_Scheduling_of_Drugs_and_Poisons#Schedule_4_Prescription_Only_Medicine" title="Standard for the Uniform Scheduling of Drugs and Poisons" class="mw-redirect">Prescription Only (S4)</a></li>
<li><small><abbr title="Canada">CA</abbr></small>: <a href="/wiki/Prescription_drug" title="Prescription drug"><span class="Unicode">℞</span>-only</a></li>
<li><small><abbr title="United Kingdom">UK</abbr>:</small> <a href="/wiki/Prescription_drug" title="Prescription drug">Prescription-only</a> (POM)</li>
<li><small><abbr title="United States">US</abbr>:</small> <a href="/wiki/Prescription_drug" title="Prescription drug"><span class="Unicode">℞</span>-only</a></li>
</ul>
</div>
</td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Route_of_administration" title="Route of administration">Routes of<br />
administration</a></th>
<td>oral</td>
</tr>
<tr>
<th colspan="2" style="text-align:center;background:#ddd"><a href="/wiki/Pharmacokinetics" title="Pharmacokinetics">Pharmacokinetic</a> data</th>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Bioavailability" title="Bioavailability">Bioavailability</a></th>
<td>90%</td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Plasma_protein_binding" title="Plasma protein binding">Protein binding</a></th>
<td>55% and 66% for the (+)-<i>R</i> and (–)-<i>S</i> enantiomers, respectively<sup id="cite_ref-clinp_1-0" class="reference"><a href="#cite_note-clinp-1"><span>[</span>1<span>]</span></a></sup></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Drug_metabolism" title="Drug metabolism">Metabolism</a></th>
<td>Hepatic (minimally via <a href="/wiki/CYP2C19" title="CYP2C19">CYP2C19</a>-mediated 5-hydroxylation; mostly via non-enzymatic hydrolysis at the four amide sites)<sup id="cite_ref-clinp_1-1" class="reference"><a href="#cite_note-clinp-1"><span>[</span>1<span>]</span></a></sup></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Biological_half-life" title="Biological half-life">Biological half-life</a></th>
<td>5-7.5 hours (dose-dependent)<sup id="cite_ref-clinp_1-2" class="reference"><a href="#cite_note-clinp-1"><span>[</span>1<span>]</span></a></sup></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;"><a href="/wiki/Excretion" title="Excretion">Excretion</a></th>
<td>Urine, faeces<sup id="cite_ref-clinp_1-3" class="reference"><a href="#cite_note-clinp-1"><span>[</span>1<span>]</span></a></sup></td>
</tr>
<tr>
<th colspan="2" style="text-align:center;background:#ddd">Identifiers</th>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/CAS_Registry_Number" title="CAS Registry Number">CAS Registry Number</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="//www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=50-35-1&amp;rn=1">50-35-1</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></th>
<td><a href="/wiki/ATC_code_L04" title="ATC code L04">L04</a><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.whocc.no/atc_ddd_index/?code=L04AX02">AX02</a></span></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/PubChem" title="PubChem">PubChem</a></th>
<td>CID: <span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="//pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5426">5426</a></span></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/IUPHAR/BPS" title="IUPHAR/BPS" class="mw-redirect">IUPHAR/BPS</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7327">7327</a></span></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/DrugBank" title="DrugBank">DrugBank</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.drugbank.ca/drugs/DB01041">DB01041</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/ChemSpider" title="ChemSpider">ChemSpider</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.chemspider.com/Chemical-Structure.5233.html">5233</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Unique_Ingredient_Identifier" title="Unique Ingredient Identifier">UNII</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=4Z8R6ORS6L">4Z8R6ORS6L</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/KEGG" title="KEGG">KEGG</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.kegg.jp/entry/D00754">D00754</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/ChEBI" title="ChEBI">ChEBI</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9513">CHEBI:9513</a></span><sup>&#160;<img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png" width="7" height="8" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/11px-X_mark.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png 2x" data-file-width="525" data-file-height="600" /><span style="display:none">N</span></sup></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/ChEMBL" title="ChEMBL">ChEMBL</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL468">CHEMBL468</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th colspan="2" style="text-align:center;background:#ddd">Chemical data</th>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;--&gt;"><a href="/wiki/Chemical_formula" title="Chemical formula">Formula</a></th>
<td><a href="/wiki/Carbon" title="Carbon"><span style="color: rgb(000,000,000); font-weight: bold;">C</span></a><sub>13</sub><a href="/wiki/Hydrogen" title="Hydrogen"><span style="color: rgb(77,77,77); font-weight: bold;">H</span></a><sub>10</sub><a href="/wiki/Nitrogen" title="Nitrogen"><span style="color: rgb(0,0,128); font-weight: bold;">N</span></a><sub>2</sub><a href="/wiki/Oxygen" title="Oxygen"><span style="color: rgb(116,35,35); font-weight: bold;">O</span></a><sub>4</sub></td>
</tr>
<tr>
<th scope="row" style="padding:0.1em 0; line-height:1.2em;--&gt;"><a href="/wiki/Molecular_mass" title="Molecular mass">Molecular mass</a></th>
<td>258.23 g/mol–</td>
</tr>
<tr>
<td colspan="2" style="text-align:center">
<div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;"><a href="/wiki/Simplified_molecular_input_line_entry_specification" title="Simplified molecular input line entry specification" class="mw-redirect">SMILES</a></div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;">
<li style="line-height: inherit; margin: 0">
<div style="word-wrap:break-word; text-indent:-1.5em">O=C(N1C2CCC(NC2=O)=O)C3=CC=CC=C3C1=O</div>
</li>
</ul>
</div>
</td>
</tr>
<tr>
<td colspan="2" style="text-align:center">
<div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;"><a href="/wiki/International_Chemical_Identifier" title="International Chemical Identifier">InChI</a></div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;">
<li style="line-height: inherit; margin: 0">
<div style="word-wrap:break-word; text-indent:-1.5em">InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)<sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup></div>
</li>
<li style="line-height: inherit; margin: 0">
<div style="word-wrap:break-word; text-indent:-1.5em">Key:UEJJHQNACJXSKW-UHFFFAOYSA-N<sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" data-file-width="600" data-file-height="600" /><span style="display:none">Y</span></sup></div>
</li>
</ul>
</div>
</td>
</tr>
<tr>
<th colspan="2" style="text-align:center;background:#ddd">&#160;<img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/14px-X_mark.svg.png" width="14" height="16" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/21px-X_mark.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/28px-X_mark.svg.png 2x" data-file-width="525" data-file-height="600" /><span style="display:none">N</span>&#160;<a href="/wiki/Wikipedia:WikiProject_Chemicals/Chembox_validation" title="Wikipedia:WikiProject Chemicals/Chembox validation">(what is this?)</a>&#160;&#160;<span class="reflink plainlinks nourlexpansion"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Special:ComparePages&amp;rev1=420478187&amp;page2=Thalidomide">(verify)</a></span></th>
</tr>
</table>
<p><b>Thalidomide</b> (<span class="nowrap"><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English" title="Help:IPA for English">/<span style="border-bottom:1px dotted"><span title="/θ/ 'th' in 'thigh'">θ</span><span title="/ə/ 'a' in 'about'">ə</span><span title="/ˈ/ primary stress follows">ˈ</span><span title="'l' in 'lie'">l</span><span title="/ɪ/ short 'i' in 'bid'">ɪ</span><span title="'d' in 'dye'">d</span><span title="/ə/ 'a' in 'about'">ə</span><span title="'m' in 'my'">m</span><span title="/aɪ/ long 'i' in 'tide'">aɪ</span><span title="'d' in 'dye'">d</span></span>/</a></span></span>; from <a href="/wiki/Phthalimide" title="Phthalimide">ph<i>thali</i>mi<i>do</i></a>-<a href="/wiki/Glutarimide" title="Glutarimide">glutari<i>mide</i></a>,<sup id="cite_ref-2" class="reference"><a href="#cite_note-2"><span>[</span>2<span>]</span></a></sup> currently sold as <b>Immunoprin</b>, <b>Talidex</b>, <b>Talizer</b>, or <b>Thalomid</b>) is an <a href="/wiki/Immunotherapy" title="Immunotherapy">immunomodulatory drug</a> and the prototype of the <a href="/wiki/Discovery_and_development_of_thalidomide_and_its_analogs" title="Discovery and development of thalidomide and its analogs" class="mw-redirect">thalidomide class of drugs</a>.</p>
<p>Today, thalidomide is sold by <a href="/wiki/Celgene_Corporation" title="Celgene Corporation" class="mw-redirect">Celgene</a>, mainly as a treatment of certain cancers (<a href="/wiki/Multiple_myeloma" title="Multiple myeloma">multiple myeloma</a>) and of a complication of <a href="/wiki/Leprosy" title="Leprosy">leprosy</a>.</p>
<p>Thalidomide was first marketed in 1957 in West Germany under the trade-name <b>Contergan</b>. The German drug company <i>Chemie Grünenthal</i> (now <a href="/wiki/Gr%C3%BCnenthal" title="Grünenthal" class="mw-redirect">Grünenthal</a>) developed and sold the drug. Primarily prescribed as a <a href="/wiki/Sedative" title="Sedative">sedative</a> or <a href="/wiki/Hypnotic" title="Hypnotic">hypnotic</a>, thalidomide also claimed to cure “<a href="/wiki/Anxiety" title="Anxiety">anxiety</a>, <a href="/wiki/Insomnia" title="Insomnia">insomnia</a>, <a href="/wiki/Gastritis" title="Gastritis">gastritis</a>, and tension".<sup id="cite_ref-miller_3-0" class="reference"><a href="#cite_note-miller-3"><span>[</span>3<span>]</span></a></sup> Afterwards, it was used against <a href="/wiki/Nausea" title="Nausea">nausea</a> and to alleviate <a href="/wiki/Morning_sickness" title="Morning sickness">morning sickness</a> in pregnant women. Thalidomide became an <a href="/wiki/Over_the_counter" title="Over the counter" class="mw-redirect">over-the-counter</a> drug in Germany on October 1, 1957. Shortly after the drug was sold in Germany, between 5,000 and 7,000 infants were born with <a href="/wiki/Phocomelia" title="Phocomelia">phocomelia</a> (malformation of the limbs). Only 40% of these children survived.<sup id="cite_ref-oncozine.com_4-0" class="reference"><a href="#cite_note-oncozine.com-4"><span>[</span>4<span>]</span></a></sup> Throughout the world, about 10,000 cases were reported of infants with phocomelia due to thalidomide; only 50% of the 10,000 survived. Those subjected to thalidomide while in the womb experienced limb deficiencies in a way that the long limbs either were not developed or presented themselves as stumps. Other effects included deformed eyes and hearts, deformed alimentary and urinary tracts, blindness and deafness.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5"><span>[</span>5<span>]</span></a></sup> The negative effects of thalidomide led to the development of more structured drug regulations and control over drug use and development.<sup id="cite_ref-The_chemical_industry_6-0" class="reference"><a href="#cite_note-The_chemical_industry-6"><span>[</span>6<span>]</span></a></sup></p>
<p></p>
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Medical_uses"><span class="tocnumber">1</span> <span class="toctext">Medical uses</span></a>
<ul>
<li class="toclevel-2 tocsection-2"><a href="#Leprosy_treatment"><span class="tocnumber">1.1</span> <span class="toctext">Leprosy treatment</span></a></li>
<li class="toclevel-2 tocsection-3"><a href="#Cancer_treatment"><span class="tocnumber">1.2</span> <span class="toctext">Cancer treatment</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-4"><a href="#Adverse_effects"><span class="tocnumber">2</span> <span class="toctext">Adverse effects</span></a>
<ul>
<li class="toclevel-2 tocsection-5"><a href="#Carcinogenicity"><span class="tocnumber">2.1</span> <span class="toctext">Carcinogenicity</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Contraindications"><span class="tocnumber">2.2</span> <span class="toctext">Contraindications</span></a></li>
<li class="toclevel-2 tocsection-7"><a href="#Interactions"><span class="tocnumber">2.3</span> <span class="toctext">Interactions</span></a></li>
<li class="toclevel-2 tocsection-8"><a href="#Overdose"><span class="tocnumber">2.4</span> <span class="toctext">Overdose</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-9"><a href="#Mechanism_of_action"><span class="tocnumber">3</span> <span class="toctext">Mechanism of action</span></a>
<ul>
<li class="toclevel-2 tocsection-10"><a href="#Inactivation_of_the_protein_cereblon"><span class="tocnumber">3.1</span> <span class="toctext">Inactivation of the protein cereblon</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-11"><a href="#Pharmacokinetics"><span class="tocnumber">4</span> <span class="toctext">Pharmacokinetics</span></a></li>
<li class="toclevel-1 tocsection-12"><a href="#History"><span class="tocnumber">5</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1 tocsection-13"><a href="#Thalidomide_analogs"><span class="tocnumber">6</span> <span class="toctext">Thalidomide analogs</span></a></li>
<li class="toclevel-1 tocsection-14"><a href="#Society_and_culture"><span class="tocnumber">7</span> <span class="toctext">Society and culture</span></a>
<ul>
<li class="toclevel-2 tocsection-15"><a href="#Regulatory_approved_uses"><span class="tocnumber">7.1</span> <span class="toctext">Regulatory approved uses</span></a></li>
<li class="toclevel-2 tocsection-16"><a href="#Birth_defects_crisis"><span class="tocnumber">7.2</span> <span class="toctext">Birth defects crisis</span></a></li>
<li class="toclevel-2 tocsection-17"><a href="#Aftermath_of_scandal"><span class="tocnumber">7.3</span> <span class="toctext">Aftermath of scandal</span></a>
<ul>
<li class="toclevel-3 tocsection-18"><a href="#Germany"><span class="tocnumber">7.3.1</span> <span class="toctext">Germany</span></a></li>
<li class="toclevel-3 tocsection-19"><a href="#United_Kingdom"><span class="tocnumber">7.3.2</span> <span class="toctext">United Kingdom</span></a></li>
<li class="toclevel-3 tocsection-20"><a href="#Australia"><span class="tocnumber">7.3.3</span> <span class="toctext">Australia</span></a></li>
<li class="toclevel-3 tocsection-21"><a href="#Canada"><span class="tocnumber">7.3.4</span> <span class="toctext">Canada</span></a></li>
<li class="toclevel-3 tocsection-22"><a href="#United_States"><span class="tocnumber">7.3.5</span> <span class="toctext">United States</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-23"><a href="#Notable_people_affected"><span class="tocnumber">7.4</span> <span class="toctext">Notable people affected</span></a></li>
<li class="toclevel-2 tocsection-24"><a href="#Change_in_drug_regulations"><span class="tocnumber">7.5</span> <span class="toctext">Change in drug regulations</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-25"><a href="#Research"><span class="tocnumber">8</span> <span class="toctext">Research</span></a></li>
<li class="toclevel-1 tocsection-26"><a href="#See_also"><span class="tocnumber">9</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-27"><a href="#References"><span class="tocnumber">10</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-28"><a href="#Further_reading"><span class="tocnumber">11</span> <span class="toctext">Further reading</span></a></li>
<li class="toclevel-1 tocsection-29"><a href="#External_links"><span class="tocnumber">12</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
<p></p>
<h2><span class="mw-headline" id="Medical_uses">Medical uses</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=1" title="Edit section: Medical uses">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Thalidomide is used for a number of conditions including <a href="/wiki/Erythema_nodosum_leprosum" title="Erythema nodosum leprosum" class="mw-redirect">erythema nodosum leprosum</a>, <a href="/wiki/Multiple_myeloma" title="Multiple myeloma">multiple myeloma</a> and various other <a href="/wiki/Cancers" title="Cancers" class="mw-redirect">cancers</a>, for some symptoms of <a href="/wiki/HIV/AIDS" title="HIV/AIDS">HIV/AIDS</a>, <a href="/wiki/Crohn%27s_disease" title="Crohn's disease">Crohn's disease</a>, <a href="/wiki/Sarcoidosis" title="Sarcoidosis">sarcoidosis</a>, <a href="/wiki/Graft-versus-host_disease" title="Graft-versus-host disease">graft-versus-host disease</a>, <a href="/wiki/Rheumatoid_arthritis" title="Rheumatoid arthritis">rheumatoid arthritis</a> and a number of skin conditions that have not responded to usual treatment.<sup id="cite_ref-AHFS_7-0" class="reference"><a href="#cite_note-AHFS-7"><span>[</span>7<span>]</span></a></sup> However, there is no good evidence that thalidomide or <a href="/wiki/Lenalidomide" title="Lenalidomide">lenalidomide</a> is useful to bring about or maintain remission in Crohn's disease.<sup id="cite_ref-8" class="reference"><a href="#cite_note-8"><span>[</span>8<span>]</span></a></sup><sup id="cite_ref-9" class="reference"><a href="#cite_note-9"><span>[</span>9<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Leprosy_treatment">Leprosy treatment</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=2" title="Edit section: Leprosy treatment">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In 1964, Israeli physician <a href="/wiki/Jacob_Sheskin" title="Jacob Sheskin">Jacob Sheskin</a> administered thalidomide to a patient critically ill with leprosy. The patient exhibited <a href="/wiki/Erythema_nodosum" title="Erythema nodosum">erythema nodosum leprosum&#160;(ENL)</a>, a painful skin condition, one of the complications of <a href="/wiki/Leprosy" title="Leprosy">leprosy</a>. This was attempted despite the ban on thalidomide's use, but results were favourable: the patient slept for hours and was able to get out of bed without aid upon awakening. A clinical trial studying the use of thalidomide in leprosy soon followed.<sup id="cite_ref-Silverman_10-0" class="reference"><a href="#cite_note-Silverman-10"><span>[</span>10<span>]</span></a></sup></p>
<p>Thalidomide has been used by Brazilian physicians as the drug of choice for the treatment of severe ENL since 1965, and by 1996, at least 33 cases of thalidomide embryopathy were recorded in people born in Brazil after 1965.<sup id="cite_ref-11" class="reference"><a href="#cite_note-11"><span>[</span>11<span>]</span></a></sup> Since 1994, the production, dispensing, and prescription of thalidomide have been strictly controlled, requiring women to use two forms of birth control and submit to regular pregnancy tests. Despite this, cases of thalidomide embryopathy continue,<sup id="cite_ref-12" class="reference"><a href="#cite_note-12"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-13" class="reference"><a href="#cite_note-13"><span>[</span>13<span>]</span></a></sup> with at least 100 cases identified in Brazil between 2005 and 2010.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14"><span>[</span>14<span>]</span></a></sup> 5.8 million thalidomide pills were distributed throughout Brazil in this time period, largely to poor Brazilians in areas with poor access to healthcare, and these cases have occurred despite the controls.</p>
<p>In 1998 the FDA approved the drug's use in the treatment of ENL.<sup id="cite_ref-nyt-fda_15-0" class="reference"><a href="#cite_note-nyt-fda-15"><span>[</span>15<span>]</span></a></sup> Because of thalidomide's potential for causing birth defects, the drug may be distributed only under tightly controlled conditions. The FDA required that <a href="/wiki/Celgene_Corporation" title="Celgene Corporation" class="mw-redirect">Celgene Corporation</a>, which planned to market thalidomide under the brand name <i>Thalomid</i>, establish a system for thalidomide education and prescribing safety (STEPS) oversight program. The conditions required under the program include limiting prescription and dispensing rights to authorized prescribers and pharmacies only, keeping a registry of all patients prescribed thalidomide, providing extensive patient education about the risks associated with the drug, and providing periodic pregnancy tests for women who take the drug.<sup id="cite_ref-nyt-fda_15-1" class="reference"><a href="#cite_note-nyt-fda-15"><span>[</span>15<span>]</span></a></sup></p>
<p>More recently, the <a href="/wiki/World_Health_Organisation" title="World Health Organisation" class="mw-redirect">World Health Organisation (WHO)</a> has stated:</p>
<blockquote>
<p>"The WHO does not recommend the use of thalidomide in leprosy as experience has shown that it is virtually impossible to develop and implement a fool-proof surveillance mechanism to combat misuse of the drug. The drug <a href="/wiki/Clofazimine" title="Clofazimine">clofazimine</a> is now a component of the multidrug therapy (MDT), introduced by WHO in 1981 as the standard treatment for leprosy and now supplied free of charge to all patients worldwide."<sup id="cite_ref-16" class="reference"><a href="#cite_note-16"><span>[</span>16<span>]</span></a></sup></p>
</blockquote>
<h3><span class="mw-headline" id="Cancer_treatment">Cancer treatment</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=3" title="Edit section: Cancer treatment">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Thalidomide was initially tested in humans as a single agent for the treatment of <a href="/wiki/Multiple_myeloma" title="Multiple myeloma">multiple myeloma</a> due to its anti-angiogenic activity.<sup id="cite_ref-nejm-myeloma_17-0" class="reference"><a href="#cite_note-nejm-myeloma-17"><span>[</span>17<span>]</span></a></sup> The early foundation for this work was laid out in a 1993 keynote lecture at the American Society of Hematology by Dr. Folkman when he hypothesized that all blood borne malignancies are angiogenesis-dependent, based upon his discovery that the levels of the angiogenic growth factor FGF were elevated in the urine of patients with leukaemia.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18"><span>[</span>18<span>]</span></a></sup> Further studies in his lab showed efficacy with the angiogenesis inhibitor TNP-470 in mouse models of leukaemia. Additionally, in 1994 Vacca had shown a fivefold increase in angiogenesis in the bone marrow of multiple myeloma patients.<sup id="cite_ref-19" class="reference"><a href="#cite_note-19"><span>[</span>19<span>]</span></a></sup> When the family of a patient with late stage multiple myeloma requested any possible help from Dr. Folkman in 1997, he attempted to obtain TNP-470 as a therapy. However TNP-470 could not be obtained outside of the ongoing clinical trial and thus Dr. D'Amato suggested that thalidomide be used instead for this patient.<sup id="cite_ref-vectorblog.org_20-0" class="reference"><a href="#cite_note-vectorblog.org-20"><span>[</span>20<span>]</span></a></sup> A small study was then initiated with thalidomide for this patient and several others by Dr. Bart Barlogie with dramatic effects.<sup id="cite_ref-nejm-myeloma_17-1" class="reference"><a href="#cite_note-nejm-myeloma-17"><span>[</span>17<span>]</span></a></sup> Since then, many studies have shown that thalidomide, in combination with <a href="/wiki/Dexamethasone" title="Dexamethasone">dexamethasone</a>, has increased the survival of multiple myeloma patients.</p>
<p>In the 2000s, the combination of thalidomide and dexamethasone, often in combination with <a href="/wiki/Melphalan" title="Melphalan">melphalan</a>, became one of the most common regimens for patients with newly diagnosed multiple myeloma.<sup id="cite_ref-21" class="reference"><a href="#cite_note-21"><span>[</span>21<span>]</span></a></sup><sup id="cite_ref-denz_22-0" class="reference"><a href="#cite_note-denz-22"><span>[</span>22<span>]</span></a></sup> Thalidomide may also cause side effects, such as <a href="/wiki/Polyneuropathy" title="Polyneuropathy">polyneuropathy</a>, fatigue, skin rash, and <a href="/wiki/Venous_thromboembolism" title="Venous thromboembolism" class="mw-redirect">venous thromboembolism (VTE)</a>, or blood clots, which could lead to <a href="/wiki/Stroke" title="Stroke">stroke</a> or <a href="/wiki/Myocardial_infarction" title="Myocardial infarction">myocardial infarction</a>.<sup id="cite_ref-pmid18182082_23-0" class="reference"><a href="#cite_note-pmid18182082-23"><span>[</span>23<span>]</span></a></sup><sup id="cite_ref-24" class="reference"><a href="#cite_note-24"><span>[</span>24<span>]</span></a></sup></p>
<p>In 2006 the U.S.&#160;Food and Drug Administration granted accelerated approval for thalidomide in combination with dexamethasone for the treatment of newly diagnosed <a href="/wiki/Multiple_myeloma" title="Multiple myeloma">multiple myeloma</a> patients.<sup id="cite_ref-25" class="reference"><a href="#cite_note-25"><span>[</span>25<span>]</span></a></sup> The FDA approval came seven years after the first reports of efficacy in the medical literature<sup id="cite_ref-Desikan_26-0" class="reference"><a href="#cite_note-Desikan-26"><span>[</span>26<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Adverse_effects">Adverse effects</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=4" title="Edit section: Adverse effects">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p><b><big>Adverse effects by frequency:</big></b><sup id="cite_ref-DM_27-0" class="reference"><a href="#cite_note-DM-27"><span>[</span>27<span>]</span></a></sup><sup id="cite_ref-MSR_28-0" class="reference"><a href="#cite_note-MSR-28"><span>[</span>28<span>]</span></a></sup><sup id="cite_ref-EMC_29-0" class="reference"><a href="#cite_note-EMC-29"><span>[</span>29<span>]</span></a></sup><sup id="cite_ref-TGA_30-0" class="reference"><a href="#cite_note-TGA-30"><span>[</span>30<span>]</span></a></sup><br />
<b>Very common (may affect more than 1 in 10 people):</b></p>
<div class="div-col columns column-count column-count-4" style="-moz-column-count: 4; -webkit-column-count: 4; column-count: 4;">
<ul>
<li>Somnolence (drowsiness; ~40%)</li>
<li><a href="/wiki/Edema" title="Edema">Edema</a> (~60%)</li>
<li>Hypotension (low blood pressure)</li>
<li>Headache</li>
<li>Haematuria (blood in the urine)</li>
<li>Arthralgia (joint pain)</li>
<li>Myalgia (muscle aches)</li>
<li>Increased bilirubin</li>
<li><a href="/wiki/Neutropenia" title="Neutropenia">Neutropenia</a> (~30%)</li>
<li><a href="/wiki/Leucopenia" title="Leucopenia" class="mw-redirect">Leucopenia</a> (~15-40%)</li>
<li><a href="/wiki/Lymphopenia" title="Lymphopenia" class="mw-redirect">Lymphopenia</a></li>
<li>Constipation</li>
<li><a href="/wiki/Peripheral_neuropathy" title="Peripheral neuropathy">Peripheral neuropathy</a><sup>†</sup></li>
<li>Dizziness</li>
<li><a href="/wiki/Paraesthesia" title="Paraesthesia" class="mw-redirect">Paraesthesia</a></li>
<li><a href="/wiki/Dysaesthesia" title="Dysaesthesia" class="mw-redirect">Dysaesthesia</a></li>
</ul>
</div>
<p><b>Common (may affect up to 1 in 10 people):</b></p>
<div class="div-col columns column-count column-count-4" style="-moz-column-count: 4; -webkit-column-count: 4; column-count: 4;">
<ul>
<li>Pulmonary embolism</li>
<li>Vomiting</li>
<li>Dry mouth</li>
<li>Toxic skin eruption</li>
<li>Dry skin</li>
<li>Rash</li>
<li>Urticaria (hives)</li>
<li>Pyrexia (fever)</li>
<li>Asthenia</li>
<li><a href="/wiki/Interstitial_lung_disease" title="Interstitial lung disease">Interstitial lung disease</a></li>
<li>Heart failure</li>
<li>Depression</li>
<li><a href="/wiki/Pneumonia" title="Pneumonia">Pneumonia</a></li>
</ul>
</div>
<p><b>Uncommon (may affect up to 1 in 100 people):</b></p>
<ul>
<li>Dyspnoea (shortness of breath/breathlessness)</li>
<li>Tremor</li>
</ul>
<p><b>Rare (may affect up to 1 in 1,000 people):</b></p>
<div class="div-col columns column-count column-count-4" style="-moz-column-count: 4; -webkit-column-count: 4; column-count: 4;">
<ul>
<li>Increased appetite</li>
<li>Bradycardia (low heart rate)</li>
<li>Tachycardia (high heart rate)</li>
<li>Cardiac arrhythmia</li>
<li>Malaise</li>
<li>Deep vein thrombosis</li>
</ul>
</div>
<p><b>Very rare (may affect up to 1 in 10,000 people):</b></p>
<div class="div-col columns column-count column-count-4" style="-moz-column-count: 4; -webkit-column-count: 4; column-count: 4;">
<ul>
<li><a href="/wiki/Thrombocytopenia" title="Thrombocytopenia">Thrombocytopenia</a></li>
<li>Anaemia</li>
<li><a href="/wiki/Hypothyroidism" title="Hypothyroidism">Hypothyroidism</a></li>
<li>Reduced libido</li>
<li>Confusion</li>
<li>Seizures</li>
<li>Orthostatic hypotension</li>
<li>Thromboembolic events</li>
<li>Bronchospasm</li>
<li>Intestinal obstruction</li>
<li>Pruritus (itchiness)</li>
<li><a href="/wiki/Stevens-Johnson_syndrome" title="Stevens-Johnson syndrome" class="mw-redirect">Stevens-Johnson syndrome</a></li>
<li><a href="/wiki/Toxic_epidermal_necrolysis" title="Toxic epidermal necrolysis">Toxic epidermal necrolysis</a></li>
<li>Facial oedema</li>
<li>Photosensitivity (light sensitivity)</li>
<li>Menstruation abnormalities</li>
</ul>
</div>
<p>† Peripheral neuropathy may be irreversible and usually results from chronic (usually a matter of months) exposure to thalidomide.<sup id="cite_ref-EMC_29-1" class="reference"><a href="#cite_note-EMC-29"><span>[</span>29<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Carcinogenicity">Carcinogenicity</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=5" title="Edit section: Carcinogenicity">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Animal studies have failed to demonstrate any <a href="/wiki/Carcinogen" title="Carcinogen">carcinogenicity</a> even when rats and mice were exposed to up to 11 times the therapeutic dose of thalidomide.<sup id="cite_ref-TGA_30-1" class="reference"><a href="#cite_note-TGA-30"><span>[</span>30<span>]</span></a></sup> Despite this there have been some concerns that it may cause secondary malignancies in patients with multiple myeloma. The FDA has issued a statement that it is investigating these concerns.<sup id="cite_ref-31" class="reference"><a href="#cite_note-31"><span>[</span>31<span>]</span></a></sup></p>
<p>Some clinical trials have supported this claim and the major secondary malignancy that thalidomide is associated with is <a href="/wiki/Acute_myeloid_leukaemia" title="Acute myeloid leukaemia" class="mw-redirect">acute myeloid leukaemia</a>.<sup id="cite_ref-32" class="reference"><a href="#cite_note-32"><span>[</span>32<span>]</span></a></sup> The <a href="/wiki/Medicines_and_Healthcare_products_Regulatory_Agency" title="Medicines and Healthcare products Regulatory Agency" class="mw-redirect">MHRA</a> of the <a href="/wiki/United_Kingdom" title="United Kingdom">UK</a> and <a href="/wiki/Health_Canada" title="Health Canada">Health Canada</a> of <a href="/wiki/Canada" title="Canada">Canada</a> have also issued warnings to healthcare professionals regarding the risk of secondary malignancies due to thalidomide exposure.<sup id="cite_ref-33" class="reference"><a href="#cite_note-33"><span>[</span>33<span>]</span></a></sup><sup id="cite_ref-34" class="reference"><a href="#cite_note-34"><span>[</span>34<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Contraindications">Contraindications</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=6" title="Edit section: Contraindications">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Contraindications include:<sup id="cite_ref-TGA_30-2" class="reference"><a href="#cite_note-TGA-30"><span>[</span>30<span>]</span></a></sup></p>
<ul>
<li>Known hypersensitivity to thalidomide</li>
<li>Pregnancy or breastfeeding</li>
<li>Patient age &lt; 12 years</li>
<li>Patients who are unable or unwilling to comply with required contraceptive measures</li>
</ul>
<h3><span class="mw-headline" id="Interactions">Interactions</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=7" title="Edit section: Interactions">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>There are no expected pharmacokinetic interactions between thalidomide and other medicines due to its neutral effects on p-glycoprotein and P450 cytochromes.<sup id="cite_ref-TGA_30-3" class="reference"><a href="#cite_note-TGA-30"><span>[</span>30<span>]</span></a></sup> It may interact with sedatives due to its sedative action.<sup id="cite_ref-TGA_30-4" class="reference"><a href="#cite_note-TGA-30"><span>[</span>30<span>]</span></a></sup> It may also interact with bradycardic agents due to its bradycardia-inducing effects.<sup id="cite_ref-TGA_30-5" class="reference"><a href="#cite_note-TGA-30"><span>[</span>30<span>]</span></a></sup> The risk of peripheral neuropathy may be increased by concomitant treatment with other agents known to cause peripheral neuropathy.<sup id="cite_ref-TGA_30-6" class="reference"><a href="#cite_note-TGA-30"><span>[</span>30<span>]</span></a></sup> The risk of venous thromboembolisms with thalidomide seems to be increased when patients are treated with oral contraceptives or other cytotoxic agents (including doxorubicin and melphalan) concurrently.<sup id="cite_ref-TGA_30-7" class="reference"><a href="#cite_note-TGA-30"><span>[</span>30<span>]</span></a></sup> Thalidomide may interfere with the contraceptive effects of various contraceptives and hence it is advised that women of reproductive age use at least two different means of contraception to ensure that no child will be conceived while they are receiving thalidomide.<sup id="cite_ref-TGA_30-8" class="reference"><a href="#cite_note-TGA-30"><span>[</span>30<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Overdose">Overdose</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=8" title="Edit section: Overdose">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Eighteen cases of overdoses have been reported to date with doses of up to 14.4 g without any reported fatalities.<sup id="cite_ref-TGA_30-9" class="reference"><a href="#cite_note-TGA-30"><span>[</span>30<span>]</span></a></sup> No specific antidote for overdoses exists and treatment is purely supportive.<sup id="cite_ref-TGA_30-10" class="reference"><a href="#cite_note-TGA-30"><span>[</span>30<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Mechanism_of_action">Mechanism of action</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=9" title="Edit section: Mechanism of action">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>The precise mechanism of action for thalidomide is unknown, but possible mechanisms include anti-angiogenic and oxidative stress-inducing effects.<sup id="cite_ref-mech_35-0" class="reference"><a href="#cite_note-mech-35"><span>[</span>35<span>]</span></a></sup> It also inhibits <a href="/wiki/Tumor_necrosis_factor_alpha" title="Tumor necrosis factor alpha">TNF-α</a>, <a href="/wiki/Interleukin_6" title="Interleukin 6">IL-6</a>, <a href="/wiki/Interleukin_10" title="Interleukin 10">IL-10</a> and <a href="/wiki/Interleukin_12" title="Interleukin 12">IL-12</a> production,<sup id="cite_ref-mech2_36-0" class="reference"><a href="#cite_note-mech2-36"><span>[</span>36<span>]</span></a></sup> modulates the production of <a href="/wiki/Interferon_gamma" title="Interferon gamma">IFN-γ</a><sup id="cite_ref-mech2_36-1" class="reference"><a href="#cite_note-mech2-36"><span>[</span>36<span>]</span></a></sup> and enhances the production of <a href="/wiki/Interleukin_2" title="Interleukin 2">IL-2</a>, <a href="/wiki/Interleukin_4" title="Interleukin 4">IL-4</a> and <a href="/wiki/Interleukin_5" title="Interleukin 5">IL-5</a> by immune cells.<sup id="cite_ref-mech2_36-2" class="reference"><a href="#cite_note-mech2-36"><span>[</span>36<span>]</span></a></sup> It increases lymphocyte count, costimulates T cells and modulates <a href="/wiki/Natural_killer_cell" title="Natural killer cell">natural killer cell</a> cytotoxicity.<sup id="cite_ref-mech2_36-3" class="reference"><a href="#cite_note-mech2-36"><span>[</span>36<span>]</span></a></sup> It also inhibits <a href="/wiki/NF-%CE%BAB" title="NF-κB">NF-κB</a> and <a href="/wiki/Cyclooxygenase_2" title="Cyclooxygenase 2" class="mw-redirect">COX-2</a> activity.<sup id="cite_ref-mech_35-1" class="reference"><a href="#cite_note-mech-35"><span>[</span>35<span>]</span></a></sup></p>
<p>In 1990, a group of researchers in Brazil noted that <a href="/wiki/TNF_alpha" title="TNF alpha" class="mw-redirect">TNF alpha</a> levels went up in leprosy reactional states and observed that TNF levels decreased in some patients on treatment with thalidomide, hence potentially explaining the efficacy of thalidomide in treating ENL.<sup id="cite_ref-37" class="reference"><a href="#cite_note-37"><span>[</span>37<span>]</span></a></sup></p>
<p>The mechanism of thalidomide's <a href="/wiki/Teratology" title="Teratology">teratogenic</a> action has led to over 2000 research papers and the proposal of 15 or 16 plausible mechanisms.<sup id="cite_ref-Stephens_38-0" class="reference"><a href="#cite_note-Stephens-38"><span>[</span>38<span>]</span></a></sup> <a href="/wiki/Angiogenesis" title="Angiogenesis">Angiogenesis</a> is critical during limb development of the foetus. Thalidomide can directly inhibit angiogenesis induced by bFGF or VEGF <i>in vivo</i>.<sup id="cite_ref-pmid7513432_39-0" class="reference"><a href="#cite_note-pmid7513432-39"><span>[</span>39<span>]</span></a></sup> Teratogenic analogs inhibit angiogenesis whereas nonteratogenic analogs do not inhibit angiogenesis.<sup id="cite_ref-pmid7513432_39-1" class="reference"><a href="#cite_note-pmid7513432-39"><span>[</span>39<span>]</span></a></sup> In 2009, research by other groups confirmed "conclusively that loss of newly formed blood vessels is the primary cause of thalidomide teratogenesis, and developing limbs are particularly susceptible because of their relatively immature, highly angiogenic vessel network".<sup id="cite_ref-40" class="reference"><a href="#cite_note-40"><span>[</span>40<span>]</span></a></sup> Thus the accepted theory is that inhibition of angiogenesis is the mechanism of teratogenicity as originally proposed by D'Amato in 1994.</p>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Thalidomide-structures.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/bb/Thalidomide-structures.png/220px-Thalidomide-structures.png" width="220" height="119" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/bb/Thalidomide-structures.png/330px-Thalidomide-structures.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/bb/Thalidomide-structures.png/440px-Thalidomide-structures.png 2x" data-file-width="1100" data-file-height="594" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Thalidomide-structures.png" class="internal" title="Enlarge"></a></div>
The two enantiomers of thalidomide:<br />
Left: (<i>S</i>)-thalidomide<br />
Right: (<i>R</i>)-thalidomide</div>
</div>
</div>
<p>Thalidomide is <a href="/wiki/Racemic_mixture" title="Racemic mixture">racemic</a>; the individual enantiomers can <a href="/wiki/Racemization" title="Racemization">racemize</a> due to the acidic hydrogen at the <a href="/wiki/Chiral_centre" title="Chiral centre" class="mw-redirect">chiral centre</a>, which is the carbon of the glutarimide ring bonded to the phthalimide substituent. The racemization process can occur <i><a href="/wiki/In_vivo" title="In vivo">in vivo</a></i><sup id="cite_ref-clinp_1-4" class="reference"><a href="#cite_note-clinp-1"><span>[</span>1<span>]</span></a></sup><sup id="cite_ref-stereospecific44_41-0" class="reference"><a href="#cite_note-stereospecific44-41"><span>[</span>41<span>]</span></a></sup><sup id="cite_ref-Muller_1996_42-0" class="reference"><a href="#cite_note-Muller_1996-42"><span>[</span>42<span>]</span></a></sup><sup id="cite_ref-pmid14505639_43-0" class="reference"><a href="#cite_note-pmid14505639-43"><span>[</span>43<span>]</span></a></sup> so that any plan to administer a purified single enantiomer to avoid the teratogenic effects will most likely be in vain.<sup id="cite_ref-Muller_1996_42-1" class="reference"><a href="#cite_note-Muller_1996-42"><span>[</span>42<span>]</span></a></sup><sup id="cite_ref-Bartlett2004_44-0" class="reference"><a href="#cite_note-Bartlett2004-44"><span>[</span>44<span>]</span></a></sup><sup id="cite_ref-pmid19256507_45-0" class="reference"><a href="#cite_note-pmid19256507-45"><span>[</span>45<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Inactivation_of_the_protein_cereblon">Inactivation of the protein cereblon</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=10" title="Edit section: Inactivation of the protein cereblon">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Thalidomide binds to and inactivates the protein <a href="/wiki/Cereblon" title="Cereblon">cereblon</a>, which is important in limb formation<sup id="cite_ref-nyt-answers_46-0" class="reference"><a href="#cite_note-nyt-answers-46"><span>[</span>46<span>]</span></a></sup> and for the proliferative capacity of myeloma cells. This was confirmed in studies that reduced the production of cereblon in developing chick and zebrafish embryos using genetic techniques. These embryos had defects similar to those treated with thalidomide.</p>
<p>However, the finding that cereblon inhibition is responsible for the teratogenic activity of thalidomide in the chick and zebrafish was cast into doubt due to a recent report that <a href="/wiki/Pomalidomide" title="Pomalidomide">pomalidomide</a>, a more potent thalidomide analog, does not cause teratogenic effects in these same model systems despite the fact that it is a stronger inhibitor of cereblon than thalidomide.<sup id="cite_ref-pmid23858438_47-0" class="reference"><a href="#cite_note-pmid23858438-47"><span>[</span>47<span>]</span></a></sup><sup id="cite_ref-pmid22552008_48-0" class="reference"><a href="#cite_note-pmid22552008-48"><span>[</span>48<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Pharmacokinetics">Pharmacokinetics</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=11" title="Edit section: Pharmacokinetics">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<table class="metadata plainlinks ambox ambox-content ambox-Unreferenced" role="presentation">
<tr>
<td class="mbox-image">
<div style="width:52px"><a href="/wiki/File:Question_book-new.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/50px-Question_book-new.svg.png" width="50" height="39" srcset="//upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/75px-Question_book-new.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/9/99/Question_book-new.svg/100px-Question_book-new.svg.png 2x" data-file-width="262" data-file-height="204" /></a></div>
</td>
<td class="mbox-text"><span class="mbox-text-span">This section <b>does not <a href="/wiki/Wikipedia:Citing_sources" title="Wikipedia:Citing sources">cite</a> any <a href="/wiki/Wikipedia:Verifiability" title="Wikipedia:Verifiability">references or sources</a></b>. <span class="hide-when-compact">Please help improve this section by <a href="/wiki/Help:Introduction_to_referencing/1" title="Help:Introduction to referencing/1">adding citations to reliable sources</a>. Unsourced material may be challenged and <a href="/wiki/Wikipedia:Verifiability#Burden_of_evidence" title="Wikipedia:Verifiability">removed</a>.</span> <small><i>(March 2014)</i></small></span></td>
</tr>
</table>
<table class="wikitable">
<caption><b><big>Pharmacokinetic parameters of Thalidomide</big></b></caption>
<tr>
<th>C<sub>max</sub></th>
<th>T<sub>max</sub></th>
<th>Half-life</th>
<th>Bioavailability</th>
<th>Plasma protein binding</th>
<th>Volume of distribution</th>
<th>Urine clearance</th>
<th>Excretion</th>
</tr>
<tr>
<td>1.15-3.2&#160;µg/mL</td>
<td>3–6 hours</td>
<td>5–7 hours</td>
<td>90%</td>
<td>55-66%</td>
<td>122&#160;L</td>
<td>1.15&#160;mL/min</td>
<td>Urine (91.9%)</td>
</tr>
</table>
<h2><span class="mw-headline" id="History">History</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=12" title="Edit section: History">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Thalidomide was developed by German pharmaceutical company <i>Chemie Grünenthal</i> (now <i><a href="/wiki/Gr%C3%BCnenthal_GmbH" title="Grünenthal GmbH">Grünenthal GmbH</a></i>).<sup id="cite_ref-oncozine.com_4-1" class="reference"><a href="#cite_note-oncozine.com-4"><span>[</span>4<span>]</span></a></sup><sup id="cite_ref-49" class="reference"><a href="#cite_note-49"><span>[</span>49<span>]</span></a></sup> After obtaining a twenty-year patent in April 1954, Chemie Grünenthal started clinical trials and as early as November 1956 marketed thalidomide for the treatment of respiratory infections under the trade name <i>Grippex</i>, a combination drug that contained thalidomide, quinine, vitamin C, phenactin and acetylsalicylic-acid.</p>
<p>Researchers at <i>Chemie Grünenthal</i> also found that thalidomide was a particularly effective <a href="/wiki/Antiemetic" title="Antiemetic">antiemetic</a> that had an inhibitory effect on <a href="/wiki/Morning_sickness" title="Morning sickness">morning sickness</a>.<sup id="cite_ref-pmid15172781_50-0" class="reference"><a href="#cite_note-pmid15172781-50"><span>[</span>50<span>]</span></a></sup> Hence, on October 1, 1957, the company launched thalidomide and began aggressively marketing it under the trade name <i>Contergan</i>®.<sup id="cite_ref-Bombay_51-0" class="reference"><a href="#cite_note-Bombay-51"><span>[</span>51<span>]</span></a></sup> It was proclaimed a "wonder drug" for <a href="/wiki/Insomnia" title="Insomnia">insomnia</a>, coughs, colds and headaches.</p>
<p>During this time period, the use of medications during pregnancy was not strictly controlled, and drugs were not thoroughly tested for potential harm to the foetus.<sup id="cite_ref-pmid15172781_50-1" class="reference"><a href="#cite_note-pmid15172781-50"><span>[</span>50<span>]</span></a></sup> Thousands of pregnant women took the drug to relieve their symptoms. At the time of the drug's development, scientists did not believe any drug taken by a pregnant woman could pass across the <a href="/wiki/Placental_barrier" title="Placental barrier" class="mw-redirect">placental barrier</a> and harm the developing <a href="/wiki/Foetus" title="Foetus" class="mw-redirect">foetus</a>,<sup id="cite_ref-The_chemical_industry_6-1" class="reference"><a href="#cite_note-The_chemical_industry-6"><span>[</span>6<span>]</span></a></sup> even though the effect of alcohol on foetal development had been documented by case studies on alcoholic mothers since at least 1957.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52"><span>[</span>52<span>]</span></a></sup> There soon appeared reports of findings of abnormalities in children being born, traced back to the use of the drug thalidomide. In late 1959, it was noticed that <a href="/wiki/Peripheral_neuritis" title="Peripheral neuritis" class="mw-redirect">peripheral neuritis</a> developed in patients who took the drug over a period of time, and it was only after this point that thalidomide ceased to be provided over the counter.<sup id="cite_ref-53" class="reference"><a href="#cite_note-53"><span>[</span>53<span>]</span></a></sup></p>
<p>Hence, while initially considered safe, the drug was responsible for <a href="/wiki/Teratology" title="Teratology">teratogenic</a> deformities in children born after their mothers used it during pregnancies, prior to the third trimester. In November 1961, thalidomide was taken off the market due to massive pressure from the press and public.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (June 2015)">citation needed</span></a></i>]</sup> Experts estimate that the drug thalidomide led to the death of approximately 2,000 children and serious birth defects in more than 10,000 children, about 5,000 of them in <a href="/wiki/West_Germany" title="West Germany">West Germany</a>. The regulatory authorities in <a href="/wiki/East_Germany" title="East Germany">East Germany</a> did not approve thalidomide.<sup id="cite_ref-oncozine.com_4-2" class="reference"><a href="#cite_note-oncozine.com-4"><span>[</span>4<span>]</span></a></sup> One reason for the initially unobserved side effects of the drug and the subsequent approval in Germany was that at that time drugs did not have to be tested for <a href="/wiki/Teratogenic" title="Teratogenic" class="mw-redirect">teratogenic</a> effects. They had been tested on rodents only, as was usual at the time.<sup id="cite_ref-VFA_54-0" class="reference"><a href="#cite_note-VFA-54"><span>[</span>54<span>]</span></a></sup></p>
<p>Thalidomide became one of the most successful prescription drugs in the history of medicine. In the UK, the British pharmaceutical company <i>The Distillers Company (Biochemicals) Ltd,</i> a subsidiary of <i>Distillers Co. Ltd</i>. (now part of <a href="/wiki/Diageo_plc" title="Diageo plc" class="mw-redirect">Diageo plc</a>), marketed thalidomide under the brand name <i>Distaval</i>® as a remedy for <a href="/wiki/Morning_sickness" title="Morning sickness">morning sickness</a> throughout the United Kingdom, Australia and New Zealand. Their advertisement claimed that "Distaval can be given with complete safety to pregnant women and nursing mothers without adverse effect on mother or child...Outstandingly safe Distaval has been prescribed for nearly three years in this country."<sup class="noprint Inline-Template"><span style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Link_rot" title="Wikipedia:Link rot"><span title="&#160;since June 2014">dead link</span></a></i>]</span></sup><sup id="cite_ref-oncozine.com_4-3" class="reference"><a href="#cite_note-oncozine.com-4"><span>[</span>4<span>]</span></a></sup> Around the world, more and more pharmaceutical companies started to produce and market the drug under license from <i>Chemie Grünenthal</i>. By the mid 1950s, 14 pharmaceutical companies were marketing thalidomide in 46 countries under 37 (some reports suggest 51) different trade names.</p>
<p>In the U.S., representatives from <i>Chemie Grünenthal</i> approached <i>Smith, Kline &amp; French</i> (SKF), now <a href="/wiki/GlaxoSmithKline" title="GlaxoSmithKline">GlaxoSmithKline</a> (GSK) with a request to market and distribute the drug in North America. A newly discovered memorandum (found hidden in 2010 in the archives of the U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)) shows that, as part of their in-licensing approach, <i>Smith, Kline and French</i> conducted animal tests and ran a clinical trial of the drug in the United States involving 875 people, including pregnant women, in 1956–57. In 1956, researchers at SKF involved in clinical trials noted that even when used in very high doses, thalidomide could not induce sleep in mice. And when administered at doses 50 to 650 times larger than that claimed by Chemie Grunenthal to be "sleep inducing", the researchers could still not achieve the hypnotic effect in animals that it had on humans. After completion of the trial, and based on reasons kept hidden for decades, SKF declined to commercialize the drug. Later, <i>Chemie Grünenthal</i>, in 1958, reached an agreement with <i>William S Merrell Company</i> in Cincinnati, Ohio, (<a href="/wiki/Marion_Merrell_Dow#Richardson-Merrell" title="Marion Merrell Dow">later Richardson-Merrell</a>, now part of <a href="/wiki/Sanofi" title="Sanofi">Sanofi</a>), to market and distribute thalidomide throughout the United States.<sup class="noprint Inline-Template"><span style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Link_rot" title="Wikipedia:Link rot"><span title="&#160;since June 2014">dead link</span></a></i>]</span></sup><sup id="cite_ref-oncozine.com_4-4" class="reference"><a href="#cite_note-oncozine.com-4"><span>[</span>4<span>]</span></a></sup></p>
<p>The U.S FDA refused to approve thalidomide for marketing and distribution. However, the drug was distributed in large quantities for testing purposes, after the American distributor and manufacturer <a href="/wiki/Marion_Merrell_Dow#Richardson-Merrell" title="Marion Merrell Dow">Richardson-Merrell</a> had applied for its approval in September 1960. The official in charge of the FDA, <a href="/wiki/Frances_Oldham_Kelsey" title="Frances Oldham Kelsey">Frances Oldham Kelsey</a>, did not rely on information from the company which did not include any test results. Richardson-Merrell was called on to perform tests and report the results. The company refused and demanded approval six times, and was refused each time. Nevertheless, a total of 17 children with thalidomide-induced malformations were born.<sup id="cite_ref-55" class="reference"><a href="#cite_note-55"><span>[</span>55<span>]</span></a></sup></p>
<p>In Canada, the history of the drug thalidomide dates back to April 1, 1961. There were many different forms sold, with the most common variant being Talimol.<sup id="cite_ref-pmid14076167_56-0" class="reference"><a href="#cite_note-pmid14076167-56"><span>[</span>56<span>]</span></a></sup> Two months after Talimol went on sale, pharmaceutical companies sent physicians letters warning about the risk of birth defects.<sup id="cite_ref-pmid14076167_56-1" class="reference"><a href="#cite_note-pmid14076167-56"><span>[</span>56<span>]</span></a></sup> It was not until March 2, 1962, that both drugs were banned from the Canadian market by the FDD, and soon afterward physicians were warned to destroy their supplies.<sup id="cite_ref-pmid14076167_56-2" class="reference"><a href="#cite_note-pmid14076167-56"><span>[</span>56<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Thalidomide_analogs">Thalidomide analogs</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=13" title="Edit section: Thalidomide analogs">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="hatnote relarticle mainarticle">Main article: <a href="/wiki/Development_of_analogs_of_thalidomide" title="Development of analogs of thalidomide">Development of analogs of thalidomide</a></div>
<p>The exploration of the <a href="/wiki/Antiangiogenic" title="Antiangiogenic" class="mw-redirect">antiangiogenic</a> and immunomodulatory activities of thalidomide has led to the study and creation of thalidomide <a href="/wiki/Analog_(chemistry)" title="Analog (chemistry)" class="mw-redirect">analogs</a>.<sup id="cite_ref-pmid10447943_57-0" class="reference"><a href="#cite_note-pmid10447943-57"><span>[</span>57<span>]</span></a></sup><sup id="cite_ref-pmid11740816_58-0" class="reference"><a href="#cite_note-pmid11740816-58"><span>[</span>58<span>]</span></a></sup> Celgene has sponsored numerous clinical trials with analogues to thalidomide, such as <a href="/wiki/Lenalidomide" title="Lenalidomide">lenalidomide</a>, that are substantially more powerful and have fewer side effects&#160;— except for greater <a href="/wiki/Myelosuppression" title="Myelosuppression" class="mw-redirect">myelosuppression</a>.<sup id="cite_ref-59" class="reference"><a href="#cite_note-59"><span>[</span>59<span>]</span></a></sup> In 2005, Celgene received FDA approval for <a href="/wiki/Lenalidomide" title="Lenalidomide">lenalidomide</a> (Revlimid) as the first commercially useful derivative. Revlimid is available only in a restricted distribution setting to avoid its use during pregnancy. Further studies are being conducted to find safer compounds with useful qualities. Another more potent analog, <a href="/wiki/Pomalidomide" title="Pomalidomide">pomalidomide</a>, is now FDA approved.<sup id="cite_ref-60" class="reference"><a href="#cite_note-60"><span>[</span>60<span>]</span></a></sup> These <a href="/wiki/Discovery_and_development_of_thalidomide_and_its_analogs" title="Discovery and development of thalidomide and its analogs" class="mw-redirect">thalidomide analogs</a> can be used to treat different diseases, or used in a regimen to fight two conditions.<sup id="cite_ref-61" class="reference"><a href="#cite_note-61"><span>[</span>61<span>]</span></a></sup></p>
<p>Interest turned to <a href="/wiki/Pomalidomide" title="Pomalidomide">Pomalidomide</a>, a <a href="/wiki/Derivative_(chemistry)" title="Derivative (chemistry)">derivative</a> of thalidomide marketed by <a href="/wiki/Celgene_Corporation" title="Celgene Corporation" class="mw-redirect">Celgene</a>. It is a very active anti-angiogenic and also acts as an <a href="/wiki/Immunomodulator" title="Immunomodulator" class="mw-redirect">immunomodulator</a>. Pomalidomide was approved in February 2013 by the U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) as a treatment for relapsed and refractory <a href="/wiki/Multiple_myeloma" title="Multiple myeloma">multiple myeloma</a>.<sup id="cite_ref-P1_62-0" class="reference"><a href="#cite_note-P1-62"><span>[</span>62<span>]</span></a></sup> It received a similar approval from the <a href="/wiki/European_Commission" title="European Commission">European Commission</a> in August 2013, and is expected to be marketed in Europe under the brand name <b>Imnovid</b>.<sup id="cite_ref-P2_63-0" class="reference"><a href="#cite_note-P2-63"><span>[</span>63<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Society_and_culture">Society and culture</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=14" title="Edit section: Society and culture">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Regulatory_approved_uses">Regulatory approved uses</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=15" title="Edit section: Regulatory approved uses">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<table class="wikitable">
<caption><b><big>Indications for thalidomide</big></b></caption>
<tr>
<th>Labelled indication</th>
<th>USA (FDA)(date)<sup id="cite_ref-DM_27-1" class="reference"><a href="#cite_note-DM-27"><span>[</span>27<span>]</span></a></sup><sup id="cite_ref-MSR_28-1" class="reference"><a href="#cite_note-MSR-28"><span>[</span>28<span>]</span></a></sup></th>
<th>Australia (TGA) (date)<sup id="cite_ref-TGA_30-11" class="reference"><a href="#cite_note-TGA-30"><span>[</span>30<span>]</span></a></sup></th>
<th>European Union (EMA) (date) <sup id="cite_ref-EMA_64-0" class="reference"><a href="#cite_note-EMA-64"><span>[</span>64<span>]</span></a></sup></th>
<th>Literature support/Notes</th>
</tr>
<tr>
<td><a href="/wiki/Crohn%27s_disease" title="Crohn's disease">Crohn's disease</a></td>
<td>No <sup class="reference" id="ref_orphan-designation"><a href="#endnote_orphan-designation">[+]</a></sup></td>
<td>No</td>
<td>No</td>
<td>Children and adolescents (in a small randomised clinical trial)<sup id="cite_ref-65" class="reference"><a href="#cite_note-65"><span>[</span>65<span>]</span></a></sup> and adults (in open-label clinical trials).<sup id="cite_ref-Rev_66-0" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></td>
</tr>
<tr>
<td><a href="/wiki/Erythema_nodosum_leprosum" title="Erythema nodosum leprosum" class="mw-redirect">Erythema nodosum leprosum</a> (ENL)</td>
<td>Yes (1998)</td>
<td>Yes (2009)</td>
<td>No</td>
<td>Some literature support, including at least two randomised placebo-controlled trials.<sup id="cite_ref-67" class="reference"><a href="#cite_note-67"><span>[</span>67<span>]</span></a></sup><sup id="cite_ref-68" class="reference"><a href="#cite_note-68"><span>[</span>68<span>]</span></a></sup><sup id="cite_ref-69" class="reference"><a href="#cite_note-69"><span>[</span>69<span>]</span></a></sup></td>
</tr>
<tr>
<td><a href="/wiki/Graft_versus_host_disease" title="Graft versus host disease" class="mw-redirect">Graft versus host disease</a> (GVHD)</td>
<td>No <sup class="reference" id="ref_orphan-designation"><a href="#endnote_orphan-designation">[+]</a></sup></td>
<td>No</td>
<td>No</td>
<td>Limited literature support.<sup id="cite_ref-Rev_66-1" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></td>
</tr>
<tr>
<td>Hematopoietic Stem Cell Transplantation</td>
<td>No <sup class="reference" id="ref_orphan-designation"><a href="#endnote_orphan-designation">[+]</a></sup></td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>HIV-associated wasting syndrome</td>
<td>No <sup class="reference" id="ref_orphan-designation"><a href="#endnote_orphan-designation">[+]</a></sup></td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td><a href="/wiki/Kaposi%27s_sarcoma" title="Kaposi's sarcoma">Kaposi's sarcoma</a> (KS)</td>
<td>No <sup class="reference" id="ref_orphan-designation"><a href="#endnote_orphan-designation">[+]</a></sup></td>
<td>No</td>
<td>No</td>
<td>Rare soft tissue cancer most commonly seen in the immunocompromised. Caused by the <a href="/wiki/Kaposi%27s_sarcoma-associated_herpesvirus" title="Kaposi's sarcoma-associated herpesvirus">Kaposi's sarcoma-associated herpesvirus</a> (KSHV). A phase II study has confirmed its efficacy.<sup id="cite_ref-70" class="reference"><a href="#cite_note-70"><span>[</span>70<span>]</span></a></sup></td>
</tr>
<tr>
<td><a href="/wiki/Multiple_myeloma" title="Multiple myeloma">Multiple myeloma</a></td>
<td>Yes (2006)</td>
<td>Yes (2009)</td>
<td>Yes (2008)</td>
<td>Numerous clinical trials have confirmed its efficacy, most often when used in combination with other medications.<sup id="cite_ref-Rev_66-2" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></td>
</tr>
<tr>
<td>Mycobacterial infection</td>
<td>No <sup class="reference" id="ref_orphan-designation"><a href="#endnote_orphan-designation">[+]</a></sup></td>
<td>No</td>
<td>No</td>
<td>Mycobacterial infections include lepropsy, tuberculosis and mycobacterium avium complex (MAC) infections.</td>
</tr>
<tr>
<td><a href="/wiki/Myelodysplastic_syndrome" title="Myelodysplastic syndrome">Myelodysplastic syndrome</a></td>
<td>No <sup class="reference" id="ref_orphan-designation"><a href="#endnote_orphan-designation">[+]</a></sup></td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Primary brain malignancy</td>
<td>No <sup class="reference" id="ref_orphan-designation"><a href="#endnote_orphan-designation">[+]</a></sup></td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Recurrent <a href="/wiki/Aphthous_ulcers" title="Aphthous ulcers" class="mw-redirect">aphthous ulcers</a></td>
<td>No <sup class="reference" id="ref_orphan-designation"><a href="#endnote_orphan-designation">[+]</a></sup></td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
</table>
<p><span class="citation wikicite" id="endnote_orphan-designation"><sup>+</sup></span>&#160;: designated <a href="/wiki/Orphan_drug" title="Orphan drug">Orphan drug</a> under the <a href="/wiki/Orphan_Drug_Act_of_1983" title="Orphan Drug Act of 1983">Orphan Drug Act of 1983</a></p>
<h3><span class="mw-headline" id="Birth_defects_crisis">Birth defects crisis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=16" title="Edit section: Birth defects crisis">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:NCP14053.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/a/a5/NCP14053.jpg/220px-NCP14053.jpg" width="220" height="142" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/a/a5/NCP14053.jpg/330px-NCP14053.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/a/a5/NCP14053.jpg/440px-NCP14053.jpg 2x" data-file-width="2840" data-file-height="1838" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:NCP14053.jpg" class="internal" title="Enlarge"></a></div>
Baby born to a mother who had taken thalidomide while pregnant.</div>
</div>
</div>
<p>In the late 1950s and early 1960s, more than 10,000 children in 46 countries were born with <a href="/wiki/Deformities" title="Deformities" class="mw-redirect">deformities</a> such as <a href="/wiki/Phocomelia" title="Phocomelia">phocomelia</a> as a consequence of thalidomide use.<sup id="cite_ref-Bren_71-0" class="reference"><a href="#cite_note-Bren-71"><span>[</span>71<span>]</span></a></sup> It is not known exactly how many worldwide victims of the drug there have been, although estimates range from 10,000 to 20,000.<sup id="cite_ref-nyt-answers_46-1" class="reference"><a href="#cite_note-nyt-answers-46"><span>[</span>46<span>]</span></a></sup> Despite the side effects, thalidomide was sold in pharmacies in Canada until 1962; Canada was the last country to end sales of the drug.<sup id="cite_ref-pmid14076167_56-3" class="reference"><a href="#cite_note-pmid14076167-56"><span>[</span>56<span>]</span></a></sup><sup id="cite_ref-72" class="reference"><a href="#cite_note-72"><span>[</span>72<span>]</span></a></sup></p>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Artificial_limbs_for_a_thalidomide_child,_1961-1965._(9660575567).jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/bd/Artificial_limbs_for_a_thalidomide_child%2C_1961-1965._%289660575567%29.jpg/220px-Artificial_limbs_for_a_thalidomide_child%2C_1961-1965._%289660575567%29.jpg" width="220" height="303" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/bd/Artificial_limbs_for_a_thalidomide_child%2C_1961-1965._%289660575567%29.jpg/330px-Artificial_limbs_for_a_thalidomide_child%2C_1961-1965._%289660575567%29.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/bd/Artificial_limbs_for_a_thalidomide_child%2C_1961-1965._%289660575567%29.jpg/440px-Artificial_limbs_for_a_thalidomide_child%2C_1961-1965._%289660575567%29.jpg 2x" data-file-width="908" data-file-height="1250" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Artificial_limbs_for_a_thalidomide_child,_1961-1965._(9660575567).jpg" class="internal" title="Enlarge"></a></div>
These artificial limbs were made for an affected child in the 1960s by the <a href="/wiki/Department_of_Health_and_Social_Security" title="Department of Health and Social Security">Department of Health and Social Security</a>'s Limb Fitting Centre in <a href="/wiki/Roehampton" title="Roehampton">Roehampton</a>, London</div>
</div>
</div>
<p>In the United Kingdom, the drug was licensed in 1958 and withdrawn in 1961. Of the approximately 2,000 babies born with defects, around half died within a few months and 466 survived to at least 2010.<sup id="cite_ref-73" class="reference"><a href="#cite_note-73"><span>[</span>73<span>]</span></a></sup></p>
<p>In Spain, thalidomide was widely available throughout the 1970s, perhaps even into the 1980s. There were two reasons for this. First, state controls and safeguarding were poor; indeed, it was not until 2008 that the government even admitted the country had ever imported thalidomide. Second, Grünenthal failed to insist that its sister company in Madrid warn Spanish doctors, and permitted it to not warn them. The Spanish advocacy group for victims of thalidomide estimates that in 2015, there were 250–300 living victims of thalidomide in Spain.<sup id="cite_ref-name_74-0" class="reference"><a href="#cite_note-name-74"><span>[</span>74<span>]</span></a></sup></p>
<p>The Australian obstetrician <a href="/wiki/William_McBride_(doctor)" title="William McBride (doctor)">William McBride</a> and the German <a href="/wiki/Paediatrician" title="Paediatrician" class="mw-redirect">paediatrician</a> <a href="/wiki/Widukind_Lenz" title="Widukind Lenz">Widukind Lenz</a> suspected a link between birth defects and the drug, a theory Lenz proved in 1961.<sup id="cite_ref-75" class="reference"><a href="#cite_note-75"><span>[</span>75<span>]</span></a></sup><sup id="cite_ref-40_years_on_76-0" class="reference"><a href="#cite_note-40_years_on-76"><span>[</span>76<span>]</span></a></sup> McBride was later awarded a number of honors, including a medal and prize money by L'Institut de la Vie in Paris.<sup id="cite_ref-77" class="reference"><a href="#cite_note-77"><span>[</span>77<span>]</span></a></sup></p>
<p>In <a href="/wiki/East_Germany" title="East Germany">East Germany</a>, the head of the central pharmacy control commission, Friedrich Jung, suspected an antivitaminic effect of thalidomide as derivative of <a href="/wiki/Glutamic_acid" title="Glutamic acid">glutamic acid</a>.<sup id="cite_ref-78" class="reference"><a href="#cite_note-78"><span>[</span>78<span>]</span></a></sup> Meanwhile, in <a href="/wiki/West_Germany" title="West Germany">West Germany</a>, it took some time before the increase in <a href="/wiki/Dysmelia" title="Dysmelia">dysmelia</a> at the end of the 1950s was connected with thalidomide. In 1958 Karl Beck, a former pediatric doctor in <a href="/wiki/Bayreuth" title="Bayreuth">Bayreuth</a> wrote an article in a local newspaper claiming a relationship between nuclear weapons testing and cases of dysmelia in children.<sup id="cite_ref-daeb_79-0" class="reference"><a href="#cite_note-daeb-79"><span>[</span>79<span>]</span></a></sup> Based on this, <a href="/wiki/Free_Democratic_Party_(Germany)" title="Free Democratic Party (Germany)">FDP</a> <a href="/wiki/Whip_(politics)" title="Whip (politics)">whip</a> <a href="/wiki/Erich_Mende" title="Erich Mende">Erich Mende</a> requested an official statement from the federal government.<sup id="cite_ref-daeb_79-1" class="reference"><a href="#cite_note-daeb-79"><span>[</span>79<span>]</span></a></sup> For statistical reasons, the main data series used to research dysmelia cases started by chance at the same time as the approval date for thalidomide.<sup id="cite_ref-daeb_79-2" class="reference"><a href="#cite_note-daeb-79"><span>[</span>79<span>]</span></a></sup> After the Nazi regime with its <a href="/wiki/Law_for_the_Prevention_of_Hereditarily_Diseased_Offspring" title="Law for the Prevention of Hereditarily Diseased Offspring">Law for the Prevention of Hereditarily Diseased Offspring</a> used mandatory statistical monitoring to commit various <a href="/wiki/Action_T4" title="Action T4">crimes</a>, western Germany had been very reluctant to monitor <a href="/wiki/Congenital_disorder" title="Congenital disorder">congenital disorders</a> in a similarly strict way.<sup id="cite_ref-th_80-0" class="reference"><a href="#cite_note-th-80"><span>[</span>80<span>]</span></a></sup> The parliamentary report rejected any relation with radioactivity and the abnormal increase of dysmelia.<sup id="cite_ref-daeb_79-3" class="reference"><a href="#cite_note-daeb-79"><span>[</span>79<span>]</span></a></sup> Also the DFG research project installed after the Mende request was not helpful. The project was led by pathologist <a href="/wiki/Franz_B%C3%BCchner_(pathologist)" title="Franz Büchner (pathologist)">Franz Büchner</a> who ran the project to propagate his <a href="/wiki/Teratology" title="Teratology">teratological</a> theory. Büchner saw lack of healthy nutrition and behavior of the mothers as being more important than genetic reasons.<sup id="cite_ref-th_80-1" class="reference"><a href="#cite_note-th-80"><span>[</span>80<span>]</span></a></sup> Furthermore, it took a while to install a Surgeon General in Germany; the <a href="/wiki/Federal_Ministry_of_Health_(Germany)" title="Federal Ministry of Health (Germany)">Federal Ministry of Health (Germany)</a> was not founded until 1962, some months after thalidomide was banned from the market.<sup id="cite_ref-daeb_79-4" class="reference"><a href="#cite_note-daeb-79"><span>[</span>79<span>]</span></a></sup> In Germany approximately 2,500 thalidomide babies were born.<sup id="cite_ref-40_years_on_76-1" class="reference"><a href="#cite_note-40_years_on-76"><span>[</span>76<span>]</span></a></sup></p>
<p>Several countries either restricted the drug's use or never approved it. Ingeborg Eichler, a member of the <a href="/wiki/Austria" title="Austria">Austrian</a> pharmaceutical admission conference, enforced thalidomide (tradename Softenon) being sold under the rules of <a href="/wiki/Prescription_medication" title="Prescription medication" class="mw-redirect">prescription medication</a> and as a result relatively few affected children were born in Austria and Switzerland.<sup id="cite_ref-81" class="reference"><a href="#cite_note-81"><span>[</span>81<span>]</span></a></sup> In the United States, <a href="/wiki/Pharmacologist" title="Pharmacologist" class="mw-redirect">pharmacologist</a> <a href="/wiki/Frances_Oldham_Kelsey" title="Frances Oldham Kelsey">Frances Oldham Kelsey</a> <a href="/wiki/M.D." title="M.D." class="mw-redirect">M.D.</a> withstood pressure from the <a href="/wiki/Marion_Merrell_Dow" title="Marion Merrell Dow">Richardson-Merrell</a> company and refused <a href="/wiki/Food_and_Drug_Administration_(United_States)" title="Food and Drug Administration (United States)" class="mw-redirect">Food and Drug Administration (FDA)</a> approval to market thalidomide, saying further studies were needed.<sup id="cite_ref-Bren_71-1" class="reference"><a href="#cite_note-Bren-71"><span>[</span>71<span>]</span></a></sup> This reduced the impact of thalidomide in United States patients. Although thalidomide was never approved for sale in the United States at the time, millions of tablets had been distributed to physicians during a clinical testing program. It was impossible to know how many pregnant women had been given the drug to help alleviate morning sickness or as a sedative.<sup id="cite_ref-82" class="reference"><a href="#cite_note-82"><span>[</span>82<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Aftermath_of_scandal">Aftermath of scandal</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=17" title="Edit section: Aftermath of scandal">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The numerous reports of malformations in babies brought about the awareness of the side effects of the drug on pregnant women. The birth defects caused by the drug thalidomide can range from moderate malformation to more severe forms. Possible birth defects include phocomelia, dysmelia, amelia, bone hypoplasticity, and other congenital defects affecting the ear, heart, or internal organs.<sup id="cite_ref-pmid15172781_50-2" class="reference"><a href="#cite_note-pmid15172781-50"><span>[</span>50<span>]</span></a></sup> Franks et al. looked at how the drug affected newborn babies, the severity of their deformities, and reviewed the drug in its early years. Webb in 1963 also reviewed the history of the drug and the different forms of birth defects it had caused. “The most common form of birth defects from thalidomide is shortened limbs, with the arms being more frequently affected. This syndrome is the presence of deformities of the long bones of the limbs resulting in shortening and other abnormalities.”<sup id="cite_ref-pmid14076167_56-4" class="reference"><a href="#cite_note-pmid14076167-56"><span>[</span>56<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Germany">Germany</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=18" title="Edit section: Germany">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>In 1968, a large criminal trial began in Germany, charging several Grünenthal officials with negligent homicide and injury. After Grünenthal settled with the victims in April 1970, the trial ended in December 1970 with no finding of guilt. As part of the settlement, Grünenthal paid 100 million <a href="/wiki/Deutsche_Mark" title="Deutsche Mark">DM</a> into a special foundation; the German government added 320 million DM. The foundation paid victims a one-time sum of 2,500-25,000 DM (depending on severity of disability) and a monthly stipend of 100-450 DM. The monthly stipends have since been raised substantially and are now paid entirely by the government (as the foundation had run out of money). Grünenthal paid another 50 million Euros into the foundation in 2008.</p>
<p>On 31 August 2012, Grünenthal chief executive Harald F. Stock, PhD, who served as the Chief Executive Officer of Grünenthal GmbH from January 2009 to May 28, 2013 and was also a Member of Executive Board until May 28, 2013, apologized for the first time for producing the drug and remaining silent about the birth defects.<sup id="cite_ref-83" class="reference"><a href="#cite_note-83"><span>[</span>83<span>]</span></a></sup> At a ceremony, Stock unveiled a statue of a disabled child to symbolize those harmed by thalidomide and apologized for not trying to reach out to victims for over 50&#160;years. At the time of the apology, there were 5,000 to 6,000 sufferers still alive. Victim advocates called the apology "insulting" and "too little, too late", and criticized the company for not compensating victims. They also criticized the company for their claim that no one could have known the harm the drug caused, arguing that there were plenty of red flags at the time.<sup id="cite_ref-84" class="reference"><a href="#cite_note-84"><span>[</span>84<span>]</span></a></sup></p>
<p><br /></p>
<h4><span class="mw-headline" id="United_Kingdom">United Kingdom</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=19" title="Edit section: United Kingdom">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>In 1968, after a long campaign by <i><a href="/wiki/The_Sunday_Times" title="The Sunday Times">The Sunday Times</a></i>, a compensation settlement for the UK victims was reached with <a href="/wiki/Distillers_Company" title="Distillers Company">Distillers Company</a> (now part of <a href="/wiki/Diageo" title="Diageo">Diageo</a>), which had distributed the drug in the UK.<sup id="cite_ref-they_didn.27t_know_85-0" class="reference"><a href="#cite_note-they_didn.27t_know-85"><span>[</span>85<span>]</span></a></sup><sup id="cite_ref-86" class="reference"><a href="#cite_note-86"><span>[</span>86<span>]</span></a></sup> This compensation, which is distributed by the Thalidomide Trust in the UK, was substantially increased by Diageo in 2005.<sup id="cite_ref-87" class="reference"><a href="#cite_note-87"><span>[</span>87<span>]</span></a></sup> The UK Government gave survivors a grant of £20 million, to be distributed through the Thalidomide Trust, in December 2009.<sup id="cite_ref-UK_Government_grant_88-0" class="reference"><a href="#cite_note-UK_Government_grant-88"><span>[</span>88<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Australia">Australia</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=20" title="Edit section: Australia">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Melbourne woman Lynette Rowe, who was born without limbs, is leading an Australian <a href="/wiki/Class_action" title="Class action">class action</a> lawsuit against the drug's manufacturer, Grünenthal, which fought to have the case heard in Germany. The Victorian Supreme Court dismissed Grünenthal's application in 2012, and the case was heard in Australia. More than a hundred Australian thalidomide survivors are involved in the class action, according to Rowe's lawyer.<sup id="cite_ref-89" class="reference"><a href="#cite_note-89"><span>[</span>89<span>]</span></a></sup> On 17 July 2012, Lynette Rowe was awarded an out-of-court settlement, believed to be in the millions of dollars and paving the way for class action victims to receive further compensation.</p>
<p><br /></p>
<h4><span class="mw-headline" id="Canada">Canada</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=21" title="Edit section: Canada">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>The drug thalidomide's birth defects in children affected many people's lives, and from these events came the formation of the group called The Thalidomide Victims Association of Canada, a group of 120 Canadian survivors.<sup id="cite_ref-90" class="reference"><a href="#cite_note-90"><span>[</span>90<span>]</span></a></sup> Their goal was to prevent future usage of drugs that could be of potential harm to mothers and babies. The members from the thalidomide victims association were involved in the STEPS program, which aimed to prevent teratogenicity.<sup id="cite_ref-pmid15172781_50-3" class="reference"><a href="#cite_note-pmid15172781-50"><span>[</span>50<span>]</span></a></sup></p>
<p>The effects of thalidomide increased fears regarding the safety of pharmaceutical drugs. The Society of Toxicology of Canada was formed after the effects of thalidomide were made public, focusing on toxicology as a discipline separate from pharmacology.<sup id="cite_ref-pmid12909394_91-0" class="reference"><a href="#cite_note-pmid12909394-91"><span>[</span>91<span>]</span></a></sup> The need for the testing and approval of the toxins in certain pharmaceutical drugs became more important after the disaster. The Society of Toxicology of Canada is responsible for the Conservation Environment Protection Act, focusing on researching the impact to human health of chemical substances.<sup id="cite_ref-pmid12909394_91-1" class="reference"><a href="#cite_note-pmid12909394-91"><span>[</span>91<span>]</span></a></sup> Thalidomide brought on changes in the way drugs are tested, what type of drugs are used during pregnancy, and increased the awareness of potential side effects of drugs.</p>
<p><br /></p>
<h4><span class="mw-headline" id="United_States">United States</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=22" title="Edit section: United States">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<div class="thumb tright">
<div class="thumbinner" style="width:172px;"><a href="/wiki/File:Kelsey_01.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/9/93/Kelsey_01.jpg/170px-Kelsey_01.jpg" width="170" height="221" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/9/93/Kelsey_01.jpg/255px-Kelsey_01.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/9/93/Kelsey_01.jpg/340px-Kelsey_01.jpg 2x" data-file-width="1182" data-file-height="1536" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Kelsey_01.jpg" class="internal" title="Enlarge"></a></div>
1962: FDA pharmacologist <a href="/wiki/Frances_Oldham_Kelsey" title="Frances Oldham Kelsey">Frances Oldham Kelsey</a> receives the <a href="/wiki/President%27s_Award_for_Distinguished_Federal_Civilian_Service" title="President's Award for Distinguished Federal Civilian Service">President's Award for Distinguished Federal Civilian Service</a> from President <a href="/wiki/John_F._Kennedy" title="John F. Kennedy">John F. Kennedy</a> for blocking sale of thalidomide in the United States.</div>
</div>
</div>
<p>For correctly denying the application despite the pressure from Richardson-Merrell, Kelsey eventually received the President's Award for Distinguished Federal Civilian Service at a 1962 ceremony with President <a href="/wiki/John_F._Kennedy" title="John F. Kennedy">John F. Kennedy</a>. In September 2010, the FDA honored Kelsey with the first Kelsey award. The award, given annually to an FDA staff member, came 50 years after Kelsey, then a new medical officer at the agency, first reviewed the application from the William S. Merrell Company of Cincinnati.<sup id="cite_ref-92" class="reference"><a href="#cite_note-92"><span>[</span>92<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Notable_people_affected">Notable people affected</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=23" title="Edit section: Notable people affected">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Niko_von_Glasow.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/16/Niko_von_Glasow.jpg/220px-Niko_von_Glasow.jpg" width="220" height="293" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/16/Niko_von_Glasow.jpg/330px-Niko_von_Glasow.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/16/Niko_von_Glasow.jpg/440px-Niko_von_Glasow.jpg 2x" data-file-width="480" data-file-height="640" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Niko_von_Glasow.jpg" class="internal" title="Enlarge"></a></div>
Niko von Glasow, German filmmaker</div>
</div>
</div>
<ul>
<li><a href="/w/index.php?title=Lorraine_Mercer&amp;action=edit&amp;redlink=1" class="new" title="Lorraine Mercer (page does not exist)">Lorraine Mercer</a>, born with phocomelia of both arms and legs, is the only Thalidomide survivor to carry the Olympic Torch UK 2012</li>
<li><a href="/wiki/Mat_Fraser" title="Mat Fraser">Mat Fraser</a>, musician, actor and performance artist born with <a href="/wiki/Phocomelia" title="Phocomelia">phocomelia</a> of both arms</li>
<li><a href="/wiki/Alvin_Law" title="Alvin Law">Alvin Law</a>, radio broadcaster, born without arms</li>
<li><a href="/wiki/Tony_Mel%C3%A9ndez" title="Tony Meléndez">Tony Meléndez</a>, award-winning singer and guitarist who plays with his feet and has been recognized by <a href="/wiki/Pope_John_Paul_II" title="Pope John Paul II">Pope John Paul&#160;II</a> and <a href="/wiki/U.S._President" title="U.S. President" class="mw-redirect">U.S.&#160;President</a> <a href="/wiki/Ronald_Reagan" title="Ronald Reagan">Ronald Reagan</a></li>
<li><a href="/wiki/Thomas_Quasthoff" title="Thomas Quasthoff">Thomas Quasthoff</a>, an internationally acclaimed bass-baritone, who describes himself: "1.34 meters tall, short arms, seven fingers&#160;— four right, three left&#160;— large, relatively well-formed head, brown eyes, distinctive lips; profession: singer"<sup id="cite_ref-93" class="reference"><a href="#cite_note-93"><span>[</span>93<span>]</span></a></sup></li>
<li><a href="/wiki/Niko_von_Glasow" title="Niko von Glasow">Niko von Glasow</a> produced a documentary called "<a href="/wiki/NoBody%27s_Perfect" title="NoBody's Perfect">NoBody's Perfect</a>", based on the lives of 12 people affected by the drug, which was released in 2008<sup id="cite_ref-94" class="reference"><a href="#cite_note-94"><span>[</span>94<span>]</span></a></sup><sup id="cite_ref-95" class="reference"><a href="#cite_note-95"><span>[</span>95<span>]</span></a></sup></li>
<li><a href="/wiki/Terry_Wiles" title="Terry Wiles">Terry Wiles</a>, born with phocomelia of both arms and legs, has become known internationally through the television drama <i><a href="/wiki/On_Giant%27s_Shoulders" title="On Giant's Shoulders">On Giant's Shoulders</a></i> and the best-selling book of the same name</li>
</ul>
<h3><span class="mw-headline" id="Change_in_drug_regulations">Change in drug regulations</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=24" title="Edit section: Change in drug regulations">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The disaster prompted many countries to introduce tougher rules for the testing and licensing of drugs, such as the <a href="/wiki/Kefauver_Harris_Amendment" title="Kefauver Harris Amendment">Kefauver Harris Amendment</a><sup id="cite_ref-96" class="reference"><a href="#cite_note-96"><span>[</span>96<span>]</span></a></sup> (U.S.) and <a href="/wiki/Directive_65/65/EEC1" title="Directive 65/65/EEC1" class="mw-redirect">Directive 65/65/EEC1</a> (E.U.).<sup id="cite_ref-97" class="reference"><a href="#cite_note-97"><span>[</span>97<span>]</span></a></sup> In the United States, the new regulations strengthened the FDA, among other ways, by requiring applicants to prove efficacy and to disclose all side-effects encountered in testing.<sup id="cite_ref-Bren_71-2" class="reference"><a href="#cite_note-Bren-71"><span>[</span>71<span>]</span></a></sup> The FDA subsequently initiated the <a href="/wiki/Drug_Efficacy_Study_Implementation" title="Drug Efficacy Study Implementation">Drug Efficacy Study Implementation</a> to reclassify drugs already on the market.</p>
<h2><span class="mw-headline" id="Research">Research</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=25" title="Edit section: Research">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Investigational uses include:</p>
<ul>
<li>AIDS wasting syndrome,<sup id="cite_ref-98" class="reference"><a href="#cite_note-98"><span>[</span>98<span>]</span></a></sup> associated diarrhoea<sup id="cite_ref-99" class="reference"><a href="#cite_note-99"><span>[</span>99<span>]</span></a></sup> and <a href="/wiki/Kaposi%27s_sarcoma" title="Kaposi's sarcoma">Kaposi's sarcoma</a>.<sup id="cite_ref-Rev_66-3" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></li>
<li><a href="/wiki/Renal_cell_carcinoma" title="Renal cell carcinoma">Renal cell carcinoma</a> (RCC)<sup id="cite_ref-Rev_66-4" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup><sup id="cite_ref-100" class="reference"><a href="#cite_note-100"><span>[</span>100<span>]</span></a></sup></li>
<li><a href="/wiki/Glioblastoma_multiforme" title="Glioblastoma multiforme">Glioblastoma multiforme</a><sup id="cite_ref-Rev_66-5" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></li>
<li><a href="/wiki/Prostate_cancer" title="Prostate cancer">Prostate cancer</a><sup id="cite_ref-Rev_66-6" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></li>
<li><a href="/wiki/Melanoma" title="Melanoma">Melanoma</a><sup id="cite_ref-Rev_66-7" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></li>
<li><a href="/wiki/Colorectal_cancer" title="Colorectal cancer">Colorectal cancer</a><sup id="cite_ref-Rev_66-8" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></li>
<li><a href="/wiki/Crohn%27s_disease" title="Crohn's disease">Crohn's disease</a><sup id="cite_ref-Rev_66-9" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></li>
<li><a href="/wiki/Rheumatoid_arthritis" title="Rheumatoid arthritis">Rheumatoid arthritis</a><sup id="cite_ref-Rev_66-10" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></li>
<li><a href="/wiki/Behcet%27s_syndrome" title="Behcet's syndrome" class="mw-redirect">Behcet's syndrome</a><sup id="cite_ref-101" class="reference"><a href="#cite_note-101"><span>[</span>101<span>]</span></a></sup></li>
<li><a href="/wiki/Breast_cancer" title="Breast cancer">Breast cancer</a><sup id="cite_ref-Rev_66-11" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></li>
<li><a href="/wiki/Head_and_neck_cancer" title="Head and neck cancer">Head and neck cancer</a><sup id="cite_ref-Rev_66-12" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></li>
<li><a href="/wiki/Ovarian_cancer" title="Ovarian cancer">Ovarian cancer</a><sup id="cite_ref-Rev_66-13" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></li>
<li>Chronic heart failure<sup id="cite_ref-Rev_66-14" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></li>
<li>Graft-versus-host disease<sup id="cite_ref-Rev_66-15" class="reference"><a href="#cite_note-Rev-66"><span>[</span>66<span>]</span></a></sup></li>
</ul>
<h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=26" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a href="/wiki/Immunomodulatory_drug" title="Immunomodulatory drug">Immunomodulatory drug</a></li>
<li><a href="/wiki/Discovery_and_development_of_thalidomide_and_its_analogs" title="Discovery and development of thalidomide and its analogs" class="mw-redirect">Discovery and development of thalidomide and its analogs</a></li>
<li><a href="/wiki/Drug_of_last_resort" title="Drug of last resort">Drug of last resort</a></li>
<li><a href="/wiki/Health_crisis" title="Health crisis">Health crisis</a></li>
<li><a href="/wiki/Holt-Oram_syndrome" title="Holt-Oram syndrome" class="mw-redirect">Holt-Oram syndrome</a></li>
<li><a href="/wiki/Category:People_with_phocomelia" title="Category:People with phocomelia">Category:People with phocomelia</a></li>
<li><a href="/wiki/Diethylstilbestrol" title="Diethylstilbestrol">Diethylstilbestrol</a></li>
</ul>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=27" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist columns references-column-width" style="-moz-column-width: 35em; -webkit-column-width: 35em; column-width: 35em; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-clinp-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-clinp_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-clinp_1-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-clinp_1-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-clinp_1-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-clinp_1-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS et al. (2004). "Clinical pharmacokinetics of thalidomide". <i>Clin Pharmacokinet</i> <b>43</b> (5): 311–27. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2165%2F00003088-200443050-00004">10.2165/00003088-200443050-00004</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15080764">15080764</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Clinical+pharmacokinetics+of+thalidomide&amp;rft.au=Colburn%2C+WA&amp;rft.aufirst=SK&amp;rft.au=Jaworsky%2C+MS&amp;rft.au=Kook%2C+KA&amp;rft.au=Laskin%2C+OL&amp;rft.aulast=Teo&amp;rft.au=Scheffler%2C+MA&amp;rft.au=Stirling%2C+DI&amp;rft.au=Teo%2C+SK&amp;rft.au=Thomas%2C+SD&amp;rft.au=Tracewell%2C+WG&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2165%2F00003088-200443050-00004&amp;rft_id=info%3Apmid%2F15080764&amp;rft.issue=5&amp;rft.jtitle=Clin+Pharmacokinet&amp;rft.pages=311-27&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=43" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-2">^</a></b></span> <span class="reference-text"><span id="Reference-OED-Thalidomide" class="citation book"><a rel="nofollow" class="external text" href="http://oed.com/search?searchType=dictionary&amp;q=Thalidomide">"Thalidomide"</a>. <i><a href="/wiki/Oxford_English_Dictionary" title="Oxford English Dictionary">Oxford English Dictionary</a></i> (3rd ed.). Oxford University Press. September 2005.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide&amp;rft.btitle=Oxford+English+Dictionary&amp;rft.date=September+2005&amp;rft.edition=3rd&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Foed.com%2Fsearch%3FsearchType%3Ddictionary%26q%3DThalidomide&amp;rft.pub=Oxford+University+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-miller-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-miller_3-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Miller, Marylin T. (1991). "Thalidomide Embryopathy: A Model for the Study of Congenital Incomitant Horizontal Strabismus". <i>Transaction of the American Ophthalmological Society</i> <b>81</b>: 623–674.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+Embryopathy%3A+A+Model+for+the+Study+of+Congenital+Incomitant+Horizontal+Strabismus&amp;rft.aufirst=Marylin+T.&amp;rft.aulast=Miller&amp;rft.au=Miller%2C+Marylin+T.&amp;rft.date=1991&amp;rft.genre=article&amp;rft.jtitle=Transaction+of+the+American+Ophthalmological+Society&amp;rft.pages=623-674&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=81" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-oncozine.com-4"><span class="mw-cite-backlink">^ <a href="#cite_ref-oncozine.com_4-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-oncozine.com_4-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-oncozine.com_4-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-oncozine.com_4-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-oncozine.com_4-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://oncozine.com/profiles/blogs/how-a-vilified-drug-became-a-life-saving-agent-against-cancer">Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the "War" Against Cancer - Onco'Zine - The International Cancer Network (November 30, 2013)</a><sup class="noprint Inline-Template"><span style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Link_rot" title="Wikipedia:Link rot"><span title="&#160;since June 2014">dead link</span></a></i>]</span></sup></span></li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><span class="citation book">Cuthbert, Alan (2001, 2003). <a rel="nofollow" class="external text" href="http://www.answers.com/topic/thalidomide"><i>The Oxford Companion to the Body</i></a>. Oxford University Press<span class="reference-accessdate">. Retrieved <span class="nowrap">26 February</span> 2012</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.au=Cuthbert%2C+Alan&amp;rft.aufirst=Alan&amp;rft.aulast=Cuthbert&amp;rft.btitle=The+Oxford+Companion+to+the+Body&amp;rft.date=2001%2C+2003&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.answers.com%2Ftopic%2Fthalidomide&amp;rft.pub=Oxford+University+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span> <span style="font-size:100%" class="error citation-comment">Check date values in: <code style="color:inherit; border:inherit; padding:inherit;">|date=</code> (<a href="/wiki/Help:CS1_errors#bad_date" title="Help:CS1 errors">help</a>)</span></span></li>
<li id="cite_note-The_chemical_industry-6"><span class="mw-cite-backlink">^ <a href="#cite_ref-The_chemical_industry_6-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-The_chemical_industry_6-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Heaton, C. A. (1994). <i>The Chemical Industry</i>. Springer. p.&#160;40. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0-7514-0018-1" title="Special:BookSources/0-7514-0018-1">0-7514-0018-1</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.aufirst=C.+A.&amp;rft.au=Heaton%2C+C.+A.&amp;rft.aulast=Heaton&amp;rft.btitle=The+Chemical+Industry&amp;rft.date=1994&amp;rft.genre=book&amp;rft.isbn=0-7514-0018-1&amp;rft.pages=40&amp;rft.pub=Springer&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-AHFS-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-AHFS_7-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.drugs.com/monograph/thalidomide.html">"Thalidomide"</a>. <i>The American Society of Health-System Pharmacists</i><span class="reference-accessdate">. Retrieved June 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.drugs.com%2Fmonograph%2Fthalidomide.html&amp;rft.jtitle=The+American+Society+of+Health-System+Pharmacists&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text"><span class="citation journal">Srinivasan R, Akobeng AK (Apr 15, 2009). "Thalidomide and thalidomide analogues for induction of remission in Crohn's disease.". <i>The Cochrane database of systematic reviews</i> (2): CD007350. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F14651858.CD007350.pub2">10.1002/14651858.CD007350.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19370684">19370684</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+and+thalidomide+analogues+for+induction+of+remission+in+Crohn%27s+disease.&amp;rft.au=Akobeng%2C+AK&amp;rft.aufirst=R&amp;rft.aulast=Srinivasan&amp;rft.au=Srinivasan%2C+R&amp;rft.date=Apr+15%2C+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD007350.pub2&amp;rft_id=info%3Apmid%2F19370684&amp;rft.issue=2&amp;rft.jtitle=The+Cochrane+database+of+systematic+reviews&amp;rft.pages=CD007350&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-9">^</a></b></span> <span class="reference-text"><span class="citation journal">Akobeng AK, Stokkers PC (Apr 15, 2009). "Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease.". <i>The Cochrane database of systematic reviews</i> (2): CD007351. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F14651858.CD007351.pub2">10.1002/14651858.CD007351.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19370685">19370685</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+and+thalidomide+analogues+for+maintenance+of+remission+in+Crohn%27s+disease.&amp;rft.au=Akobeng%2C+AK&amp;rft.aufirst=AK&amp;rft.aulast=Akobeng&amp;rft.au=Stokkers%2C+PC&amp;rft.date=Apr+15%2C+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD007351.pub2&amp;rft_id=info%3Apmid%2F19370685&amp;rft.issue=2&amp;rft.jtitle=The+Cochrane+database+of+systematic+reviews&amp;rft.pages=CD007351&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Silverman-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-Silverman_10-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Silverman WA (August 2002). "The schizophrenic career of a 'monster drug<span style="padding-right:0.2em;">'</span>". <i>Pediatrics</i> <b>110</b> (2 Pt 1): 404–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1542%2Fpeds.110.2.404">10.1542/peds.110.2.404</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12165600">12165600</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=The+schizophrenic+career+of+a+%27monster+drug%27&amp;rft.aufirst=WA&amp;rft.aulast=Silverman&amp;rft.au=Silverman%2C+WA&amp;rft.date=August+2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1542%2Fpeds.110.2.404&amp;rft_id=info%3Apmid%2F12165600&amp;rft.issue=2+Pt+1&amp;rft.jtitle=Pediatrics&amp;rft.pages=404-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=110" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-11">^</a></b></span> <span class="reference-text"><span class="citation journal">Castilla EE, Ashton-Prolla P, Barreda-Mejia E, Brunoni D, Cavalcanti DP, Correa-Neto J et al. (December 1996). "Thalidomide, a current teratogen in South America". <i>Teratology</i> <b>54</b> (6): 273–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:10.1002/(SICI)1096-9926(199612)54:6&lt;273::AID-TERA1&gt;3.0.CO;2-# (inactive 2015-01-09). <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9098920">9098920</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide%2C+a+current+teratogen+in+South+America&amp;rft.au=Ashton-Prolla%2C+P&amp;rft.au=Barreda-Mejia%2C+E&amp;rft.au=Brunoni%2C+D&amp;rft.au=Castilla%2C+EE&amp;rft.au=Cavalcanti%2C+DP&amp;rft.au=Correa-Neto%2C+J&amp;rft.au=Delgadillo%2C+JL&amp;rft.au=Dutra%2C+MG&amp;rft.au=Felix%2C+T&amp;rft.aufirst=EE&amp;rft.au=Giraldo%2C+A&amp;rft.au=Juarez%2C+N&amp;rft.aulast=Castilla&amp;rft.au=Lopez-Camelo%2C+JS&amp;rft.au=Nazer%2C+J&amp;rft.au=Orioli%2C+IM&amp;rft.au=Paz%2C+JE&amp;rft.au=Pessoto%2C+MA&amp;rft.au=Pina-Neto%2C+JM&amp;rft.au=Quadrelli%2C+R&amp;rft.au=Rittler%2C+M&amp;rft.au=Rueda%2C+S&amp;rft.au=Saltos%2C+M&amp;rft.au=S%C3%A1nchez%2C+O&amp;rft.au=Sch%C3%BCler%2C+L&amp;rft.date=December+1996&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F%28SICI%291096-9926%28199612%2954%3A6%3C273%3A%3AAID-TERA1%3E3.0.CO%3B2-%23&amp;rft_id=info%3Apmid%2F9098920&amp;rft.issue=6&amp;rft.jtitle=Teratology&amp;rft.pages=273-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=54" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text"><span class="citation journal">Paumgartten FJ, Chahoud I (July 2006). "Thalidomide embryopathy cases in Brazil after 1965". <i>Reprod. Toxicol.</i> <b>22</b> (1): 1–2. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.reprotox.2005.11.007">10.1016/j.reprotox.2005.11.007</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16427249">16427249</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+embryopathy+cases+in+Brazil+after+1965&amp;rft.au=Chahoud%2C+I&amp;rft.aufirst=FJ&amp;rft.aulast=Paumgartten&amp;rft.au=Paumgartten%2C+FJ&amp;rft.date=July+2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.reprotox.2005.11.007&amp;rft_id=info%3Apmid%2F16427249&amp;rft.issue=1&amp;rft.jtitle=Reprod.+Toxicol.&amp;rft.pages=1-2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=22" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text"><span class="citation journal">Correio Braziliense (January 2006). <a rel="nofollow" class="external text" href="http://www.saude.df.gov.br/003/00301009.asp?ttCD_CHAVE=31041">"Talidomida volta a assustar"</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.au=Correio+Braziliense&amp;rft.aulast=Correio+Braziliense&amp;rft.btitle=Talidomida+volta+a+assustar&amp;rft.date=January+2006&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.saude.df.gov.br%2F003%2F00301009.asp%3FttCD_CHAVE%3D31041&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span><sup class="noprint Inline-Template"><span style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Link_rot" title="Wikipedia:Link rot"><span title="&#160;since June 2013">dead link</span></a></i>]</span></sup></span></li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><span class="citation news">Crawford, Angus (23 July 2013). <a rel="nofollow" class="external text" href="http://www.bbc.co.uk/news/magazine-23418102">"Brazil's new generation of Thalidomide babies"</a>. <i>BBC News</i>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Brazil%27s+new+generation+of+Thalidomide+babies&amp;rft.au=Crawford%2C+Angus&amp;rft.aufirst=Angus&amp;rft.aulast=Crawford&amp;rft.date=23+July+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.bbc.co.uk%2Fnews%2Fmagazine-23418102&amp;rft.jtitle=BBC+News&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-nyt-fda-15"><span class="mw-cite-backlink">^ <a href="#cite_ref-nyt-fda_15-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-nyt-fda_15-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation news">Sheryl Gay Stolberg (17 July 1998). <a rel="nofollow" class="external text" href="http://www.nytimes.com/1998/07/17/us/thalidomide-approved-to-treat-leprosy-with-other-uses-seen.html">"Thalidomide Approved to Treat Leprosy, With Other Uses Seen"</a>. <i>New York Times</i><span class="reference-accessdate">. Retrieved <span class="nowrap">8 January</span> 2012</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+Approved+to+Treat+Leprosy%2C+With+Other+Uses+Seen&amp;rft.aulast=Sheryl+Gay+Stolberg&amp;rft.au=Sheryl+Gay+Stolberg&amp;rft.date=17+July+1998&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.nytimes.com%2F1998%2F07%2F17%2Fus%2Fthalidomide-approved-to-treat-leprosy-with-other-uses-seen.html&amp;rft.jtitle=New+York+Times&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-16">^</a></b></span> <span class="reference-text"><span class="citation web">Anon. <a rel="nofollow" class="external text" href="http://www.who.int/lep/research/thalidomide/en/index.html">"Use of thalidomide in leprosy"</a>. <i>WHO:leprosy elimination</i>. WHO<span class="reference-accessdate">. Retrieved <span class="nowrap">22 April</span> 2010</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Use+of+thalidomide+in+leprosy&amp;rft.au=Anon&amp;rft.aulast=Anon&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.who.int%2Flep%2Fresearch%2Fthalidomide%2Fen%2Findex.html&amp;rft.jtitle=WHO%3Aleprosy+elimination&amp;rft.pub=WHO&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-nejm-myeloma-17"><span class="mw-cite-backlink">^ <a href="#cite_ref-nejm-myeloma_17-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-nejm-myeloma_17-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. (November 1999). "Antitumor activity of thalidomide in refractory multiple myeloma". <i>N. Engl. J. Med.</i> <b>341</b> (21): 1565–71. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJM199911183412102">10.1056/NEJM199911183412102</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10564685">10564685</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Antitumor+activity+of+thalidomide+in+refractory+multiple+myeloma&amp;rft.au=Anaissie%2C+E&amp;rft.au=Ayers%2C+D&amp;rft.au=Barlogie%2C+B&amp;rft.au=Desikan%2C+R&amp;rft.au=Dhodapkar%2C+M&amp;rft.au=Eddlemon%2C+P&amp;rft.aufirst=S&amp;rft.aulast=Singhal&amp;rft.au=Mehta%2C+J&amp;rft.au=Munshi%2C+N&amp;rft.au=Roberson%2C+P&amp;rft.au=Singhal%2C+S&amp;rft.au=Wilson%2C+C&amp;rft.au=Zeddis%2C+J&amp;rft.date=November+1999&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM199911183412102&amp;rft_id=info%3Apmid%2F10564685&amp;rft.issue=21&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=1565-71&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=341" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-18">^</a></b></span> <span class="reference-text"><span class="citation journal">Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J (March 1994). <a rel="nofollow" class="external text" href="http://jnci.oxfordjournals.org/cgi/pmidlookup?view=long&amp;pmid=7508518">"Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers"</a>. <i>J. Natl. Cancer Inst.</i> <b>86</b> (5): 356–61. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1093%2Fjnci%2F86.5.356">10.1093/jnci/86.5.356</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7508518">7508518</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Elevated+levels+of+an+angiogenic+peptide%2C+basic+fibroblast+growth+factor%2C+in+the+urine+of+patients+with+a+wide+spectrum+of+cancers&amp;rft.au=Budson%2C+AE&amp;rft.aufirst=M&amp;rft.au=Folkman%2C+J&amp;rft.au=Hayes%2C+DF&amp;rft.aulast=Nguyen&amp;rft.au=Nguyen%2C+M&amp;rft.au=Richie%2C+JP&amp;rft.au=Watanabe%2C+H&amp;rft.date=March+1994&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D7508518&amp;rft_id=info%3Adoi%2F10.1093%2Fjnci%2F86.5.356&amp;rft_id=info%3Apmid%2F7508518&amp;rft.issue=5&amp;rft.jtitle=J.+Natl.+Cancer+Inst.&amp;rft.pages=356-61&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=86" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-19">^</a></b></span> <span class="reference-text"><span class="citation journal">Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F et al. (July 1994). "Bone marrow angiogenesis and progression in multiple myeloma". <i>Br. J. Haematol.</i> <b>87</b> (3): 503–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1365-2141.1994.tb08304.x">10.1111/j.1365-2141.1994.tb08304.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7527645">7527645</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Bone+marrow+angiogenesis+and+progression+in+multiple+myeloma&amp;rft.au=Dammacco%2C+F&amp;rft.aufirst=A&amp;rft.aulast=Vacca&amp;rft.au=Ranieri%2C+G&amp;rft.au=Ribatti%2C+D&amp;rft.au=Roncali%2C+L&amp;rft.au=Serio%2C+G&amp;rft.au=Silvestris%2C+F&amp;rft.au=Vacca%2C+A&amp;rft.date=July+1994&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1365-2141.1994.tb08304.x&amp;rft_id=info%3Apmid%2F7527645&amp;rft.issue=3&amp;rft.jtitle=Br.+J.+Haematol.&amp;rft.pages=503-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=87" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-vectorblog.org-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-vectorblog.org_20-0">^</a></b></span> <span class="reference-text"><span class="citation web">David Altman (2013-04-02). <a rel="nofollow" class="external text" href="http://vectorblog.org/2013/04/from-thalidomide-to-pomalyst-better-living-through-chemistry/">"From thalidomide to Pomalyst: Better living through chemistry — Vector"</a>. Vectorblog.org<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-05-22</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.au=David+Altman&amp;rft.aulast=David+Altman&amp;rft.btitle=From+thalidomide+to+Pomalyst%3A+Better+living+through+chemistry+%E2%80%94+Vector&amp;rft.date=2013-04-02&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fvectorblog.org%2F2013%2F04%2Ffrom-thalidomide-to-pomalyst-better-living-through-chemistry%2F&amp;rft.pub=Vectorblog.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><span class="citation journal">Gieseler F (June 2008). "Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates". <i>Thromb. Haemost.</i> <b>99</b> (6): 1001–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1160%2FTH08-01-0009">10.1160/TH08-01-0009</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18521500">18521500</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Pathophysiological+considerations+to+thrombophilia+in+the+treatment+of+multiple+myeloma+with+thalidomide+and+derivates&amp;rft.aufirst=F&amp;rft.au=Gieseler%2C+F&amp;rft.aulast=Gieseler&amp;rft.date=June+2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1160%2FTH08-01-0009&amp;rft_id=info%3Apmid%2F18521500&amp;rft.issue=6&amp;rft.jtitle=Thromb.+Haemost.&amp;rft.pages=1001-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=99" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-denz-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-denz_22-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Denz U, Haas PS, Wäsch R, Einsele H, Engelhardt M (July 2006). "State of the art therapy in multiple myeloma and future perspectives". <i>Eur. J. Cancer</i> <b>42</b> (11): 1591–600. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.ejca.2005.11.040">10.1016/j.ejca.2005.11.040</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16815703">16815703</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=State+of+the+art+therapy+in+multiple+myeloma+and+future+perspectives&amp;rft.au=Denz%2C+U&amp;rft.au=Einsele%2C+H&amp;rft.au=Engelhardt%2C+M&amp;rft.aufirst=U&amp;rft.au=Haas%2C+PS&amp;rft.aulast=Denz&amp;rft.au=W%C3%A4sch%2C+R&amp;rft.date=July+2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ejca.2005.11.040&amp;rft_id=info%3Apmid%2F16815703&amp;rft.issue=11&amp;rft.jtitle=Eur.+J.+Cancer&amp;rft.pages=1591-600&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=42" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid18182082-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid18182082_23-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Haas PS, Denz U, Ihorst G, Engelhardt M (April 2008). "Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses". <i>Eur. J. Haematol.</i> <b>80</b> (4): 303–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1600-0609.2007.01022.x">10.1111/j.1600-0609.2007.01022.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18182082">18182082</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+in+consecutive+multiple+myeloma+patients%3A+single-center+analysis+on+practical+aspects%2C+efficacy%2C+side+effects+and+prognostic+factors+with+lower+thalidomide+doses&amp;rft.au=Denz%2C+U&amp;rft.au=Engelhardt%2C+M&amp;rft.aufirst=PS&amp;rft.au=Haas%2C+PS&amp;rft.au=Ihorst%2C+G&amp;rft.aulast=Haas&amp;rft.date=April+2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1600-0609.2007.01022.x&amp;rft_id=info%3Apmid%2F18182082&amp;rft.issue=4&amp;rft.jtitle=Eur.+J.+Haematol.&amp;rft.pages=303-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=80" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><span class="citation journal">Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW et al. (December 2006). "Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer". <i>JAMA</i> <b>296</b> (21): 2558–60. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1001%2Fjama.296.21.2558-c">10.1001/jama.296.21.2558-c</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17148721">17148721</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide-+and+lenalidomide-associated+thromboembolism+among+patients+with+cancer&amp;rft.au=Angelotta%2C+C&amp;rft.au=Bennett%2C+CL&amp;rft.au=Evens%2C+AM&amp;rft.aufirst=CL&amp;rft.aulast=Bennett&amp;rft.au=Raisch%2C+DW&amp;rft.au=Richardson%2C+P&amp;rft.au=Yarnold%2C+PR&amp;rft.au=Zonder%2C+JA&amp;rft.date=December+2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.296.21.2558-c&amp;rft_id=info%3Apmid%2F17148721&amp;rft.issue=21&amp;rft.jtitle=JAMA&amp;rft.pages=2558-60&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=296" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-25">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancer.gov/cancertopics/druginfo/fda-thalidomide">"FDA Approval for Thalidomide"</a>. National Cancer Institute<span class="reference-accessdate">. Retrieved <span class="nowrap">8 January</span> 2012</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.btitle=FDA+Approval+for+Thalidomide&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fdruginfo%2Ffda-thalidomide&amp;rft.pub=National+Cancer+Institute&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Desikan-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-Desikan_26-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Desikan R, Munsi N, Zeldis J (1999). "Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease". <i>Blood</i> <b>94</b> (Suppl. 1): 603a–603a.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Activity+of+thalidomide+%28THAL%29+in+multiple+myeloma+%28MM%29+confirmed+in+180+patients+with+advanced+disease&amp;rft.au=Desikan%2C+R&amp;rft.aufirst=R&amp;rft.aulast=Desikan&amp;rft.au=Munsi%2C+N&amp;rft.au=Zeldis%2C+J&amp;rft.date=1999&amp;rft.genre=article&amp;rft.issue=Suppl.+1&amp;rft.jtitle=Blood&amp;rft.pages=603a-603a&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=94" class="Z3988"><span style="display:none;">&#160;</span></span><sup class="noprint Inline-Template" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Verifiability" title="Wikipedia:Verifiability"><span title="The material near this tag needs to be fact-checked with the cited source(s). (June 2013)">verification needed</span></a></i>]</sup></span></li>
<li id="cite_note-DM-27"><span class="mw-cite-backlink">^ <a href="#cite_ref-DM_27-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-DM_27-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2eda833b-1357-4ed4-a093-194524fcb061">"THALOMID (thalidomide) capsule [Celgene Corporation]"</a>. <i>DailyMed</i>. Celgene Corporation. November 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">17 January</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=THALOMID+%28thalidomide%29+capsule+%5BCelgene+Corporation%5D&amp;rft.date=November+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2Flookup.cfm%3Fsetid%3D2eda833b-1357-4ed4-a093-194524fcb061&amp;rft.jtitle=DailyMed&amp;rft.pub=Celgene+Corporation&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-MSR-28"><span class="mw-cite-backlink">^ <a href="#cite_ref-MSR_28-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-MSR_28-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://reference.medscape.com/drug/thalomid-thalidomide-343211#showall">"Thalomid (thalidomide) dosing, indications, interactions, adverse effects, and more"</a>. <i>Medscape Reference</i>. WebMD<span class="reference-accessdate">. Retrieved <span class="nowrap">17 January</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalomid+%28thalidomide%29+dosing%2C+indications%2C+interactions%2C+adverse+effects%2C+and+more&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Freference.medscape.com%2Fdrug%2Fthalomid-thalidomide-343211%23showall&amp;rft.jtitle=Medscape+Reference&amp;rft.pub=WebMD&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-EMC-29"><span class="mw-cite-backlink">^ <a href="#cite_ref-EMC_29-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-EMC_29-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.medicines.org.uk/emc/medicine/21005/SPC/Thalidomide+Celgene+50+mg+Hard+Capsules/">"Thalidomide Celgene 50 mg Hard Capsules"</a>. <i>electronic Medicines Compendium</i>. Celgene Ltd. 1 August 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">17 January</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+Celgene+50+mg+Hard+Capsules&amp;rft.date=1+August+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.medicines.org.uk%2Femc%2Fmedicine%2F21005%2FSPC%2FThalidomide%2BCelgene%2B50%2Bmg%2BHard%2BCapsules%2F&amp;rft.jtitle=electronic+Medicines+Compendium&amp;rft.pub=Celgene+Ltd&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-TGA-30"><span class="mw-cite-backlink">^ <a href="#cite_ref-TGA_30-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-TGA_30-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-TGA_30-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-TGA_30-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-TGA_30-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-TGA_30-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-TGA_30-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-TGA_30-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-TGA_30-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-TGA_30-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-TGA_30-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-TGA_30-11"><sup><i><b>l</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&amp;id=CP-2010-PI-03581-3">"THALOMID® CAPSULES"</a> <span style="font-size:85%;">(PDF)</span>. <i>TGA eBusiness Services</i>. Celgene Pty Limited. 21 June 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">17 January</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=THALOMID%C2%AE+CAPSULES&amp;rft.date=21+June+2013&amp;rft.genre=article&amp;rft_id=https%3A%2F%2Fwww.ebs.tga.gov.au%2Febs%2Fpicmi%2Fpicmirepository.nsf%2Fpdf%3FOpenAgent%26id%3DCP-2010-PI-03581-3&amp;rft.jtitle=TGA+eBusiness+Services&amp;rft.pub=Celgene+Pty+Limited&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><span class="citation news">The Myeloma Beacon Staff (8 April 2011). <a rel="nofollow" class="external text" href="http://www.myelomabeacon.com/news/2011/04/08/fda-announces-investigation-into-revlimid-lenalidomide-thalidomide-thalomid-and-secondary-cancers/">"FDA Announces Investigation Into Revlimid, Thalidomide, And Secondary Cancers"</a>. <i>The Myeloma Beacon</i><span class="reference-accessdate">. Retrieved <span class="nowrap">17 January</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=FDA+Announces+Investigation+Into+Revlimid%2C+Thalidomide%2C+And+Secondary+Cancers&amp;rft.aulast=The+Myeloma+Beacon+Staff&amp;rft.au=The+Myeloma+Beacon+Staff&amp;rft.date=8+April+2011&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.myelomabeacon.com%2Fnews%2F2011%2F04%2F08%2Ffda-announces-investigation-into-revlimid-lenalidomide-thalidomide-thalomid-and-secondary-cancers%2F&amp;rft.jtitle=The+Myeloma+Beacon&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-32">^</a></b></span> <span class="reference-text"><span class="citation journal">Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S et al. (August 2012). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/content/120/8/1597.full.pdf">"Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance"</a> <span style="font-size:85%;">(PDF)</span>. <i>Blood</i> <b>120</b> (8): 1597–1600. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2012-04-421883">10.1182/blood-2012-04-421883</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3429303">3429303</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22674807">22674807</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Second+malignancies+in+total+therapy+2+and+3+for+newly+diagnosed+multiple+myeloma%3A+influence+of+thalidomide+and+lenalidomide+during+maintenance&amp;rft.au=Ahmad%2C+N&amp;rft.au=Al+Sayed%2C+Y&amp;rft.au=Atrash%2C+S&amp;rft.au=Barlogie%2C+B&amp;rft.au=Chauhan%2C+N&amp;rft.au=Crowley%2C+J&amp;rft.aufirst=SZ&amp;rft.au=Heuck%2C+CJ&amp;rft.au=Hoering%2C+A&amp;rft.aulast=Usmani&amp;rft.au=Nair%2C+B&amp;rft.au=Petty%2C+N&amp;rft.au=Sexton%2C+R&amp;rft.au=Usmani%2C+SZ&amp;rft.au=van+Rhee%2C+F&amp;rft.au=Waheed%2C+S&amp;rft.date=August+2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcontent%2F120%2F8%2F1597.full.pdf&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2012-04-421883&amp;rft_id=info%3Apmc%2F3429303&amp;rft_id=info%3Apmid%2F22674807&amp;rft.issue=8&amp;rft.jtitle=Blood&amp;rft.pages=1597-1600&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=120" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON282739">"Thalidomide: risk of second primary malignancies"</a>. <i>Medicines and Healthcare products Regulatory Agency</i>. May 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">17 January</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide%3A+risk+of+second+primary+malignancies&amp;rft.date=May+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.mhra.gov.uk%2FSafetyinformation%2FDrugSafetyUpdate%2FCON282739&amp;rft.jtitle=Medicines+and+Healthcare+products+Regulatory+Agency&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cbc.ca/news/health/story/2013/05/22/thalidomide-cancer.html">"Thalidomide drug label to warn of cancer risk"</a>. <i>CBC News</i>. May 22, 2013.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+drug+label+to+warn+of+cancer+risk&amp;rft.date=May+22%2C+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cbc.ca%2Fnews%2Fhealth%2Fstory%2F2013%2F05%2F22%2Fthalidomide-cancer.html&amp;rft.jtitle=CBC+News&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-mech-35"><span class="mw-cite-backlink">^ <a href="#cite_ref-mech_35-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-mech_35-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Kim JH, Scialli AR (July 2011). <a rel="nofollow" class="external text" href="http://toxsci.oxfordjournals.org/content/122/1/1.full.pdf">"Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease"</a> <span style="font-size:85%;">(PDF)</span>. <i>Toxicological Sciences</i> <b>122</b> (1): 1–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1093%2Ftoxsci%2Fkfr088">10.1093/toxsci/kfr088</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21507989">21507989</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide%3A+The+Tragedy+of+Birth+Defects+and+the+Effective+Treatment+of+Disease&amp;rft.aufirst=JH&amp;rft.au=Kim%2C+JH&amp;rft.aulast=Kim&amp;rft.au=Scialli%2C+AR&amp;rft.date=July+2011&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Ftoxsci.oxfordjournals.org%2Fcontent%2F122%2F1%2F1.full.pdf&amp;rft_id=info%3Adoi%2F10.1093%2Ftoxsci%2Fkfr088&amp;rft_id=info%3Apmid%2F21507989&amp;rft.issue=1&amp;rft.jtitle=Toxicological+Sciences&amp;rft.pages=1-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=122" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-mech2-36"><span class="mw-cite-backlink">^ <a href="#cite_ref-mech2_36-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-mech2_36-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-mech2_36-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-mech2_36-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Singhal S, Mehta J (February 2002). "Thalidomide in cancer". <i>Biomedicine &amp; Pharmacotherapy</i> <b>56</b> (1): 4–12. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0753-3322%2801%2900146-9">10.1016/S0753-3322(01)00146-9</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11905508">11905508</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+in+cancer&amp;rft.aufirst=S&amp;rft.aulast=Singhal&amp;rft.au=Mehta%2C+J&amp;rft.au=Singhal%2C+S&amp;rft.date=February+2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0753-3322%2801%2900146-9&amp;rft_id=info%3Apmid%2F11905508&amp;rft.issue=1&amp;rft.jtitle=Biomedicine+%26+Pharmacotherapy&amp;rft.pages=4-12&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=56" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-37">^</a></b></span> <span class="reference-text"><span class="citation journal">Sarno EN, Grau GE, Vieira LM, Nery JA (April 1991). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1535359">"Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states"</a>. <i>Clin. Exp. Immunol.</i> <b>84</b> (1): 103–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1365-2249.1991.tb08131.x">10.1111/j.1365-2249.1991.tb08131.x</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1535359">1535359</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2015700">2015700</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Serum+levels+of+tumour+necrosis+factor-alpha+and+interleukin-1+beta+during+leprosy+reactional+states&amp;rft.aufirst=EN&amp;rft.au=Grau%2C+GE&amp;rft.aulast=Sarno&amp;rft.au=Nery%2C+JA&amp;rft.au=Sarno%2C+EN&amp;rft.au=Vieira%2C+LM&amp;rft.date=April+1991&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1535359&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1365-2249.1991.tb08131.x&amp;rft_id=info%3Apmc%2F1535359&amp;rft_id=info%3Apmid%2F2015700&amp;rft.issue=1&amp;rft.jtitle=Clin.+Exp.+Immunol.&amp;rft.pages=103-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=84" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Stephens-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-Stephens_38-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Stephens TD, Bunde CJ, Fillmore BJ (June 2000). "Mechanism of action in thalidomide teratogenesis". <i>Biochem. Pharmacol.</i> <b>59</b> (12): 1489–99. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0006-2952%2899%2900388-3">10.1016/S0006-2952(99)00388-3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10799645">10799645</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Mechanism+of+action+in+thalidomide+teratogenesis&amp;rft.au=Bunde%2C+CJ&amp;rft.au=Fillmore%2C+BJ&amp;rft.aufirst=TD&amp;rft.aulast=Stephens&amp;rft.au=Stephens%2C+TD&amp;rft.date=June+2000&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0006-2952%2899%2900388-3&amp;rft_id=info%3Apmid%2F10799645&amp;rft.issue=12&amp;rft.jtitle=Biochem.+Pharmacol.&amp;rft.pages=1489-99&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=59" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid7513432-39"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid7513432_39-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid7513432_39-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC43727">"Thalidomide is an inhibitor of angiogenesis"</a>. <i>Proceedings of the National Academy of Sciences of the United States of America</i> <b>91</b> (9): 4082–4085. <a href="/wiki/Bibcode" title="Bibcode">Bibcode</a>:<a rel="nofollow" class="external text" href="http://adsabs.harvard.edu/abs/1994PNAS...91.4082D">1994PNAS...91.4082D</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1073%2Fpnas.91.9.4082">10.1073/pnas.91.9.4082</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC43727">43727</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7513432">7513432</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+is+an+inhibitor+of+angiogenesis&amp;rft.au=D%27Amato%2C+RJ&amp;rft.aufirst=RJ&amp;rft.au=Flynn%2C+E&amp;rft.au=Folkman%2C+J&amp;rft.aulast=D%27Amato&amp;rft.au=Loughnan%2C+MS&amp;rft.date=1994&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC43727&amp;rft_id=info%3Abibcode%2F1994PNAS...91.4082D&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.91.9.4082&amp;rft_id=info%3Apmc%2F43727&amp;rft_id=info%3Apmid%2F7513432&amp;rft.issue=9&amp;rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America&amp;rft.pages=4082-4085&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=91" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-40"><span class="mw-cite-backlink"><b><a href="#cite_ref-40">^</a></b></span> <span class="reference-text"><span class="citation journal">Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N (May 2009). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2688998">"Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation"</a>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <b>106</b> (21): 8573–8. <a href="/wiki/Bibcode" title="Bibcode">Bibcode</a>:<a rel="nofollow" class="external text" href="http://adsabs.harvard.edu/abs/2009PNAS..106.8573T">2009PNAS..106.8573T</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1073%2Fpnas.0901505106">10.1073/pnas.0901505106</a>. <a href="/wiki/JSTOR" title="JSTOR">JSTOR</a>&#160;<a rel="nofollow" class="external text" href="//www.jstor.org/stable/40482723">40482723</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2688998">2688998</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19433787">19433787</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+induces+limb+defects+by+preventing+angiogenic+outgrowth+during+early+limb+formation&amp;rft.au=Erskine%2C+L&amp;rft.au=Figg%2C+WD&amp;rft.aufirst=C&amp;rft.au=Gardner%2C+ER&amp;rft.aulast=Therapontos&amp;rft.au=Therapontos%2C+C&amp;rft.au=Vargesson%2C+N&amp;rft.date=May+2009&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2688998&amp;rft_id=info%3Abibcode%2F2009PNAS..106.8573T&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.0901505106&amp;rft_id=info%3Apmc%2F2688998&amp;rft_id=info%3Apmid%2F19433787&amp;rft.issue=21&amp;rft.jstor=40482723&amp;rft.jtitle=Proc.+Natl.+Acad.+Sci.+U.S.A.&amp;rft.pages=8573-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=106" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-stereospecific44-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-stereospecific44_41-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Eriksson T, Björkman S, Roth B, Fyge A, Höglund P (1995). "Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide". <i>Chirality</i> <b>7</b> (1): 44–52. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2Fchir.530070109">10.1002/chir.530070109</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7702998">7702998</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Stereospecific+determination%2C+chiral+inversion+in+vitro+and+pharmacokinetics+in+humans+of+the+enantiomers+of+thalidomide&amp;rft.au=Bj%C3%B6rkman%2C+S&amp;rft.au=Eriksson%2C+T&amp;rft.aufirst=T&amp;rft.au=Fyge%2C+A&amp;rft.au=H%C3%B6glund%2C+P&amp;rft.aulast=Eriksson&amp;rft.au=Roth%2C+B&amp;rft.date=1995&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fchir.530070109&amp;rft_id=info%3Apmid%2F7702998&amp;rft.issue=1&amp;rft.jtitle=Chirality&amp;rft.pages=44-52&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=7" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Muller_1996-42"><span class="mw-cite-backlink">^ <a href="#cite_ref-Muller_1996_42-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Muller_1996_42-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G et al. (August 1996). "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity". <i>J. Med. Chem.</i> <b>39</b> (17): 3238–40. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1021%2Fjm9603328">10.1021/jm9603328</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8765505">8765505</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Structural+modifications+of+thalidomide+produce+analogs+with+enhanced+tumor+necrosis+factor+inhibitory+activity&amp;rft.au=Corral%2C+LG&amp;rft.aufirst=GW&amp;rft.au=Kaplan%2C+G&amp;rft.aulast=Muller&amp;rft.au=Moreira%2C+A&amp;rft.au=Muller%2C+GW&amp;rft.au=Shire%2C+MG&amp;rft.au=Stirling%2C+DI&amp;rft.au=Wang%2C+H&amp;rft.date=August+1996&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1021%2Fjm9603328&amp;rft_id=info%3Apmid%2F8765505&amp;rft.issue=17&amp;rft.jtitle=J.+Med.+Chem.&amp;rft.pages=3238-40&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=39" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid14505639-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid14505639_43-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Man HW, Corral LG, Stirling DI, Muller GW (October 2003). "Alpha-fluoro-substituted thalidomide analogues". <i>Bioorg. Med. Chem. Lett.</i> <b>13</b> (20): 3415–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0960-894X%2803%2900778-9">10.1016/S0960-894X(03)00778-9</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14505639">14505639</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Alpha-fluoro-substituted+thalidomide+analogues&amp;rft.au=Corral%2C+LG&amp;rft.aufirst=HW&amp;rft.aulast=Man&amp;rft.au=Man%2C+HW&amp;rft.au=Muller%2C+GW&amp;rft.au=Stirling%2C+DI&amp;rft.date=October+2003&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0960-894X%2803%2900778-9&amp;rft_id=info%3Apmid%2F14505639&amp;rft.issue=20&amp;rft.jtitle=Bioorg.+Med.+Chem.+Lett.&amp;rft.pages=3415-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=13" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Bartlett2004-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-Bartlett2004_44-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Bartlett JB, Dredge K, Dalgleish AG (April 2004). "The evolution of thalidomide and its IMiD derivatives as anticancer agents". <i>Nat. Rev. Cancer</i> <b>4</b> (4): 314–22. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fnrc1323">10.1038/nrc1323</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15057291">15057291</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=The+evolution+of+thalidomide+and+its+IMiD+derivatives+as+anticancer+agents&amp;rft.au=Bartlett%2C+JB&amp;rft.au=Dalgleish%2C+AG&amp;rft.au=Dredge%2C+K&amp;rft.aufirst=JB&amp;rft.aulast=Bartlett&amp;rft.date=April+2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fnrc1323&amp;rft_id=info%3Apmid%2F15057291&amp;rft.issue=4&amp;rft.jtitle=Nat.+Rev.+Cancer&amp;rft.pages=314-22&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=4" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid19256507-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid19256507_45-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Man HW, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H et al. (March 2009). "Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor". <i>J. Med. Chem.</i> <b>52</b> (6): 1522–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1021%2Fjm900210d">10.1021/jm900210d</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19256507">19256507</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Discovery+of+%28S%29-N-%5B2-%5B1-%283-ethoxy-4-methoxyphenyl%29-2-methanesulfonylethyl%5D-1%2C3-dioxo-2%2C3-dihydro-1H-isoindol-4-yl%5D+acetamide+%28apremilast%29%2C+a+potent+and+orally+active+phosphodiesterase+4+and+tumor+necrosis+factor-alpha+inhibitor&amp;rft.au=Babusis%2C+DM&amp;rft.au=Blease%2C+K&amp;rft.au=Chen%2C+R&amp;rft.au=Corral%2C+LG&amp;rft.aufirst=HW&amp;rft.aulast=Man&amp;rft.au=Leisten%2C+J&amp;rft.au=Man%2C+HW&amp;rft.au=Muller%2C+GW&amp;rft.au=Patterson%2C+RT&amp;rft.au=Raymon%2C+H&amp;rft.au=Schafer%2C+P&amp;rft.au=Shirley%2C+MA&amp;rft.au=Stirling%2C+D&amp;rft.au=Tang%2C+Y&amp;rft.au=Wong%2C+LM&amp;rft.date=March+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1021%2Fjm900210d&amp;rft_id=info%3Apmid%2F19256507&amp;rft.issue=6&amp;rft.jtitle=J.+Med.+Chem.&amp;rft.pages=1522-4&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=52" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-nyt-answers-46"><span class="mw-cite-backlink">^ <a href="#cite_ref-nyt-answers_46-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-nyt-answers_46-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation news"><a href="/wiki/Carl_Zimmer" title="Carl Zimmer">Zimmer C</a> (March 15, 2010). <a rel="nofollow" class="external text" href="http://www.nytimes.com/2010/03/16/science/16limb.html?ref=science&amp;pagewanted=all">"Answers Begin to Emerge on How Thalidomide Caused Defects"</a>. <a href="/wiki/New_York_Times" title="New York Times" class="mw-redirect">New York Times</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2010-03-21</span></span>. <q>As they report in the current issue of Science, a protein known as cereblon latched on tightly to the thalidomide</q></span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.aulast=Zimmer+C&amp;rft.au=Zimmer+C&amp;rft.btitle=Answers+Begin+to+Emerge+on+How+Thalidomide+Caused+Defects&amp;rft.date=March+15%2C+2010&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.nytimes.com%2F2010%2F03%2F16%2Fscience%2F16limb.html%3Fref%3Dscience%26pagewanted%3Dall&amp;rft.pub=New+York+Times&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid23858438-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid23858438_47-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Mahony C, Erskine L, Niven J, Greig NH, Figg WD, Vargesson N (2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3732931">"Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro"</a>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <b>110</b> (31): 12703–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1073%2Fpnas.1307684110">10.1073/pnas.1307684110</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3732931">3732931</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23858438">23858438</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Pomalidomide+is+nonteratogenic+in+chicken+and+zebrafish+embryos+and+nonneurotoxic+in+vitro&amp;rft.aulast=Mahony+C%2C+Erskine+L%2C+Niven+J%2C+Greig+NH%2C+Figg+WD%2C+Vargesson+N&amp;rft.au=Mahony+C%2C+Erskine+L%2C+Niven+J%2C+Greig+NH%2C+Figg+WD%2C+Vargesson+N&amp;rft.date=2013&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3732931&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.1307684110&amp;rft_id=info%3Apmc%2F3732931&amp;rft_id=info%3Apmid%2F23858438&amp;rft.issue=31&amp;rft.jtitle=Proc.+Natl.+Acad.+Sci.+U.S.A.&amp;rft.pages=12703-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=110" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22552008-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid22552008_48-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R (2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3496085">"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide"</a>. <i>Leukemia</i> <b>26</b> (11): 2326–35. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fleu.2012.119">10.1038/leu.2012.119</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3496085">3496085</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22552008">22552008</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Cereblon+is+a+direct+protein+target+for+immunomodulatory+and+antiproliferative+activities+of+lenalidomide+and+pomalidomide&amp;rft.aulast=Lopez-Girona+A%2C+Mendy+D%2C+Ito+T%2C+Miller+K%2C+Gandhi+AK%2C+Kang+J%2C+Karasawa+S%2C+Carmel+G%2C+Jackson+P%2C+Abbasian+M%2C+Mahmoudi+A%2C+Cathers+B%2C+Rychak+E%2C+Gaidarova+S%2C+Chen+R%2C+Schafer+PH%2C+Handa+H%2C+Daniel+TO%2C+Evans+JF%2C+Chopra+R&amp;rft.au=Lopez-Girona+A%2C+Mendy+D%2C+Ito+T%2C+Miller+K%2C+Gandhi+AK%2C+Kang+J%2C+Karasawa+S%2C+Carmel+G%2C+Jackson+P%2C+Abbasian+M%2C+Mahmoudi+A%2C+Cathers+B%2C+Rychak+E%2C+Gaidarova+S%2C+Chen+R%2C+Schafer+PH%2C+Handa+H%2C+Daniel+TO%2C+Evans+JF%2C+Chopra+R&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3496085&amp;rft_id=info%3Adoi%2F10.1038%2Fleu.2012.119&amp;rft_id=info%3Apmc%2F3496085&amp;rft_id=info%3Apmid%2F22552008&amp;rft.issue=11&amp;rft.jtitle=Leukemia&amp;rft.pages=2326-35&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=26" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://oncozine.com/page/thalidomide-secret-past-the-link-with-nazi-germany">Thalidomide's Secret Past: The Link with Nazi Germany -Onco'Zine - The International Oncology Network (November 30, 2013)</a></span></li>
<li id="cite_note-pmid15172781-50"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid15172781_50-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid15172781_50-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid15172781_50-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid15172781_50-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Franks ME, Macpherson GR, Figg WD (May 2004). "Thalidomide". <i>Lancet</i> <b>363</b> (9423): 1802–11. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0140-6736%2804%2916308-3">10.1016/S0140-6736(04)16308-3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15172781">15172781</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide&amp;rft.au=Figg%2C+WD&amp;rft.aufirst=ME&amp;rft.au=Franks%2C+ME&amp;rft.aulast=Franks&amp;rft.au=Macpherson%2C+GR&amp;rft.date=May+2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2804%2916308-3&amp;rft_id=info%3Apmid%2F15172781&amp;rft.issue=9423&amp;rft.jtitle=Lancet&amp;rft.pages=1802-11&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=363" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Bombay-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-Bombay_51-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Moghe VV, Kulkarni U, Parmar UI (2008). <a rel="nofollow" class="external text" href="http://web.archive.org/web/20110722164029/http://www.bhj.org/journal/2008_5003_july/download/page-472-476.pdf">"Thalidomide"</a> <span style="font-size:85%;">(PDF)</span>. <i>Bombay Hospital Journal</i> (Bombay: Bombay Hospital) <b>50</b> (3): 473. Archived from <a rel="nofollow" class="external text" href="http://www.bhj.org/journal/2008_5003_july/download/page-472-476.pdf">the original</a> <span style="font-size:85%;">(PDF)</span> on 22 July 2011.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide&amp;rft.aufirst=VV&amp;rft.au=Kulkarni%2C+U&amp;rft.aulast=Moghe&amp;rft.au=Moghe%2C+VV&amp;rft.au=Parmar%2C+UI&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.bhj.org%2Fjournal%2F2008_5003_july%2Fdownload%2Fpage-472-476.pdf&amp;rft.issue=3&amp;rft.jtitle=Bombay+Hospital+Journal&amp;rft.pages=473&amp;rft.place=Bombay&amp;rft.pub=Bombay+Hospital&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=50" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-52">^</a></b></span> <span class="reference-text">See Rouquette (1957) cited by <span class="citation journal">Landesman-Dwyer S (1982). "Maternal drinking and pregnancy outcome". <i>Appl Res Ment Retard</i> <b>3</b> (3): 241–63. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2F0270-3092%2882%2990018-2">10.1016/0270-3092(82)90018-2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7149705">7149705</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Maternal+drinking+and+pregnancy+outcome&amp;rft.aufirst=S&amp;rft.au=Landesman-Dwyer%2C+S&amp;rft.aulast=Landesman-Dwyer&amp;rft.date=1982&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2F0270-3092%2882%2990018-2&amp;rft_id=info%3Apmid%2F7149705&amp;rft.issue=3&amp;rft.jtitle=Appl+Res+Ment+Retard&amp;rft.pages=241-63&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=3" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-53">^</a></b></span> <span class="reference-text"><span class="citation journal">Kelsey FO (1967). "Events after thalidomide". <i>J. Dent. Res.</i> <b>46</b> (6): 1201–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1177%2F00220345670460061201">10.1177/00220345670460061201</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/5235007">5235007</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Events+after+thalidomide&amp;rft.aufirst=FO&amp;rft.au=Kelsey%2C+FO&amp;rft.aulast=Kelsey&amp;rft.date=1967&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1177%2F00220345670460061201&amp;rft_id=info%3Apmid%2F5235007&amp;rft.issue=6&amp;rft.jtitle=J.+Dent.+Res.&amp;rft.pages=1201-5&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=46" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-VFA-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-VFA_54-0">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.vfa.de/de/arzneimittel-forschung/artikel-arzneimittel-forschung/teratogenitaet.html">VFA: teratogenic effects</a> 6. July 2011.</span></li>
<li id="cite_note-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-55">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.fda.gov/fdac/features/2001/201_kelsey.html">Report</a> on the website of the U.S. Food and Drug Administration</span></li>
<li id="cite_note-pmid14076167-56"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid14076167_56-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid14076167_56-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid14076167_56-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid14076167_56-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-pmid14076167_56-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Webb JF (November 1963). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1921912">"Canadian Thalidomide Experience"</a>. <i>Can Med Assoc J</i> <b>89</b>: 987–92. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1921912">1921912</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14076167">14076167</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Canadian+Thalidomide+Experience&amp;rft.aufirst=JF&amp;rft.aulast=Webb&amp;rft.au=Webb%2C+JF&amp;rft.date=November+1963&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1921912&amp;rft_id=info%3Apmc%2F1921912&amp;rft_id=info%3Apmid%2F14076167&amp;rft.jtitle=Can+Med+Assoc+J&amp;rft.pages=987-92&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=89" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid10447943-57"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid10447943_57-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Shah JH, Swartz GM, Papathanassiu AE, Treston AM, Fogler WE, Madsen JW et al. (1999). "Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis". <i>J. Med. Chem.</i> <b>42</b> (16): 3014–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1021%2Fjm990083y">10.1021/jm990083y</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10447943">10447943</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Synthesis+and+enantiomeric+separation+of+2-phthalimidino-glutaric+acid+analogues%3A+potent+inhibitors+of+tumor+metastasis&amp;rft.aufirst=JH&amp;rft.au=Fogler%2C+WE&amp;rft.au=Green%2C+SJ&amp;rft.aulast=Shah&amp;rft.au=Madsen%2C+JW&amp;rft.au=Papathanassiu%2C+AE&amp;rft.au=Shah%2C+JH&amp;rft.au=Swartz%2C+GM&amp;rft.au=Treston%2C+AM&amp;rft.date=1999&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1021%2Fjm990083y&amp;rft_id=info%3Apmid%2F10447943&amp;rft.issue=16&amp;rft.jtitle=J.+Med.+Chem.&amp;rft.pages=3014-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=42" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid11740816-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid11740816_58-0">^</a></b></span> <span class="reference-text"><span class="citation journal">D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS (2001). "Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma". <i>Seminars in Oncology</i> <b>28</b> (6): 597–601. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0093-7754%2801%2990031-4">10.1016/S0093-7754(01)90031-4</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11740816">11740816</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Mechanism+of+action+of+thalidomide+and+3-aminothalidomide+in+multiple+myeloma&amp;rft.au=Anderson%2C+KC&amp;rft.au=D%27Amato%2C+RJ&amp;rft.aufirst=RJ&amp;rft.aulast=D%27Amato&amp;rft.au=Lentzsch%2C+S&amp;rft.au=Rogers%2C+MS&amp;rft.date=2001&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0093-7754%2801%2990031-4&amp;rft_id=info%3Apmid%2F11740816&amp;rft.issue=6&amp;rft.jtitle=Seminars+in+Oncology&amp;rft.pages=597-601&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=28" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-59">^</a></b></span> <span class="reference-text"><span class="citation journal">Rao KV (September 2007). "Lenalidomide in the treatment of multiple myeloma". <i>Am J Health Syst Pharm</i> <b>64</b> (17): 1799–807. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2146%2Fajhp070029">10.2146/ajhp070029</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17724360">17724360</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Lenalidomide+in+the+treatment+of+multiple+myeloma&amp;rft.aufirst=KV&amp;rft.aulast=Rao&amp;rft.au=Rao%2C+KV&amp;rft.date=September+2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2146%2Fajhp070029&amp;rft_id=info%3Apmid%2F17724360&amp;rft.issue=17&amp;rft.jtitle=Am+J+Health+Syst+Pharm&amp;rft.pages=1799-807&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=64" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-60"><span class="mw-cite-backlink"><b><a href="#cite_ref-60">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://clinicaltrials.gov/ct/search?term=pomalidomide&amp;submit=Search">"Search of: pomalidomide"</a>. Clinicaltrials.gov<span class="reference-accessdate">. Retrieved <span class="nowrap">2012-09-01</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.btitle=Search+of%3A+pomalidomide&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fclinicaltrials.gov%2Fct%2Fsearch%3Fterm%3Dpomalidomide%26submit%3DSearch&amp;rft.pub=Clinicaltrials.gov&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-61"><span class="mw-cite-backlink"><b><a href="#cite_ref-61">^</a></b></span> <span class="reference-text"><span class="citation journal">Raghupathy R, Billett HH (March 2009). "Promising therapies in sickle cell disease". <i>Cardiovasc Hematol Disord Drug Targets</i> <b>9</b> (1): 1–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2174%2F187152909787581354">10.2174/187152909787581354</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19275572">19275572</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Promising+therapies+in+sickle+cell+disease&amp;rft.au=Billett%2C+HH&amp;rft.aufirst=R&amp;rft.aulast=Raghupathy&amp;rft.au=Raghupathy%2C+R&amp;rft.date=March+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.2174%2F187152909787581354&amp;rft_id=info%3Apmid%2F19275572&amp;rft.issue=1&amp;rft.jtitle=Cardiovasc+Hematol+Disord+Drug+Targets&amp;rft.pages=1-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-P1-62"><span class="mw-cite-backlink"><b><a href="#cite_ref-P1_62-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.myelomabeacon.com/news/2013/02/08/pomalyst-pomalidomide-fda-approval-multiple-myeloma/">"Pomalyst (Pomalidomide) Approved By FDA For Relapsed And Refractory Multiple Myeloma"</a>. The Myeloma Beacon<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-08-10</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.btitle=Pomalyst+%28Pomalidomide%29+Approved+By+FDA+For+Relapsed+And+Refractory+Multiple+Myeloma&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.myelomabeacon.com%2Fnews%2F2013%2F02%2F08%2Fpomalyst-pomalidomide-fda-approval-multiple-myeloma%2F&amp;rft.pub=The+Myeloma+Beacon&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-P2-63"><span class="mw-cite-backlink"><b><a href="#cite_ref-P2_63-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.myelomabeacon.com/news/2013/08/09/pomalidomide-imnovid-pomalyst-europe-ema-approval-multiple-myeloma/">"Pomalidomide Approved In Europe For Relapsed And Refractory Multiple Myeloma"</a>. The Myeloma Beacon<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-08-10</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.btitle=Pomalidomide+Approved+In+Europe+For+Relapsed+And+Refractory+Multiple+Myeloma&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.myelomabeacon.com%2Fnews%2F2013%2F08%2F09%2Fpomalidomide-imnovid-pomalyst-europe-ema-approval-multiple-myeloma%2F&amp;rft.pub=The+Myeloma+Beacon&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-EMA-64"><span class="mw-cite-backlink"><b><a href="#cite_ref-EMA_64-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000823/WC500037050.pdf">"Thalidomide Celgene&#160;: EPAR - Product Information"</a> <span style="font-size:85%;">(PDF)</span>. <i>European Medicines Agency</i>. Celgene Europe Limited. 29 August 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">19 January</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+Celgene+%3A+EPAR+-+Product+Information&amp;rft.date=29+August+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FEPAR_-_Product_Information%2Fhuman%2F000823%2FWC500037050.pdf&amp;rft.jtitle=European+Medicines+Agency&amp;rft.pub=Celgene+Europe+Limited&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-65"><span class="mw-cite-backlink"><b><a href="#cite_ref-65">^</a></b></span> <span class="reference-text"><span class="citation web">Lewis, R (26 November 2013). <a rel="nofollow" class="external text" href="http://www.medscape.com/viewarticle/815047">"Thalidomide Induced Remission in Early-Onset Crohn's Disease"</a>. <i>Medscape Medical News</i>. WebMD<span class="reference-accessdate">. Retrieved <span class="nowrap">19 January</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+Induced+Remission+in+Early-Onset+Crohn%27s+Disease&amp;rft.aulast=Lewis%2C+R&amp;rft.au=Lewis%2C+R&amp;rft.date=26+November+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F815047&amp;rft.jtitle=Medscape+Medical+News&amp;rft.pub=WebMD&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Rev-66"><span class="mw-cite-backlink">^ <a href="#cite_ref-Rev_66-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Rev_66-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Rev_66-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Rev_66-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Rev_66-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Rev_66-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Rev_66-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Rev_66-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Rev_66-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Rev_66-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Rev_66-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Rev_66-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Rev_66-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Rev_66-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Rev_66-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Rev_66-15"><sup><i><b>p</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Franks ME, Macpherson GR, Figg WD (May 2004). "Thalidomide". <i>Lancet</i> <b>363</b> (9423): 1802–1811. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0140-6736%2804%2916308-3">10.1016/S0140-6736(04)16308-3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15172781">15172781</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide&amp;rft.au=Figg%2C+WD&amp;rft.aufirst=ME&amp;rft.au=Franks%2C+ME&amp;rft.aulast=Franks&amp;rft.au=Macpherson%2C+GR&amp;rft.date=May+2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0140-6736%2804%2916308-3&amp;rft_id=info%3Apmid%2F15172781&amp;rft.issue=9423&amp;rft.jtitle=Lancet&amp;rft.pages=1802-1811&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=363" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-67"><span class="mw-cite-backlink"><b><a href="#cite_ref-67">^</a></b></span> <span class="reference-text"><span class="citation web">Okafor, MC (2003). <a rel="nofollow" class="external text" href="http://www.medscape.com/viewarticle/451859">"Thalidomide for Erythema Nodosum Leprosum and Other Applications"</a>. <i>Medscape Medical News</i>. WebMD<span class="reference-accessdate">. Retrieved <span class="nowrap">19 January</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+for+Erythema+Nodosum+Leprosum+and+Other+Applications&amp;rft.aulast=Okafor%2C+MC&amp;rft.au=Okafor%2C+MC&amp;rft.date=2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.medscape.com%2Fviewarticle%2F451859&amp;rft.jtitle=Medscape+Medical+News&amp;rft.pub=WebMD&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-68">^</a></b></span> <span class="reference-text"><span class="citation journal">Waters MF (March 1971). "An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum". <i>Leprosy Review</i> <b>42</b> (1): 26–42. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/4338720">4338720</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=An+internally-controlled+double+blind+trial+of+thalidomide+in+severe+erythema+nodosum+leprosum&amp;rft.aufirst=MF&amp;rft.aulast=Waters&amp;rft.au=Waters%2C+MF&amp;rft.date=March+1971&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F4338720&amp;rft.issue=1&amp;rft.jtitle=Leprosy+Review&amp;rft.pages=26-42&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=42" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-69"><span class="mw-cite-backlink"><b><a href="#cite_ref-69">^</a></b></span> <span class="reference-text"><span class="citation journal">Villahermosa LG, Fajardo TT, Abalos RM, Balagon MV, Tan EV, Cellona RV et al. (May 2005). <a rel="nofollow" class="external text" href="http://www.ajtmh.org/content/72/5/518.full.pdf">"A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum"</a> <span style="font-size:85%;">(PDF)</span>. <i>The American Journal of Tropical Medicine and Hygiene</i> <b>72</b> (5): 518–526. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15891124">15891124</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=A+randomized%2C+double-blind%2C+double-dummy%2C+controlled+dose+comparison+of+thalidomide+for+treatment+of+erythema+nodosum+leprosum&amp;rft.au=Abalos%2C+RM&amp;rft.au=Balagon%2C+MV&amp;rft.au=Cellona%2C+RV&amp;rft.au=Fajardo%2C+TT&amp;rft.aufirst=LG&amp;rft.au=Kook%2C+KA&amp;rft.aulast=Villahermosa&amp;rft.au=Palmer%2C+JP&amp;rft.au=Tan%2C+EV&amp;rft.au=Thomas%2C+SD&amp;rft.au=Villahermosa%2C+LG&amp;rft.au=Walsh%2C+DS&amp;rft.au=Walsh%2C+GP&amp;rft.au=Wittes%2C+J&amp;rft.date=May+2005&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.ajtmh.org%2Fcontent%2F72%2F5%2F518.full.pdf&amp;rft_id=info%3Apmid%2F15891124&amp;rft.issue=5&amp;rft.jtitle=The+American+Journal+of+Tropical+Medicine+and+Hygiene&amp;rft.pages=518-526&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=72" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-70">^</a></b></span> <span class="reference-text"><span class="citation web">Rose, LJ; Fishman, AD; Sparano, JA (11 March 2013). Talavera, F; McKenna, R; Harris, JE, ed. <a rel="nofollow" class="external text" href="http://emedicine.medscape.com/article/279734-treatment#showall">"Kaposi Sarcoma Treatment &amp; Management"</a>. <i>Medscape Reference</i>. WebMD<span class="reference-accessdate">. Retrieved <span class="nowrap">19 January</span> 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Kaposi+Sarcoma+Treatment+%26+Management&amp;rft.aulast=Rose%2C+LJ%3B+Fishman%2C+AD%3B+Sparano%2C+JA&amp;rft.au=Rose%2C+LJ%3B+Fishman%2C+AD%3B+Sparano%2C+JA&amp;rft.date=11+March+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Femedicine.medscape.com%2Farticle%2F279734-treatment%23showall&amp;rft.jtitle=Medscape+Reference&amp;rft.pub=WebMD&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Bren-71"><span class="mw-cite-backlink">^ <a href="#cite_ref-Bren_71-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Bren_71-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Bren_71-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation news">Bren L (2001-02-28). <a rel="nofollow" class="external text" href="http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/features/2001/201_kelsey.html">"Frances Oldham Kelsey: FDA Medical Reviewer Leaves Her Mark on History"</a>. <i>FDA Consumer</i> (U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a>)<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-12-23</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Frances+Oldham+Kelsey%3A+FDA+Medical+Reviewer+Leaves+Her+Mark+on+History&amp;rft.au=Bren+L&amp;rft.aulast=Bren+L&amp;rft.date=2001-02-28&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fpermanent.access.gpo.gov%2Flps1609%2Fwww.fda.gov%2Ffdac%2Ffeatures%2F2001%2F201_kelsey.html&amp;rft.jtitle=FDA+Consumer&amp;rft.pub=U.S.+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-72"><span class="mw-cite-backlink"><b><a href="#cite_ref-72">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.history.ca/ontv/titledetails.aspx?titleid=21267">"Turning Points of History–Prescription for Disaster"</a>. History Television<span class="reference-accessdate">. Retrieved <span class="nowrap">24 February</span> 2010</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.btitle=Turning+Points+of+History%E2%80%93Prescription+for+Disaster&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.history.ca%2Fontv%2Ftitledetails.aspx%3Ftitleid%3D21267&amp;rft.pub=History+Television&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span><sup class="noprint Inline-Template"><span style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Link_rot" title="Wikipedia:Link rot"><span title="&#160;since September 2012">dead link</span></a></i>]</span></sup></span></li>
<li id="cite_note-73"><span class="mw-cite-backlink"><b><a href="#cite_ref-73">^</a></b></span> <span class="reference-text"><span class="citation news"><a rel="nofollow" class="external text" href="http://news.bbc.co.uk/1/hi/health/8458855.stm">"Apology for thalidomide survivors"</a>. <i>BBCNews:Health</i> (BBC News). 14 January 2010<span class="reference-accessdate">. Retrieved <span class="nowrap">2010-01-14</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Apology+for+thalidomide+survivors&amp;rft.date=14+January+2010&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F1%2Fhi%2Fhealth%2F8458855.stm&amp;rft.jtitle=BBCNews%3AHealth&amp;rft.pub=BBC+News&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-name-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-name_74-0">^</a></b></span> <span class="reference-text"><span class="citation news">Scott, Caroline; Haupt, Oliver (3 May 2015). <a rel="nofollow" class="external text" href="http://www.thesundaytimes.co.uk/sto/Magazine/article1551306.ece">"The forgotten victims"</a>. <i><a href="/wiki/The_Sunday_Times_Magazine" title="The Sunday Times Magazine">The Sunday Times Magazine</a></i>. pp.&#160;12–19<span class="reference-accessdate">. Retrieved <span class="nowrap">8 May</span> 2015</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=The+forgotten+victims&amp;rft.aufirst=Caroline&amp;rft.au=Haupt%2C+Oliver&amp;rft.aulast=Scott&amp;rft.au=Scott%2C+Caroline&amp;rft.date=3+May+2015&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.thesundaytimes.co.uk%2Fsto%2FMagazine%2Farticle1551306.ece&amp;rft.jtitle=The+Sunday+Times+Magazine&amp;rft.pages=12-19&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-75"><span class="mw-cite-backlink"><b><a href="#cite_ref-75">^</a></b></span> <span class="reference-text"><span class="citation web">Anon. <a rel="nofollow" class="external text" href="http://www.whonamedit.com/doctor.cfm/1002.html">"Widukind Lenz"</a>. <i>who name it?</i>. Ole Daniel Enersen<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-05-01</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Widukind+Lenz&amp;rft.au=Anon&amp;rft.aulast=Anon&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.whonamedit.com%2Fdoctor.cfm%2F1002.html&amp;rft.jtitle=who+name+it%3F&amp;rft.pub=Ole+Daniel+Enersen&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-40_years_on-76"><span class="mw-cite-backlink">^ <a href="#cite_ref-40_years_on_76-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-40_years_on_76-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation news">Anon (2002-06-07). <a rel="nofollow" class="external text" href="http://news.bbc.co.uk/1/hi/uk/2031459.stm">"Thalidomide:40 years on"</a>. <i>BBC news</i> (BBC)<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-05-01</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide%3A40+years+on&amp;rft.au=Anon&amp;rft.aulast=Anon&amp;rft.date=2002-06-07&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F1%2Fhi%2Fuk%2F2031459.stm&amp;rft.jtitle=BBC+news&amp;rft.pub=BBC&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-77"><span class="mw-cite-backlink"><b><a href="#cite_ref-77">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://embryology.med.unsw.edu.au/Defect/page5i.htm">"Report of Thalidomide at University of New South Wales"</a>. Embryology.med.unsw.edu.au<span class="reference-accessdate">. Retrieved <span class="nowrap">2012-12-30</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.btitle=Report+of+Thalidomide+at+University+of+New+South+Wales&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fembryology.med.unsw.edu.au%2FDefect%2Fpage5i.htm&amp;rft.pub=Embryology.med.unsw.edu.au&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-78"><span class="mw-cite-backlink"><b><a href="#cite_ref-78">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="https://www.neues-deutschland.de/artikel/120351.html">"DDR-Bürger schliefen ohne Contergan" [East German citizens slept without thalidomide]</a>. <i><a href="/wiki/Neues_Deutschland" title="Neues Deutschland">Neues Deutschland</a></i> (in German). 4 November 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">Jun 6,</span> 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=DDR-B%C3%BCrger+schliefen+ohne+Contergan&amp;rft.date=4+November+2007&amp;rft.genre=article&amp;rft_id=https%3A%2F%2Fwww.neues-deutschland.de%2Fartikel%2F120351.html&amp;rft.jtitle=Neues+Deutschland&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-daeb-79"><span class="mw-cite-backlink">^ <a href="#cite_ref-daeb_79-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-daeb_79-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-daeb_79-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-daeb_79-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-daeb_79-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Thomann, Klaus-Dieter (2007). <a rel="nofollow" class="external text" href="http://www.aerzteblatt.de/archiv/57224/">"Die Contergan-Katastrophe: Die trügerische Sicherheit der "harten" Daten" [The thalidomide disaster: The false security of 'hard' data]</a>. <i>Deutsches Ärzteblatt</i> (in German) <b>104</b> (41): A–2778 / B–2454 / C–2382. <a rel="nofollow" class="external text" href="http://www.contergan-ag50.de/Seiten/presse/20111125-27_artikel/2007_Die_Contergan-Katastrophe_Die_truegerische_Sicherheit_der_harten_Daten-Deutsches_Aerzteblatt.pdf">Archived</a> <span style="font-size:85%;">(PDF)</span> from the original on December 6, 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">June 6,</span> 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Die+Contergan-Katastrophe%3A+Die+tr%C3%BCgerische+Sicherheit+der+%22harten%22+Daten&amp;rft.aufirst=Klaus-Dieter&amp;rft.aulast=Thomann&amp;rft.au=Thomann%2C+Klaus-Dieter&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.aerzteblatt.de%2Farchiv%2F57224%2F&amp;rft.issue=41&amp;rft.jtitle=Deutsches+%C3%84rzteblatt&amp;rft.pages=A-2778+%2F+B-2454+%2F+C-2382&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=104" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-th-80"><span class="mw-cite-backlink">^ <a href="#cite_ref-th_80-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-th_80-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Die Contergankatastrophe: Eine Bilanz Nach 40 Jahren, Ludwig Zichner, Michael A. Rauschmann, Klaus-Dieter Thomann, Gabler Wissenschaftsverlage, 2005 – 190 Seiten</span></li>
<li id="cite_note-81"><span class="mw-cite-backlink"><b><a href="#cite_ref-81">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://orf.at/070930-17124/index.html">"10.000 Fälle von Missbildungen" [10,000 cases of malformations]</a> (in German). <a href="/wiki/ORF_(broadcaster)" title="ORF (broadcaster)">ORF</a><span class="reference-accessdate">. Retrieved <span class="nowrap">June 6,</span> 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.btitle=10.000+F%C3%A4lle+von+Missbildungen&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Forf.at%2F070930-17124%2Findex.html&amp;rft.pub=ORF&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-82"><span class="mw-cite-backlink"><b><a href="#cite_ref-82">^</a></b></span> <span class="reference-text"><span class="citation web">Mekdeci, Betty. <a rel="nofollow" class="external text" href="http://www.birthdefects.org/research/bendectin_1.php">"Bendectin Part 1 (PDF link) How a Commonly Used Drug Caused Birth Defects"</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.aufirst=Betty&amp;rft.aulast=Mekdeci&amp;rft.au=Mekdeci%2C+Betty&amp;rft.btitle=Bendectin+Part+1+%28PDF+link%29++How+a+Commonly+Used+Drug+Caused+Birth+Defects&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.birthdefects.org%2Fresearch%2Fbendectin_1.php&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-83"><span class="mw-cite-backlink"><b><a href="#cite_ref-83">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.contergan.grunenthal.info/grt-ctg/GRT-CTG/Stellungnahme/Rede_anlaesslich_Einweihung_des_Contergan-Denkmals/224600963.jsp">Speech on the occasion of the inauguration of Thalidomide-Memorial; Grünenthal GmbH Website (Last accessed on December 3, 2013)</a></span></li>
<li id="cite_note-84"><span class="mw-cite-backlink"><b><a href="#cite_ref-84">^</a></b></span> <span class="reference-text"><span class="citation news"><a rel="nofollow" class="external text" href="http://www.bbc.co.uk/news/health-19448046">"Thalidomide apology insulting, campaigners say"</a>. <i>BBC News</i>. September 1, 2012.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+apology+insulting%2C+campaigners+say&amp;rft.date=September+1%2C+2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.bbc.co.uk%2Fnews%2Fhealth-19448046&amp;rft.jtitle=BBC+News&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-they_didn.27t_know-85"><span class="mw-cite-backlink"><b><a href="#cite_ref-they_didn.27t_know_85-0">^</a></b></span> <span class="reference-text"><span class="citation news">Ryan, Caroline (1 April 2004). <a rel="nofollow" class="external text" href="http://news.bbc.co.uk/1/hi/health/3589173.stm">"They just didn't know what it would do"</a>. <i>BBC <a rel="nofollow" class="external free" href="News:Health">News:Health</a></i> (BBC news)<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-05-01</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=They+just+didn%27t+know+what+it+would+do&amp;rft.aufirst=Caroline&amp;rft.aulast=Ryan&amp;rft.au=Ryan%2C+Caroline&amp;rft.date=1+April+2004&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F1%2Fhi%2Fhealth%2F3589173.stm&amp;rft.jtitle=BBC+News%3AHealth&amp;rft.pub=BBC+news&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-86"><span class="mw-cite-backlink"><b><a href="#cite_ref-86">^</a></b></span> <span class="reference-text"><span class="citation news">Flintoff, John-Paul (March 23, 2008). <a rel="nofollow" class="external text" href="http://www.timesonline.co.uk/tol/life_and_style/health/article3602694.ece">"Thalidomide: the battle for compensation goes on"</a>. <i>The Sunday Times</i> (London: Times Newspapers Ltd.)<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-05-01</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide%3A+the+battle+for+compensation+goes+on&amp;rft.aufirst=John-Paul&amp;rft.au=Flintoff%2C+John-Paul&amp;rft.aulast=Flintoff&amp;rft.date=March+23%2C+2008&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.timesonline.co.uk%2Ftol%2Flife_and_style%2Fhealth%2Farticle3602694.ece&amp;rft.jtitle=The+Sunday+Times&amp;rft.place=London&amp;rft.pub=Times+Newspapers+Ltd.&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-87"><span class="mw-cite-backlink"><b><a href="#cite_ref-87">^</a></b></span> <span class="reference-text"><span class="citation news"><a rel="nofollow" class="external text" href="http://news.bbc.co.uk/1/hi/health/4658919.stm">"Compensation offer on Thalidomide"</a>. BBC News. 7 July 2005<span class="reference-accessdate">. Retrieved <span class="nowrap">26 July</span> 2011</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.btitle=Compensation+offer+on+Thalidomide&amp;rft.date=7+July+2005&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F1%2Fhi%2Fhealth%2F4658919.stm&amp;rft.pub=BBC+News&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-UK_Government_grant-88"><span class="mw-cite-backlink"><b><a href="#cite_ref-UK_Government_grant_88-0">^</a></b></span> <span class="reference-text"><span class="citation news"><a rel="nofollow" class="external text" href="http://news.bbc.co.uk/1/hi/8428838.stm">"Thalidomide survivors to get £20m"</a>. BBC News. 23 December 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">26 July</span> 2011</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.btitle=Thalidomide+survivors+to+get+%C2%A320m&amp;rft.date=23+December+2009&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fnews.bbc.co.uk%2F1%2Fhi%2F8428838.stm&amp;rft.pub=BBC+News&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-89"><span class="mw-cite-backlink"><b><a href="#cite_ref-89">^</a></b></span> <span class="reference-text"><span class="citation news"><a rel="nofollow" class="external text" href="http://www.abc.net.au/news/2011-12-19/australian-thalidomide-victims-win-hearing-bid/3738116">"Australian thalidomide victims win right for hearing"</a>. <i>ABC News</i>. 19 December 2011.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Australian+thalidomide+victims+win+right+for+hearing&amp;rft.date=19+December+2011&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.abc.net.au%2Fnews%2F2011-12-19%2Faustralian-thalidomide-victims-win-hearing-bid%2F3738116&amp;rft.jtitle=ABC+News&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-90"><span class="mw-cite-backlink"><b><a href="#cite_ref-90">^</a></b></span> <span class="reference-text"><span class="citation journal">Warren R (2001). <a rel="nofollow" class="external text" href="http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/departs/2001/201_word.html">"Living in a World With Thalidomide: A Dose of Reality"</a>. <i>FDA Consumer</i> <b>35</b> (2): 40. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11444250">11444250</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Living+in+a+World+With+Thalidomide%3A+A+Dose+of+Reality&amp;rft.aufirst=R&amp;rft.aulast=Warren&amp;rft.au=Warren%2C+R&amp;rft.date=2001&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fpermanent.access.gpo.gov%2Flps1609%2Fwww.fda.gov%2Ffdac%2Fdeparts%2F2001%2F201_word.html&amp;rft_id=info%3Apmid%2F11444250&amp;rft.issue=2&amp;rft.jtitle=FDA+Consumer&amp;rft.pages=40&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=35" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid12909394-91"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid12909394_91-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid12909394_91-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Racz WJ, Ecobichon DJ, Baril M (August 2003). "On-line sources of toxicological information in Canada". <i>Toxicology</i> <b>190</b> (1–2): 3–14. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0300-483X%2803%2900192-6">10.1016/S0300-483X(03)00192-6</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12909394">12909394</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=On-line+sources+of+toxicological+information+in+Canada&amp;rft.au=Baril%2C+M&amp;rft.au=Ecobichon%2C+DJ&amp;rft.aufirst=WJ&amp;rft.aulast=Racz&amp;rft.au=Racz%2C+WJ&amp;rft.date=August+2003&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0300-483X%2803%2900192-6&amp;rft_id=info%3Apmid%2F12909394&amp;rft.issue=1%E2%80%932&amp;rft.jtitle=Toxicology&amp;rft.pages=3-14&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=190" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-92"><span class="mw-cite-backlink"><b><a href="#cite_ref-92">^</a></b></span> <span class="reference-text"><span class="citation news"><a rel="nofollow" class="external text" href="http://www.nytimes.com/2010/09/14/health/14kelsey.html?_r=1&amp;8dpc">"The Public's Quiet Savior From Harmful Medicines"</a>. <i>The New York Times</i>. 13 September 2010.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=The+Public%27s+Quiet+Savior+From+Harmful+Medicines&amp;rft.date=13+September+2010&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.nytimes.com%2F2010%2F09%2F14%2Fhealth%2F14kelsey.html%3F_r%3D1%268dpc&amp;rft.jtitle=The+New+York+Times&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-93"><span class="mw-cite-backlink"><b><a href="#cite_ref-93">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.portlandphoenix.com/archive/music/02/04/19/classical_Orpheus.html">"Orpheus lives: A small good thing in Quastoff"</a>. <i>The Portland Phoenix</i>. April 19, 2002<span class="reference-accessdate">. Retrieved <span class="nowrap">June 6,</span> 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Orpheus+lives%3A+A+small+good+thing+in+Quastoff&amp;rft.date=April+19%2C+2002&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.portlandphoenix.com%2Farchive%2Fmusic%2F02%2F04%2F19%2Fclassical_Orpheus.html&amp;rft.jtitle=The+Portland+Phoenix&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-94"><span class="mw-cite-backlink"><b><a href="#cite_ref-94">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.imdb.com/title/tt1266093/releaseinfo">"NoBody's Perfect (2008): Release Info"</a>. IMDB<span class="reference-accessdate">. Retrieved <span class="nowrap">June 6,</span> 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.btitle=NoBody%27s+Perfect+%282008%29%3A+Release+Info&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.imdb.com%2Ftitle%2Ftt1266093%2Freleaseinfo&amp;rft.pub=IMDB&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-95"><span class="mw-cite-backlink"><b><a href="#cite_ref-95">^</a></b></span> <span class="reference-text"><span class="citation web">Brussat, Frederic; Brussat, Mary Ann. <a rel="nofollow" class="external text" href="http://www.spiritualityandpractice.com/films/films.php?id=19559">"Film Review: NoBody's Perfect"</a>. Spirituality &amp; Practice<span class="reference-accessdate">. Retrieved <span class="nowrap">June 6,</span> 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.au=Brussat%2C+Frederic&amp;rft.au=Brussat%2C+Mary+Ann&amp;rft.aufirst=Frederic&amp;rft.aulast=Brussat&amp;rft.btitle=Film+Review%3A+NoBody%27s+Perfect&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.spiritualityandpractice.com%2Ffilms%2Ffilms.php%3Fid%3D19559&amp;rft.pub=Spirituality+%26+Practice&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-96"><span class="mw-cite-backlink"><b><a href="#cite_ref-96">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.fda.gov/Drugs/NewsEvents/ucm320924.htm">"50 Years: The Kefauver-Harris Amendments"</a>. <a href="/wiki/Food_and_Drug_Administration_(United_States)" title="Food and Drug Administration (United States)" class="mw-redirect">Food and Drug Administration (United States)</a><span class="reference-accessdate">. Retrieved <span class="nowrap">6 June</span> 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.btitle=50+Years%3A+The+Kefauver-Harris+Amendments&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FDrugs%2FNewsEvents%2Fucm320924.htm&amp;rft.pub=Food+and+Drug+Administration+%28United+States%29&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-97"><span class="mw-cite-backlink"><b><a href="#cite_ref-97">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.crncc.nihr.ac.uk/workforce_development/learning_and_development/gcp/gcp_resource/research_standards/history/thalidomide">"Thalidomide"</a>. <a href="/wiki/National_Health_Service_(England)" title="National Health Service (England)">National Health Service (England)</a><span class="reference-accessdate">. Retrieved <span class="nowrap">6 June</span> 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.btitle=Thalidomide&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.crncc.nihr.ac.uk%2Fworkforce_development%2Flearning_and_development%2Fgcp%2Fgcp_resource%2Fresearch_standards%2Fhistory%2Fthalidomide&amp;rft.pub=National+Health+Service+%28England%29&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-98"><span class="mw-cite-backlink"><b><a href="#cite_ref-98">^</a></b></span> <span class="reference-text"><span class="citation journal">Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM (April 2005). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774430/pdf/gut05400540.pdf">"Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial"</a> <span style="font-size:85%;">(PDF)</span>. <i>GUT</i> <b>54</b> (4): 540–545. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1136%2Fgut.2004.047563">10.1136/gut.2004.047563</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1774430">1774430</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15753541">15753541</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Effects+of+thalidomide+on+HIV-associated+wasting+syndrome%3A+a+randomized%2C+double-blind%2C+placebo-controlled+clinical+trial&amp;rft.au=Duncan%2C+HD&amp;rft.au=Ellis%2C+RD&amp;rft.aufirst=JN&amp;rft.au=Goggin%2C+PM&amp;rft.au=Gordon%2C+JN&amp;rft.au=Johns%2C+T&amp;rft.aulast=Gordon&amp;rft.au=Trebble%2C+TM&amp;rft.date=April+2005&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1774430%2Fpdf%2Fgut05400540.pdf&amp;rft_id=info%3Adoi%2F10.1136%2Fgut.2004.047563&amp;rft_id=info%3Apmc%2F1774430&amp;rft_id=info%3Apmid%2F15753541&amp;rft.issue=4&amp;rft.jtitle=GUT&amp;rft.pages=540-545&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=54" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-99"><span class="mw-cite-backlink"><b><a href="#cite_ref-99">^</a></b></span> <span class="reference-text"><span class="citation journal">Sharpstone D, Rowbottom A, Francis N, Tovey G, Ellis D, Barrett M et al. (June 1997). "Thalidomide: a novel therapy for microsporidiosis". <i>Gastroenterology</i> <b>112</b> (6): 1823–1829. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1053%2Fgast.1997.v112.pm9178672">10.1053/gast.1997.v112.pm9178672</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9178672">9178672</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide%3A+a+novel+therapy+for+microsporidiosis&amp;rft.au=Barrett%2C+M&amp;rft.au=Ellis%2C+D&amp;rft.aufirst=D&amp;rft.au=Francis%2C+N&amp;rft.au=Gazzard%2C+B&amp;rft.aulast=Sharpstone&amp;rft.au=Rowbottom%2C+A&amp;rft.au=Sharpstone%2C+D&amp;rft.au=Tovey%2C+G&amp;rft.date=June+1997&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1053%2Fgast.1997.v112.pm9178672&amp;rft_id=info%3Apmid%2F9178672&amp;rft.issue=6&amp;rft.jtitle=Gastroenterology&amp;rft.pages=1823-1829&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=112" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-100"><span class="mw-cite-backlink"><b><a href="#cite_ref-100">^</a></b></span> <span class="reference-text"><span class="citation journal">Tunio MA, Hashmi A, Qayyum A, Naimatullah N, Masood R (September 2012). "Low-dose thalidomide in patients with metastatic renal cell carcinoma". <i>Journal of the Pakistan Medical Association</i> <b>62</b> (9): 876–879. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23139966">23139966</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Low-dose+thalidomide+in+patients+with+metastatic+renal+cell+carcinoma&amp;rft.aufirst=MA&amp;rft.au=Hashmi%2C+A&amp;rft.aulast=Tunio&amp;rft.au=Masood%2C+R&amp;rft.au=Naimatullah%2C+N&amp;rft.au=Qayyum%2C+A&amp;rft.au=Tunio%2C+MA&amp;rft.date=September+2012&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F23139966&amp;rft.issue=9&amp;rft.jtitle=Journal+of+the+Pakistan+Medical+Association&amp;rft.pages=876-879&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=62" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-101"><span class="mw-cite-backlink"><b><a href="#cite_ref-101">^</a></b></span> <span class="reference-text"><span class="citation journal">Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S et al. (March 1998). "Thalidomide in the treatment of the mucocutaneous lesions of the Behcet Syndrome: a randomized, double-blind, placebo-controlled trial". <i>Annals of Internal Medicine</i> <b>128</b> (6): 443–450. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.7326%2F0003-4819-128-6-199803150-00004">10.7326/0003-4819-128-6-199803150-00004</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9499327">9499327</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide+in+the+treatment+of+the+mucocutaneous+lesions+of+the+Behcet+Syndrome%3A+a+randomized%2C+double-blind%2C+placebo-controlled+trial&amp;rft.aufirst=V&amp;rft.au=Hamuryudan%2C+V&amp;rft.aulast=Hamuryudan&amp;rft.au=Mat%2C+C&amp;rft.au=Ozyazgan%2C+Y&amp;rft.au=Saip%2C+S&amp;rft.au=Siva%2C+A&amp;rft.au=Yazici%2C+H&amp;rft.au=Yurdakul%2C+S&amp;rft.au=Zwingenberger%2C+K&amp;rft.date=March+1998&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.7326%2F0003-4819-128-6-199803150-00004&amp;rft_id=info%3Apmid%2F9499327&amp;rft.issue=6&amp;rft.jtitle=Annals+of+Internal+Medicine&amp;rft.pages=443-450&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=128" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="Further_reading">Further reading</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=28" title="Edit section: Further reading">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><span class="citation book">Stephens, Trent; Brynner, Rock (2001-12-24). <i>Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine</i>. <a href="/wiki/Perseus_Books" title="Perseus Books" class="mw-redirect">Perseus Books</a>. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0-7382-0590-7" title="Special:BookSources/0-7382-0590-7">0-7382-0590-7</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.au=Brynner%2C+Rock&amp;rft.aufirst=Trent&amp;rft.aulast=Stephens&amp;rft.au=Stephens%2C+Trent&amp;rft.btitle=Dark+Remedy%3A+The+Impact+of+Thalidomide+and+Its+Revival+as+a+Vital+Medicine&amp;rft.date=2001-12-24&amp;rft.genre=book&amp;rft.isbn=0-7382-0590-7&amp;rft.pub=Perseus+Books&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></li>
<li><span class="citation book"><a href="/wiki/Phillip_Knightley" title="Phillip Knightley">Knightley, Phillip</a>; <a href="/wiki/Harold_Evans" title="Harold Evans">Evans, Harold</a> (1979). <i>Suffer The Children: The Story of Thalidomide</i>. New York: <a href="/wiki/The_Viking_Press" title="The Viking Press" class="mw-redirect">The Viking Press</a>. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0-670-68114-8" title="Special:BookSources/0-670-68114-8">0-670-68114-8</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.au=Evans%2C+Harold&amp;rft.aufirst=Phillip&amp;rft.au=Knightley%2C+Phillip&amp;rft.aulast=Knightley&amp;rft.btitle=Suffer+The+Children%3A+The+Story+of+Thalidomide&amp;rft.date=1979&amp;rft.genre=book&amp;rft.isbn=0-670-68114-8&amp;rft.place=New+York&amp;rft.pub=The+Viking+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></li>
</ul>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Thalidomide&amp;action=edit&amp;section=29" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><span class="citation journal">Rouhi, Maureen (2005). <a rel="nofollow" class="external text" href="http://pubs.acs.org/cen/coverstory/83/8325/8325thalidomide.html">"Thalidomide"</a>. <i>Chemical &amp; Engineering News</i> <b>83</b> (25): 122. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:10.1021/cen-v083n025.p122 (inactive 2015-01-09). <a rel="nofollow" class="external text" href="http://www.webcitation.org/5nWHyOCfI">Archived</a> from the original on February 13, 2010<span class="reference-accessdate">. Retrieved <span class="nowrap">June 6,</span> 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AThalidomide&amp;rft.atitle=Thalidomide&amp;rft.aufirst=Maureen&amp;rft.aulast=Rouhi&amp;rft.au=Rouhi%2C+Maureen&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fpubs.acs.org%2Fcen%2Fcoverstory%2F83%2F8325%2F8325thalidomide.html&amp;rft_id=info%3Adoi%2F10.1021%2Fcen-v083n025.p122&amp;rft.issue=25&amp;rft.jtitle=Chemical+%26+Engineering+News&amp;rft.pages=122&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=83" class="Z3988"><span style="display:none;">&#160;</span></span></li>
<li><a rel="nofollow" class="external autonumber" href="http://www.thalidomide.com.au/corporateweb/thalidomideau/home.nsf/Content/ThalidomideMonograph.pdf/$FILE/ThalidomideMonograph.pdfThalidomideproductmonograph">[1]</a> (Needs registration)</li>
<li><a rel="nofollow" class="external text" href="http://myeloma.org/IndexPage.action?tabId=1&amp;menuId=151&amp;indexPageId=66&amp;parentTabId=0&amp;parentKeywordId=0&amp;parentLinkId=975&amp;parentNuggetId=0&amp;parentMenuItemId=0&amp;categoryId=201InternationalMyelomaFoundationarticle">on Thalidomide</a></li>
<li><a rel="nofollow" class="external text" href="http://www.k-faktor.com/thalidomide/">Thalidomide&#160;— Annotated List of Links (covering English and German pages)</a></li>
<li><a rel="nofollow" class="external text" href="http://www.who.int/entity/medicines/publications/newsletter/en/news2003_2.pdf">WHO Pharmaceuticals Newsletter No. 2, 2003 – See page 11, Feature Article</a></li>
<li><a rel="nofollow" class="external text" href="http://www.contergan.grunenthal.info/grt-ctg/GRT-CTG/Stellungnahme/Was_bedeutet_die_Contergan-Tragoedie_fur_Grunenthal_/157000151.jspGrünenthal">GmbH — Thalidomide</a></li>
<li><a rel="nofollow" class="external text" href="http://www.thalomid.com/">Celgene website on Thalomid</a></li>
<li><a rel="nofollow" class="external text" href="http://www.bbc.co.uk/insideout/southwest/series7/thalidomide.shtml">The Return of Thalidomide&#160;— BBC</a></li>
<li><a rel="nofollow" class="external text" href="http://archives.cbc.ca/IDD-1-75-88/science_technology/thalidomide/">CBC Digital Archives&#160;– Thalidomide: Bitter Pills, Broken Promises</a></li>
<li><a rel="nofollow" class="external text" href="http://www.thalidomideuk.com/">Thalidomide UK</a></li>
<li><a rel="nofollow" class="external text" href="http://www.thalidomidetrust.org/">The Thalidomide Trust</a></li>
<li><a rel="nofollow" class="external text" href="http://www.ictacampaign.com/">The International Contergan Thalidomide Alliance website</a></li>
<li><a rel="nofollow" class="external text" href="http://www.prweekus.com/THE-BIG-PITCH-How-would-you-conduct-a-PR-campaign-for-the-newThalidomide-drugs/article/41655/">"The Big Pitch: How would you conduct a campaign for the new Thalidomide Drugs?"</a>, forum of pharmaceutical and medical marketing professionals commenting on how they would address the thalidomine controversies.</li>
<li><a rel="nofollow" class="external text" href="http://www.smh.com.au/national/the-50year-global-coverup-20120725-22r5c.html">The 50-year global cover-up</a></li>
</ul>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Immunosuppressants" title="Template:Immunosuppressants"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Immunosuppressants" title="Template talk:Immunosuppressants"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Immunosuppressants&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%"><a href="/wiki/Immunosuppressive_drug" title="Immunosuppressive drug">Immunosuppressive drugs</a>&#160;/ <a href="/wiki/Immunosuppression" title="Immunosuppression">Immunosuppressants</a> (<a href="/wiki/ATC_code_L04" title="ATC code L04">L04</a>)</div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Intracellular<br />
(initiation)</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Antimetabolite" title="Antimetabolite">Antimetabolites</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/Purine_synthesis_inhibitor" title="Purine synthesis inhibitor" class="mw-redirect">purine synthesis inhibitors</a>:</i> <a href="/wiki/Azathioprine" title="Azathioprine">Azathioprine</a></li>
<li><a href="/wiki/Mycophenolic_acid" title="Mycophenolic acid">Mycophenolic acid</a></li>
</ul>
<ul>
<li><i><a href="/wiki/Pyrimidine_synthesis_inhibitor" title="Pyrimidine synthesis inhibitor" class="mw-redirect">pyrimidine synthesis inhibitors</a>:</i> <a href="/wiki/Leflunomide" title="Leflunomide">Leflunomide</a></li>
<li><a href="/wiki/Teriflunomide" title="Teriflunomide">Teriflunomide</a></li>
</ul>
<ul>
<li><i><a href="/wiki/Antifolate" title="Antifolate">antifolate</a>:</i> <a href="/wiki/Methotrexate" title="Methotrexate">Methotrexate</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Macrolide" title="Macrolide">Macrolides</a>/<br />
other <a href="/wiki/Interleukin_2" title="Interleukin 2">IL-2</a> inhibitors</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/FKBP" title="FKBP">FKBP</a>/<a href="/wiki/Cyclophilin" title="Cyclophilin">Cyclophilin</a>/<a href="/wiki/Calcineurin" title="Calcineurin">Calcineurin</a>:</i> <a href="/wiki/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><a href="/wiki/Ciclosporin" title="Ciclosporin">Ciclosporin</a></li>
<li><a href="/wiki/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li>
</ul>
<ul>
<li><a href="/wiki/Abetimus" title="Abetimus">Abetimus</a></li>
<li><a href="/wiki/Gusperimus" title="Gusperimus">Gusperimus</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">IMiDs</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Lenalidomide" title="Lenalidomide">Lenalidomide</a></li>
<li><a href="/wiki/Pomalidomide" title="Pomalidomide">Pomalidomide</a></li>
<li><strong class="selflink">Thalidomide</strong></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Intracellular<br />
(reception)</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Interleukin_1_receptor_antagonist" title="Interleukin 1 receptor antagonist">IL-1 receptor antagonists</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Anakinra" title="Anakinra">Anakinra</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Mammalian_target_of_rapamycin" title="Mammalian target of rapamycin" class="mw-redirect">mTOR</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Sirolimus" title="Sirolimus">Sirolimus</a></li>
<li><a href="/wiki/Everolimus" title="Everolimus">Everolimus</a></li>
<li><a href="/wiki/Ridaforolimus" title="Ridaforolimus">Ridaforolimus</a></li>
<li><a href="/wiki/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li>
<li><a href="/wiki/Umirolimus" title="Umirolimus">Umirolimus</a></li>
<li><a href="/wiki/Zotarolimus" title="Zotarolimus">Zotarolimus</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Extracellular</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Antibody" title="Antibody">Antibodies</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Monoclonal_antibodies" title="Monoclonal antibodies" class="mw-redirect">Monoclonal</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group">Serum target<br />
(noncellular)</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/Complement_component_5" title="Complement component 5">Complement component 5</a></i> (<a href="/wiki/Eculizumab" title="Eculizumab">Eculizumab</a>)</li>
<li><i><a href="/wiki/TNF_inhibitor" title="TNF inhibitor">TNF</a></i> (<a href="/wiki/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li><a href="/wiki/Afelimomab" title="Afelimomab">Afelimomab</a></li>
<li><a href="/wiki/Certolizumab_pegol" title="Certolizumab pegol">Certolizumab pegol</a></li>
<li><a href="/wiki/Golimumab" title="Golimumab">Golimumab</a></li>
<li><a href="/wiki/Infliximab" title="Infliximab">Infliximab</a></li>
<li><a href="/wiki/Nerelimomab" title="Nerelimomab">Nerelimomab</a>)</li>
<li><i><a href="/wiki/Interleukin_5" title="Interleukin 5">Interleukin 5</a></i> (<a href="/wiki/Mepolizumab" title="Mepolizumab">Mepolizumab</a>)</li>
<li><i><a href="/wiki/Immunoglobulin_E" title="Immunoglobulin E">Immunoglobulin E</a></i> (<a href="/wiki/Omalizumab" title="Omalizumab">Omalizumab</a>)</li>
</ul>
<ul>
<li><i><a href="/wiki/Interferon" title="Interferon">Interferon</a></i> (<a href="/wiki/Faralimomab" title="Faralimomab">Faralimomab</a>)</li>
</ul>
<ul>
<li><i><a href="/wiki/Interleukin_6" title="Interleukin 6">IL-6</a></i> (<a href="/wiki/Elsilimomab" title="Elsilimomab">Elsilimomab</a>)</li>
</ul>
<ul>
<li><i><a href="/wiki/Interleukin_12" title="Interleukin 12">IL-12</a> and <a href="/wiki/Interleukin_23" title="Interleukin 23">IL-23</a></i> (<a href="/wiki/Lebrikizumab" title="Lebrikizumab">Lebrikizumab</a></li>
<li><a href="/wiki/Ustekinumab" title="Ustekinumab">Ustekinumab</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Cellular target</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/CD3_(immunology)" title="CD3 (immunology)">CD3</a></i> (<a href="/wiki/Muromonab-CD3" title="Muromonab-CD3">Muromonab-CD3</a></li>
<li><a href="/wiki/Otelixizumab" title="Otelixizumab">Otelixizumab</a></li>
<li><a href="/wiki/Teplizumab" title="Teplizumab">Teplizumab</a></li>
<li><a href="/wiki/Visilizumab" title="Visilizumab">Visilizumab</a>)</li>
<li><i><a href="/wiki/CD4" title="CD4">CD4</a></i> (<a href="/wiki/Clenoliximab" title="Clenoliximab">Clenoliximab</a></li>
<li><a href="/wiki/Keliximab" title="Keliximab">Keliximab</a></li>
<li><a href="/wiki/Zanolimumab" title="Zanolimumab">Zanolimumab</a>)</li>
<li><i><a href="/wiki/CD11a" title="CD11a">CD11a</a></i> (<a href="/wiki/Efalizumab" title="Efalizumab">Efalizumab</a>)</li>
<li><i><a href="/wiki/CD18" title="CD18">CD18</a></i> (<a href="/wiki/Erlizumab" title="Erlizumab">Erlizumab</a>)</li>
<li><i><a href="/wiki/CD20" title="CD20">CD20</a></i> (<a href="/wiki/Obinutuzumab" title="Obinutuzumab">Obinutuzumab</a></li>
<li><a href="/wiki/Rituximab" title="Rituximab">Rituximab</a></li>
<li><a href="/wiki/Ocrelizumab" title="Ocrelizumab">Ocrelizumab</a></li>
<li><a href="/wiki/Pascolizumab" title="Pascolizumab">Pascolizumab</a>)</li>
<li><i><a href="/wiki/CD23" title="CD23">CD23</a></i> (<a href="/wiki/Gomiliximab" title="Gomiliximab">Gomiliximab</a></li>
<li><a href="/wiki/Lumiliximab" title="Lumiliximab">Lumiliximab</a>)</li>
<li><i><a href="/wiki/CD40_(protein)" title="CD40 (protein)">CD40</a></i> (<a href="/wiki/Teneliximab" title="Teneliximab">Teneliximab</a></li>
<li><a href="/wiki/Toralizumab" title="Toralizumab">Toralizumab</a>)</li>
<li><i><a href="/wiki/L-selectin" title="L-selectin">CD62L/L-selectin</a></i> (<a href="/wiki/Aselizumab" title="Aselizumab">Aselizumab</a>)</li>
<li><i><a href="/wiki/CD80" title="CD80">CD80</a></i> (<a href="/wiki/Galiximab" title="Galiximab">Galiximab</a>)</li>
<li><i><a href="/wiki/Basigin" title="Basigin">CD147/Basigin</a></i> (<a href="/wiki/Gavilimomab" title="Gavilimomab">Gavilimomab</a>)</li>
<li><i><a href="/wiki/CD154" title="CD154">CD154</a></i> (<a href="/wiki/Ruplizumab" title="Ruplizumab">Ruplizumab</a>)</li>
</ul>
<ul>
<li><i>BLyS</i> (<a href="/wiki/Belimumab" title="Belimumab">Belimumab</a></li>
<li><a href="/wiki/Blisibimod" title="Blisibimod">Blisibimod</a>)</li>
<li><i><a href="/wiki/CTLA-4" title="CTLA-4">CTLA-4</a></i> (<a href="/wiki/Ipilimumab" title="Ipilimumab">Ipilimumab</a></li>
<li><a href="/wiki/Tremelimumab" title="Tremelimumab">Tremelimumab</a>)</li>
<li><i><a href="/wiki/Chloramphenicol_acetyltransferase" title="Chloramphenicol acetyltransferase">CAT</a></i> (<a href="/wiki/Bertilimumab" title="Bertilimumab">Bertilimumab</a></li>
<li><a href="/wiki/Lerdelimumab" title="Lerdelimumab">Lerdelimumab</a></li>
<li><a href="/wiki/Metelimumab" title="Metelimumab">Metelimumab</a>)</li>
<li><i><a href="/wiki/Integrin" title="Integrin">Integrin</a></i> (<a href="/wiki/Natalizumab" title="Natalizumab">Natalizumab</a>)</li>
<li><i><a href="/wiki/Interleukin-6_receptor" title="Interleukin-6 receptor">Interleukin-6 receptor</a></i> (<a href="/wiki/Tocilizumab" title="Tocilizumab">Tocilizumab</a>)</li>
<li><i><a href="/wiki/Lymphocyte_function-associated_antigen_1" title="Lymphocyte function-associated antigen 1">LFA-1</a></i> (<a href="/wiki/Odulimomab" title="Odulimomab">Odulimomab</a>)</li>
</ul>
<ul>
<li><i><a href="/wiki/IL-2_receptor" title="IL-2 receptor">IL-2 receptor/CD25</a></i> (<a href="/wiki/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li><a href="/wiki/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li><a href="/wiki/Inolimomab" title="Inolimomab">Inolimomab</a>)</li>
</ul>
<ul>
<li><i><a href="/wiki/T_cell" title="T cell">T-lymphocyte</a></i> (<a href="/wiki/Zolimomab_aritox" title="Zolimomab aritox">Zolimomab aritox</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Unsorted</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Atorolimumab" title="Atorolimumab">Atorolimumab</a></li>
<li><a href="/wiki/Cedelizumab" title="Cedelizumab">Cedelizumab</a></li>
<li><a href="/wiki/Fontolizumab" title="Fontolizumab">Fontolizumab</a></li>
<li><a href="/wiki/Maslimomab" title="Maslimomab">Maslimomab</a></li>
<li><a href="/wiki/Morolimumab" title="Morolimumab">Morolimumab</a></li>
<li><a href="/wiki/Pexelizumab" title="Pexelizumab">Pexelizumab</a></li>
<li><a href="/wiki/Reslizumab" title="Reslizumab">Reslizumab</a></li>
<li><a href="/wiki/Rovelizumab" title="Rovelizumab">Rovelizumab</a></li>
<li><a href="/wiki/Siplizumab" title="Siplizumab">Siplizumab</a></li>
<li><a href="/wiki/Talizumab" title="Talizumab">Talizumab</a></li>
<li><a href="/wiki/Telimomab_aritox" title="Telimomab aritox">Telimomab aritox</a></li>
<li><a href="/wiki/Vapaliximab" title="Vapaliximab">Vapaliximab</a></li>
<li><a href="/wiki/Vepalimomab" title="Vepalimomab">Vepalimomab</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Polyclonal_antibodies" title="Polyclonal antibodies">Polyclonal</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Anti-thymocyte_globulin" title="Anti-thymocyte globulin">Anti-thymocyte globulin</a></li>
<li><a href="/wiki/Anti-lymphocyte_globulin" title="Anti-lymphocyte globulin">Anti-lymphocyte globulin</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">-cept (<a href="/wiki/Fusion_protein" title="Fusion protein">Fusion</a>)</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/CTLA-4" title="CTLA-4">CTLA-4</a></i> (<a href="/wiki/Abatacept" title="Abatacept">Abatacept</a></li>
<li><a href="/wiki/Belatacept" title="Belatacept">Belatacept</a>)</li>
<li><i><a href="/wiki/TNF_inhibitor" title="TNF inhibitor">TNF inhibitor</a></i> (<a href="/wiki/Etanercept" title="Etanercept">Etanercept</a></li>
<li><a href="/wiki/Pegsunercept" title="Pegsunercept">Pegsunercept</a>)</li>
<li><a href="/wiki/Aflibercept" title="Aflibercept">Aflibercept</a></li>
<li><a href="/wiki/Alefacept" title="Alefacept">Alefacept</a></li>
<li><a href="/wiki/Rilonacept" title="Rilonacept">Rilonacept</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;">
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Lymph_immune_and_complement_navs" title="Template:Lymph immune and complement navs"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Lymph_immune_and_complement_navs" title="Template talk:Lymph immune and complement navs"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Lymph_immune_and_complement_navs&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%">Index of the <a href="/wiki/Immune_system" title="Immune system">immune system</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Description</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Lymphocytic_immune_system" title="Template:Lymphocytic immune system">Physiology</a>
<ul>
<li><a href="/wiki/Template:Lymphocytes" title="Template:Lymphocytes">cells</a></li>
<li><a href="/wiki/Template:Autoantigens" title="Template:Autoantigens">autoantigens</a></li>
<li><a href="/wiki/Template:Autoantibodies" title="Template:Autoantibodies">autoantibodies</a></li>
<li><a href="/wiki/Template:Complement_system" title="Template:Complement system">complement</a></li>
<li><a href="/wiki/Template:Surface_antigens" title="Template:Surface antigens">surface antigens</a></li>
<li><a href="/wiki/Template:Immunoglobulin_superfamily_immune_receptors" title="Template:Immunoglobulin superfamily immune receptors">IG receptors</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Disease</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Allergic_conditions" title="Template:Allergic conditions">Allergies</a></li>
<li><a href="/wiki/Template:Lymphoid_and_complement_immunodeficiency" title="Template:Lymphoid and complement immunodeficiency">Immunodeficiency</a></li>
<li><a href="/wiki/Template:Immunoproliferative_immunoglobulin_disorders" title="Template:Immunoproliferative immunoglobulin disorders">Immunoproliferative immunoglobulin disorders</a></li>
<li><a href="/wiki/Template:Hypersensitivity_and_autoimmune_diseases" title="Template:Hypersensitivity and autoimmune diseases">Hypersensitivity and autoimmune disorders</a></li>
<li><a href="/wiki/Template:Lymphoid_malignancy" title="Template:Lymphoid malignancy">Neoplasms and cancer</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Treatment</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Immunologic_techniques_and_tests" title="Template:Immunologic techniques and tests">Procedures</a></li>
<li>Drugs
<ul>
<li><a href="/wiki/Template:Antihistamines" title="Template:Antihistamines">antihistamines</a></li>
<li><a href="/wiki/Template:Immunostimulants" title="Template:Immunostimulants">immunostimulants</a></li>
<li><a href="/wiki/Template:Immunosuppressants" title="Template:Immunosuppressants">immunosuppressants</a></li>
<li><a href="/wiki/Template:Monoclonals_for_immune_system" title="Template:Monoclonals for immune system">monoclonal antibodies</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks hlist navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Help:Authority_control" title="Help:Authority control">Authority control</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Integrated_Authority_File" title="Integrated Authority File">GND</a>: <span class="uid"><a rel="nofollow" class="external text" href="http://d-nb.info/gnd/4184973-5">4184973-5</a></span></li>
<li><a href="/wiki/National_Diet_Library" title="National Diet Library">NDL</a>: <span class="uid"><a rel="nofollow" class="external text" href="http://id.ndl.go.jp/auth/ndlna/00570209">00570209</a></span></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Parsed by mw1025
CPU time usage: 1.774 seconds
Real time usage: 2.069 seconds
Preprocessor visited node count: 11391/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 380306/2097152 bytes
Template argument size: 9121/2097152 bytes
Highest expansion depth: 20/40
Expensive parser function count: 7/500
Lua time usage: 0.839/10.000 seconds
Lua memory usage: 5.31 MB/50 MB
-->

<!-- 
Transclusion expansion time report (%,ms,calls,template)
100.00% 1735.263      1 - -total
 50.17%  870.531      1 - Template:Reflist
 26.57%  461.051      3 - Template:Infobox
 25.79%  447.546      1 - Template:Drugbox
 22.23%  385.830     44 - Template:Vcite2_journal
  7.26%  125.969     28 - Template:Cite_web
  5.73%   99.366      7 - Template:Navbox
  4.27%   74.113     15 - Template:Cite_news
  3.42%   59.339      1 - Template:Immunosuppressants
  2.92%   50.636      7 - Template:Fix
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:51078-0!*!0!!en!4!* and timestamp 20150709180643 and revision id 670707794
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>					<div class="printfooter">
						Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Thalidomide&amp;oldid=670707794">https://en.wikipedia.org/w/index.php?title=Thalidomide&amp;oldid=670707794</a>"					</div>
				<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Congenital_amputations" title="Category:Congenital amputations">Congenital amputations</a></li><li><a href="/wiki/Category:German_inventions" title="Category:German inventions">German inventions</a></li><li><a href="/wiki/Category:Glutarimides" title="Category:Glutarimides">Glutarimides</a></li><li><a href="/wiki/Category:Health_disasters" title="Category:Health disasters">Health disasters</a></li><li><a href="/wiki/Category:Immunosuppressants" title="Category:Immunosuppressants">Immunosuppressants</a></li><li><a href="/wiki/Category:Leprosy" title="Category:Leprosy">Leprosy</a></li><li><a href="/wiki/Category:Phthalimides" title="Category:Phthalimides">Phthalimides</a></li><li><a href="/wiki/Category:Teratogens" title="Category:Teratogens">Teratogens</a></li><li><a href="/wiki/Category:Withdrawn_drugs" title="Category:Withdrawn drugs">Withdrawn drugs</a></li><li><a href="/wiki/Category:Chirality" title="Category:Chirality">Chirality</a></li><li><a href="/wiki/Category:Medical_controversies" title="Category:Medical controversies">Medical controversies</a></li><li><a href="/wiki/Category:Health_disasters_in_the_United_Kingdom" title="Category:Health disasters in the United Kingdom">Health disasters in the United Kingdom</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:All_articles_with_dead_external_links" title="Category:All articles with dead external links">All articles with dead external links</a></li><li><a href="/wiki/Category:Articles_with_dead_external_links_from_June_2014" title="Category:Articles with dead external links from June 2014">Articles with dead external links from June 2014</a></li><li><a href="/wiki/Category:CS1_errors:_dates" title="Category:CS1 errors: dates">CS1 errors: dates</a></li><li><a href="/wiki/Category:Pages_with_DOIs_inactive_since_2015" title="Category:Pages with DOIs inactive since 2015">Pages with DOIs inactive since 2015</a></li><li><a href="/wiki/Category:Articles_with_dead_external_links_from_June_2013" title="Category:Articles with dead external links from June 2013">Articles with dead external links from June 2013</a></li><li><a href="/wiki/Category:All_pages_needing_factual_verification" title="Category:All pages needing factual verification">All pages needing factual verification</a></li><li><a href="/wiki/Category:Wikipedia_articles_needing_factual_verification_from_June_2013" title="Category:Wikipedia articles needing factual verification from June 2013">Wikipedia articles needing factual verification from June 2013</a></li><li><a href="/wiki/Category:Articles_with_dead_external_links_from_September_2012" title="Category:Articles with dead external links from September 2012">Articles with dead external links from September 2012</a></li><li><a href="/wiki/Category:CS1_German-language_sources_(de)" title="Category:CS1 German-language sources (de)">CS1 German-language sources (de)</a></li><li><a href="/wiki/Category:Articles_with_changed_EBI_identifier" title="Category:Articles with changed EBI identifier">Articles with changed EBI identifier</a></li><li><a href="/wiki/Category:Chemical_articles_having_calculated_molecular_weight_overwritten" title="Category:Chemical articles having calculated molecular weight overwritten">Chemical articles having calculated molecular weight overwritten</a></li><li><a href="/wiki/Category:Drugboxes_which_contain_changes_to_verified_fields" title="Category:Drugboxes which contain changes to verified fields">Drugboxes which contain changes to verified fields</a></li><li><a href="/wiki/Category:Drugboxes_which_contain_changes_to_watched_fields" title="Category:Drugboxes which contain changes to watched fields">Drugboxes which contain changes to watched fields</a></li><li><a href="/wiki/Category:Articles_needing_additional_references_from_March_2014" title="Category:Articles needing additional references from March 2014">Articles needing additional references from March 2014</a></li><li><a href="/wiki/Category:All_articles_needing_additional_references" title="Category:All articles needing additional references">All articles needing additional references</a></li><li><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_June_2015" title="Category:Articles with unsourced statements from June 2015">Articles with unsourced statements from June 2015</a></li><li><a href="/wiki/Category:Articles_that_use_a_Medicine_navs_subtemplate" title="Category:Articles that use a Medicine navs subtemplate">Articles that use a Medicine navs subtemplate</a></li><li><a href="/wiki/Category:Wikipedia_articles_with_GND_identifiers" title="Category:Wikipedia articles with GND identifiers">Wikipedia articles with GND identifiers</a></li></ul></div></div>				<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>

			<div id="mw-head">
									<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
						<h3 id="p-personal-label">Personal tools</h3>
						<ul>
							<li id="pt-createaccount"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Thalidomide&amp;type=signup" title="You are encouraged to create an account and log in; however, it is not mandatory">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Thalidomide" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>						</ul>
					</div>
									<div id="left-navigation">
										<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
						<h3 id="p-namespaces-label">Namespaces</h3>
						<ul>
															<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Thalidomide"  title="View the content page [c]" accesskey="c">Article</a></span></li>
															<li  id="ca-talk"><span><a href="/wiki/Talk:Thalidomide"  title="Discussion about the content page [t]" accesskey="t" rel="discussion">Talk</a></span></li>
													</ul>
					</div>
										<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
												<h3 id="p-variants-label">
							<span>Variants</span><a href="#"></a>
						</h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
									</div>
				<div id="right-navigation">
										<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
						<h3 id="p-views-label">Views</h3>
						<ul>
															<li id="ca-view" class="selected"><span><a href="/wiki/Thalidomide" >Read</a></span></li>
															<li id="ca-edit"><span><a href="/w/index.php?title=Thalidomide&amp;action=edit"  title="Edit this page [e]" accesskey="e">Edit</a></span></li>
															<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Thalidomide&amp;action=history"  title="Past versions of this page [h]" accesskey="h">View history</a></span></li>
													</ul>
					</div>
										<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
						<h3 id="p-cactions-label"><span>More</span><a href="#"></a></h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
										<div id="p-search" role="search">
						<h3>
							<label for="searchInput">Search</label>
						</h3>

						<form action="/w/index.php" id="searchform">
							<div id="simpleSearch">
							<input type="search" name="search" placeholder="Search" title="Search Wikipedia [f]" accesskey="f" id="searchInput" /><input type="hidden" value="Special:Search" name="title" /><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton" /><input type="submit" name="go" value="Go" title="Go to a page with this exact name if one exists" id="searchButton" class="searchButton" />							</div>
						</form>
					</div>
									</div>
			</div>
			<div id="mw-panel">
				<div id="p-logo" role="banner"><a class="mw-wiki-logo" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
						<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
			<h3 id='p-navigation-label'>Navigation</h3>

			<div class="body">
									<ul>
						<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li><li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li><li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li><li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li><li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikimedia Shop">Wikipedia store</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
			<h3 id='p-interaction-label'>Interaction</h3>

			<div class="body">
									<ul>
						<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li><li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li><li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li><li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
			<h3 id='p-tb-label'>Tools</h3>

			<div class="body">
									<ul>
						<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Thalidomide" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Thalidomide" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink"><a href="/w/index.php?title=Thalidomide&amp;oldid=670707794" title="Permanent link to this revision of the page">Permanent link</a></li><li id="t-info"><a href="/w/index.php?title=Thalidomide&amp;action=info" title="More information about this page">Page information</a></li><li id="t-wikibase"><a href="//www.wikidata.org/wiki/Q203174" title="Link to connected data repository item [g]" accesskey="g">Wikidata item</a></li><li id="t-cite"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Thalidomide&amp;id=670707794" title="Information on how to cite this page">Cite this page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
			<h3 id='p-coll-print_export-label'>Print/export</h3>

			<div class="body">
									<ul>
						<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Thalidomide">Create a book</a></li><li id="coll-download-as-rdf2latex"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Thalidomide&amp;oldid=670707794&amp;writer=rdf2latex">Download as PDF</a></li><li id="t-print"><a href="/w/index.php?title=Thalidomide&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
			<h3 id='p-lang-label'>Languages</h3>

			<div class="body">
									<ul>
						<li class="interlanguage-link interwiki-ar"><a href="//ar.wikipedia.org/wiki/%D8%AB%D8%A7%D9%84%D9%8A%D8%AF%D9%88%D9%85%D9%8A%D8%AF" title="ثاليدوميد – Arabic" lang="ar" hreflang="ar">العربية</a></li><li class="interlanguage-link interwiki-ca"><a href="//ca.wikipedia.org/wiki/Talidomida" title="Talidomida – Catalan" lang="ca" hreflang="ca">Català</a></li><li class="interlanguage-link interwiki-cs"><a href="//cs.wikipedia.org/wiki/Thalidomid" title="Thalidomid – Czech" lang="cs" hreflang="cs">Čeština</a></li><li class="interlanguage-link interwiki-cy"><a href="//cy.wikipedia.org/wiki/Thalidomid" title="Thalidomid – Welsh" lang="cy" hreflang="cy">Cymraeg</a></li><li class="interlanguage-link interwiki-da"><a href="//da.wikipedia.org/wiki/Thalidomid" title="Thalidomid – Danish" lang="da" hreflang="da">Dansk</a></li><li class="interlanguage-link interwiki-de"><a href="//de.wikipedia.org/wiki/Thalidomid" title="Thalidomid – German" lang="de" hreflang="de">Deutsch</a></li><li class="interlanguage-link interwiki-el"><a href="//el.wikipedia.org/wiki/%CE%98%CE%B1%CE%BB%CE%B9%CE%B4%CE%BF%CE%BC%CE%AF%CE%B4%CE%B7" title="Θαλιδομίδη – Greek" lang="el" hreflang="el">Ελληνικά</a></li><li class="interlanguage-link interwiki-es"><a href="//es.wikipedia.org/wiki/Talidomida" title="Talidomida – Spanish" lang="es" hreflang="es">Español</a></li><li class="interlanguage-link interwiki-eo"><a href="//eo.wikipedia.org/wiki/Talidomido" title="Talidomido – Esperanto" lang="eo" hreflang="eo">Esperanto</a></li><li class="interlanguage-link interwiki-eu"><a href="//eu.wikipedia.org/wiki/Talidomida" title="Talidomida – Basque" lang="eu" hreflang="eu">Euskara</a></li><li class="interlanguage-link interwiki-fa"><a href="//fa.wikipedia.org/wiki/%D8%AA%D8%A7%D9%84%DB%8C%D8%AF%D9%88%D9%85%DB%8C%D8%AF" title="تالیدومید – Persian" lang="fa" hreflang="fa">فارسی</a></li><li class="interlanguage-link interwiki-fr"><a href="//fr.wikipedia.org/wiki/Thalidomide" title="Thalidomide – French" lang="fr" hreflang="fr">Français</a></li><li class="interlanguage-link interwiki-ga"><a href="//ga.wikipedia.org/wiki/Tail%C3%ADdim%C3%ADd" title="Tailídimíd – Irish" lang="ga" hreflang="ga">Gaeilge</a></li><li class="interlanguage-link interwiki-gl"><a href="//gl.wikipedia.org/wiki/Talidomida" title="Talidomida – Galician" lang="gl" hreflang="gl">Galego</a></li><li class="interlanguage-link interwiki-ko"><a href="//ko.wikipedia.org/wiki/%ED%83%88%EB%A6%AC%EB%8F%84%EB%A7%88%EC%9D%B4%EB%93%9C" title="탈리도마이드 – Korean" lang="ko" hreflang="ko">한국어</a></li><li class="interlanguage-link interwiki-it"><a href="//it.wikipedia.org/wiki/Talidomide" title="Talidomide – Italian" lang="it" hreflang="it">Italiano</a></li><li class="interlanguage-link interwiki-he"><a href="//he.wikipedia.org/wiki/%D7%AA%D7%9C%D7%99%D7%93%D7%95%D7%9E%D7%99%D7%93" title="תלידומיד – Hebrew" lang="he" hreflang="he">עברית</a></li><li class="interlanguage-link interwiki-ka"><a href="//ka.wikipedia.org/wiki/%E1%83%97%E1%83%90%E1%83%9A%E1%83%98%E1%83%93%E1%83%9D%E1%83%9B%E1%83%98%E1%83%93%E1%83%98" title="თალიდომიდი – Georgian" lang="ka" hreflang="ka">ქართული</a></li><li class="interlanguage-link interwiki-hu"><a href="//hu.wikipedia.org/wiki/Thalidomid" title="Thalidomid – Hungarian" lang="hu" hreflang="hu">Magyar</a></li><li class="interlanguage-link interwiki-mk"><a href="//mk.wikipedia.org/wiki/%D0%A2%D0%B0%D0%BB%D0%B8%D0%B4%D0%BE%D0%BC%D0%B8%D0%B4" title="Талидомид – Macedonian" lang="mk" hreflang="mk">Македонски</a></li><li class="interlanguage-link interwiki-xmf"><a href="//xmf.wikipedia.org/wiki/%E1%83%A2%E1%83%94%E1%83%9A%E1%83%90%E1%83%93%E1%83%9D%E1%83%9B%E1%83%98%E1%83%93%E1%83%98" title="ტელადომიდი – Mingrelian" lang="xmf" hreflang="xmf">მარგალური</a></li><li class="interlanguage-link interwiki-nl"><a href="//nl.wikipedia.org/wiki/Thalidomide" title="Thalidomide – Dutch" lang="nl" hreflang="nl">Nederlands</a></li><li class="interlanguage-link interwiki-ja"><a href="//ja.wikipedia.org/wiki/%E3%82%B5%E3%83%AA%E3%83%89%E3%83%9E%E3%82%A4%E3%83%89" title="サリドマイド – Japanese" lang="ja" hreflang="ja">日本語</a></li><li class="interlanguage-link interwiki-no"><a href="//no.wikipedia.org/wiki/Thalidomid" title="Thalidomid – Norwegian" lang="no" hreflang="no">Norsk bokmål</a></li><li class="interlanguage-link interwiki-pl"><a href="//pl.wikipedia.org/wiki/Talidomid" title="Talidomid – Polish" lang="pl" hreflang="pl">Polski</a></li><li class="interlanguage-link interwiki-pt"><a href="//pt.wikipedia.org/wiki/Talidomida" title="Talidomida – Portuguese" lang="pt" hreflang="pt">Português</a></li><li class="interlanguage-link interwiki-ru"><a href="//ru.wikipedia.org/wiki/%D0%A2%D0%B0%D0%BB%D0%B8%D0%B4%D0%BE%D0%BC%D0%B8%D0%B4" title="Талидомид – Russian" lang="ru" hreflang="ru">Русский</a></li><li class="interlanguage-link interwiki-si"><a href="//si.wikipedia.org/wiki/%E0%B6%AD%E0%B7%90%E0%B6%BD%E0%B7%92%E0%B6%B8%E0%B7%9C%E0%B6%BA%E0%B7%92%E0%B6%A9%E0%B7%8A" title="තැලිමොයිඩ් – Sinhala" lang="si" hreflang="si">සිංහල</a></li><li class="interlanguage-link interwiki-simple"><a href="//simple.wikipedia.org/wiki/Thalidomide" title="Thalidomide – Simple English" lang="simple" hreflang="simple">Simple English</a></li><li class="interlanguage-link interwiki-sk"><a href="//sk.wikipedia.org/wiki/Talidomid" title="Talidomid – Slovak" lang="sk" hreflang="sk">Slovenčina</a></li><li class="interlanguage-link interwiki-sl"><a href="//sl.wikipedia.org/wiki/Talidomid" title="Talidomid – Slovenian" lang="sl" hreflang="sl">Slovenščina</a></li><li class="interlanguage-link interwiki-sr"><a href="//sr.wikipedia.org/wiki/Talidomid" title="Talidomid – Serbian" lang="sr" hreflang="sr">Српски / srpski</a></li><li class="interlanguage-link interwiki-sh"><a href="//sh.wikipedia.org/wiki/Talidomid" title="Talidomid – Serbo-Croatian" lang="sh" hreflang="sh">Srpskohrvatski / српскохрватски</a></li><li class="interlanguage-link interwiki-fi"><a href="//fi.wikipedia.org/wiki/Talidomidi" title="Talidomidi – Finnish" lang="fi" hreflang="fi">Suomi</a></li><li class="interlanguage-link interwiki-sv"><a href="//sv.wikipedia.org/wiki/Talidomid" title="Talidomid – Swedish" lang="sv" hreflang="sv">Svenska</a></li><li class="interlanguage-link interwiki-ta"><a href="//ta.wikipedia.org/wiki/%E0%AE%A4%E0%AE%BE%E0%AE%B2%E0%AE%BF%E0%AE%9F%E0%AF%8B%E0%AE%AE%E0%AF%88%E0%AE%9F%E0%AF%81" title="தாலிடோமைடு – Tamil" lang="ta" hreflang="ta">தமிழ்</a></li><li class="interlanguage-link interwiki-tr"><a href="//tr.wikipedia.org/wiki/Talidomit" title="Talidomit – Turkish" lang="tr" hreflang="tr">Türkçe</a></li><li class="interlanguage-link interwiki-uk"><a href="//uk.wikipedia.org/wiki/%D0%A2%D0%B0%D0%BB%D1%96%D0%B4%D0%BE%D0%BC%D1%96%D0%B4" title="Талідомід – Ukrainian" lang="uk" hreflang="uk">Українська</a></li><li class="interlanguage-link interwiki-vi"><a href="//vi.wikipedia.org/wiki/Thalidomide" title="Thalidomide – Vietnamese" lang="vi" hreflang="vi">Tiếng Việt</a></li><li class="interlanguage-link interwiki-zh"><a href="//zh.wikipedia.org/wiki/%E6%B2%99%E5%88%A9%E5%BA%A6%E8%83%BA" title="沙利度胺 – Chinese" lang="zh" hreflang="zh">中文</a></li><li class="uls-p-lang-dummy"><a href="#"></a></li>					</ul>
				<div class='after-portlet after-portlet-lang'><span class="wb-langlinks-edit wb-langlinks-link"><a href="//www.wikidata.org/wiki/Q203174#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>			</div>
		</div>
				</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 9 July 2015, at 18:06.</li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="//wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Thalidomide&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
											<li id="footer-copyrightico">
							<a href="//wikimediafoundation.org/"><img src="/static/images/wikimedia-button.png" srcset="/static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation"/></a>						</li>
											<li id="footer-poweredbyico">
							<a href="//www.mediawiki.org/"><img src="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_132x47.png 1.5x, //en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" /></a>						</li>
									</ul>
						<div style="clear:both"></div>
		</div>
		<script>if(window.jQuery)jQuery.ready();</script><script>if(window.mw){
mw.loader.state({"ext.globalCssJs.site":"ready","ext.globalCssJs.user":"ready","site":"loading","user":"ready","user.groups":"ready"});
}</script>
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.cite.styles%7Cext.gadget.DRN-wizard%2CReferenceTooltips%2CWatchlistGreenIndicators%2Ccharinsert%2Cfeatured-articles-links%2CrefToolbar%2Cswitcher%2Cteahouse%7Cext.wikimediaBadges&amp;only=styles&amp;skin=vector&amp;*" />
<script>if(window.mw){
mw.loader.load(["ext.cite.a11y","mediawiki.toc","mediawiki.action.view.postEdit","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.searchSuggest","ext.cirrusSearch.loggingSchema","mmv.bootstrap.autostart","ext.imageMetrics.loader","ext.eventLogging.subscriber","ext.wikimediaEvents","ext.wikimediaEvents.statsd","ext.navigationTiming","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.WatchlistGreenIndicators","ext.gadget.DRN-wizard","ext.gadget.charinsert","ext.gadget.refToolbar","ext.gadget.switcher","ext.gadget.featured-articles-links","ext.visualEditor.targetLoader","schema.UniversalLanguageSelector","ext.uls.eventlogger","ext.uls.interlanguage"],null,true);
}</script>
<script>if(window.mw){
document.write("\u003Cscript src=\"//en.wikipedia.org/w/load.php?debug=false\u0026amp;lang=en\u0026amp;modules=site\u0026amp;only=scripts\u0026amp;skin=vector\u0026amp;*\"\u003E\u003C/script\u003E");
}</script>
<script>if(window.mw){
mw.config.set({"wgBackendResponseTime":110,"wgHostname":"mw1238"});
}</script>
	</body>
</html>
